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Familial  adenomatous  polyposis  (FAP)  is  an  autosomal  dominant  disease  characterized  by  
APC  germline  mutations  and  the  development  of  hundreds  to  thousands  of  premalignant  
adenomas  in  the  gastrointestinal  tract  at  a  young  age.    If  left  untreated,  these  patients  
inevitably  develop  colon  cancer  (CRC)  and  small  bowel  tumors.    We  performed  exome  
sequencing  of  samples  from  12  FAP  patients  to  characterize  adenomas  and  to  identify  
candidate  genes  of  adenoma  development  that  may  serve  as  potential  targets  for  
chemoprevention  drug  development.    From  each  patient,  a  blood  and  at  least  one  polyp  were  
sequenced  with  a  total  of  25  polyps  analyzed.      In  some  cases,  normal  mucosa  samples  were  
also  sequenced.    We  characterized  point  mutations,  insertions,  deletions  and  chromosomal  
allelic  imbalance.  In  addition,  we  performed  RNA  sequencing  of  8  polyps  and  4  normal  
mucosa  samples  from  the  colon  and  small  bowel  of  2  additional  FAP  patients.    
Somatic  APC  truncating  mutations  and  loss  of  chromosome  5q  were  recurrent  across  
polyps,  although  we  found  no  recurrent  intra-‐‑patient  somatic  APC  point  mutations,  indicating  
intra-‐‑patient  polyp  heterogeneity.  Oncogenic  driver  events  such  as  activating  KRAS  mutations  
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were  identified  in  multiple  polyps.    Further,  analysis  of  mutation  allele  fractions  suggests  that  
several  of  the  polyps  studied  are  multi-‐‑clonal  in  nature.  Excluding  the  known  genes  APC  and  
KRAS,  50  candidate  genes  were  identified  that  are  putatively  involved  in  the  early  
development  of  CRC.    These  genes  could  play  a  role  in  future  chemoprevention  strategies.    
Most  of  these  genes  have  been  previously  associated  with  CRC.    In  addition,  a  gene  fusion  in  
PTEN  was  detected  and  a  novel,  recurrent  REG3A  fusion  was  identified  in  duodenum  polyps.    
The  WNT  signaling  pathway,  aberrant  in  92%  of  CRCs,  was  recurrently  altered  in  80%  of  
polyps.    
We  identified  colon  and  duodenum  gene  expression  signatures  of  FAP  patients  and  
screened  them  against  drug-‐‑induced  signatures  using  our  Cancer  in-‐‑silico  Drug  Discovery  
(CiDD)  software.      CiDD  identified  Celecoxib,  a  COX-‐‑2  inhibitor  that  has  already  been  clinically  
tested  as  a  chemopreventive  drug,  providing  validity  to  our  drug  development  approach.    
CiDD  also  identified  a  novel  candidate  compound,  TTNPB,  which  targets  the  Retinoid  
pathway  as  a  potential  drug  for  chemopreventive  treatment  of  FAP  patients.     
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classifier  had  lower  sensitivity  (71%)  but  achieved  better  specificity  (62%)  on  the  CCLE  
data  set.  These  results  suggest  that  the  systematically  obtained  BRAF  V600E  classifier  from  
CiDD  is  comparable  to  the  published  PETACC3-‐‑derived  signature  and  that  the  TCGA-‐‑
derived  classifier  may  even  have  improved  specificity  for  distinguishing  BRAF  wild-‐‑type  
cell  lines  from  the  BRAF  mutant  cell  lines.  ................................................................................  146  
Table  25:  Candidate  drug  compounds  identified  systematically  by  CiDD  for  BRAF  V600E  CRC  
based  on  the  TCGA-‐‑derived  gene  expression  signature.  Nine  drugs  were  identified  having  
both  a  negative  enrichment  score  and  a  maximum  permutation  P-‐‑value  of  0.1.  Three  of  
these  drugs  (*)  were  also  identified  using  the  PETACC3-‐‑derived  gene  expression  
signature.  .........................................................................................................................................  147  
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1 Introduction  
1.1 Background  
1.1.1

Genetic  basis  and  clinical  description  of  Familial  Adenomatous  Polyposis  (FAP)  
Colorectal  cancer  (CRC)  is  the  second  leading  cause  of  mortality  in  the  United  States1  and  

fourth  worldwide2.    Nearly  half  of  the  general  population  will  develop  at  least  one  benign  
colonic  polyp  in  their  lifetime  with  approximately  3%  going  on  to  develop  CRC3.    Symptoms  are  
rare  until  late  stages,  thus  most  sporadic  CRC  cases  go  undetected.    There  are  two  primary  
forms  of  hereditary  CRC:  Familial  Adenomatous  Polyposis  (FAP)  and  Lynch  Syndrome  (or  
hereditary  non-‐‑polyposis  colorectal  cancer,  HNPCC).    These  are  both  autosomal  dominant  
diseases  where  patients  are  predisposed  to  cancers  due  to  germline  mutations  in  key  genes.    
FAP  is  characterized  by  mutations  in  the  Adenomatous  Polyposis  Coli  (APC)  gene,  whereas  Lynch  
Syndrome  patients  have  germline  mutations  in  genes  involved  in  the  DNA  mismatch  repair  
pathway  including  MLH1,  MSH2,  TACSTD1,  MSH6  and  PMS24.    As  such,  FAP  patients  are  born  
with  only  one  normal  allele  of  the  APC  tumor  suppressor  gene,  predisposing  them  to  the  
development  of  adenomas  at  younger  ages  compared  to  the  general  population.    Similarly,  
Lynch  Syndrome  patients  are  born  with  a  defect  that  predisposes  them  to  higher  mutation  rates  
compared  to  normal  individuals,  giving  them  increased  probabilities  of  obtaining  key  genomic  
aberrations  in  genes  crucial  for  the  development  of  carcinomas.    Both  of  these  patient  
populations  are  more  likely  to  develop  tumors  compared  to  the  general  population.    The  focus  
of  the  research  described  in  this  dissertation  will  be  on  FAP.  
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CRCs  are  thought  to  progress  from  a  normal  epithelium  to  an  adenoma,  or  pre-‐‑malignant  
lesion,  and  then  to  a  carcinoma  (the  so-‐‑called  adenoma-‐‑to-‐‑carcinoma  sequence  model5).    This  
sequence  describes  steps  of  gene  and  pathway  alterations  that  give  abnormal  cells  a  selective  
advantage  to  proliferate  (see  Figure  1).    The  initial  step  in  tumorigenesis  in  the  majority  of  
adenomas,  which  are  premalignant  lesions,  is  the  loss  of  the  APC  gene.    Intermediate  adenomas  
have  activating  mutations  in  KRAS,  late  adenomas  are  characterized  by  loss  of  SMAD4,  and  
carcinomas  have  acquired  TP53  mutations  among  other  alterations.      
  

  
Figure  1:  Step-‐‑wise  progression  of  sporadic  and  inherited  (FAP  and  HNPCC)  forms  of  CRC  from  normal  epithelia  to  
adenomas  and  carcinomas  (http://syscol-‐‑project.eu/about-‐‑syscol/).  
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The  APC  germline  mutations  of  FAP  patients  accelerate  the  initiation  of  the  adenoma-‐‑to-‐‑
carcinoma  sequence,  resulting  in  the  development  of  hundreds  to  thousands  of  polyps,  
generally  in  the  colon  and  rectum  and  with  lower  densities  in  the  small  intestine  such  as  the  
duodenum,  ileum  and  jejunum4  (see  Figure  2).    The  development  of  these  polyps  in  large  
numbers  greater  than  100  is  termed  polyposis.    If  left  untreated,  some  polyps  will  inevitably  
progress  into  cancer  in  the  lower  gastrointestinal  tract  and  less  frequently  in  the  upper  
gastrointestinal  tract6.    FAP  accounts  for  less  than  1  percent  of  all  CRC  cases  and  affects  
approximately  1  in  10,000  people7.    Patients  with  FAP  develop  CRC  at  an  average  age  of  35  
years  if  left  untreated,  although  there  is  variability  within  and  between  families,  some  of  which  
can  be  explained  by  specific  germline  mutations  in  APC4.      
  

  
Figure  2:  Overview  of  the  gastrointestinal  tract  (http://en.wikipedia.org/wiki/Human_gastrointestinal_tract).    In  FAP  
patients,  polyps  develop  and  proliferate  both  in  the  lower  (e.g.,  the  colon  and  rectum)  and  the  upper  gastrointestinal  
tract  (e.g.,  the  duodenum  and  ileum).    Malignancy  rates  of  lower  gastrointestinal  tract  polyps  are  higher  than  those  in  
the  upper  tract.    Therefore,  resection  of  the  colon  and  rectum  are  common  prophylactic  surgical  procedures  in  FAP  
patients.  
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The  primary  cause  of  death  for  FAP  patients  has  historically  been  CRC,  which  generally  
develops  by  the  third  or  fourth  decade  of  life8.      However,  the  current  standard  of  treatment,  
which  includes  regular  surveillance  through  colonoscopy  until  the  polyp  burden  becomes  
unmanageable,  often  by  20  years  of  age,  at  which  point  prophylactic  surgical  resection  of  the  
colon  with  colectomy  or  proctocolectomy,  which  includes  removal  of  the  rectum,  is  performed  
for  cancer  prevention  purposes  and  has  reduced  the  mortality  by  CRC  greatly  in  the  last  2  to  3  
decades6.    While  surgery  significantly  improves  the  overall  survival  of  FAP  patients,  the  
quality-‐‑of-‐‑life  of  these  patients  is  reduced,  apart  from  negative  psychological  aspects  that  are  
also  associated  with  these  surgeries.    For  example,  reports  have  associated  infertility  with  these  
surgeries9.    In  addition,  patients  with  colectomies  have  a  25%  risk  of  developing  cancer  in  the  
preserved  rectum  6.    These  patients  require  surveillance  of  the  rectum  throughout  the  remainder  
of  their  lives.    
The  second  leading  cause  of  death  after  CRC  in  FAP  patients  stems  from  desmoid  tumors  
and  duodenal  adenocarcinoma10.    Studies  have  shown  that  duodenal  adenomas  have  a  
prevalence  of  around  65%  in  FAP  patients  at  a  median  age  of  38  years  and  the  lifetime  risk  for  
these  patients  of  developing  these  lesions  approaches  100%11.    Although  chemopreventive  
strategies  have  shown  some  effectiveness  for  inducing  regression  of  colorectal  polyps,  their  
value  in  delaying  or  preventing  duodenal  polyps  has  been  disappointing8.  
The  inevitable  risk  of  cancer  in  the  colorectum  and  potentially  the  duodenum,  and  the  
young  age  at  which  FAP  patients  must  undergo  life-‐‑altering  preventive  surgery  make  
chemoprevention  in  both  the  large  and  small  intestine  an  urgent  need.    Thus,  it  has  been  our  
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goal  to  molecularly  profile  the  differences  between  the  at-‐‑risk  normal  mucosa  and  polyps  of  
FAP  patients  to  gain  biological  insights  into  the  development  of  pre-‐‑malignant  lesions,  
which  may  guide  the  development  of  chemopreventive  strategies  to  delay  or  prevent  the  
development  of  polyps  and  cancer  in  the  colorectum  and  duodenum.  
  
1.1.2

Role  of  the  Adenomatous  Polyposis  Coli  (APC)  gene  in  adenoma  formation  
APC  is  a  gene  with  15  exons  located  in  the  long  arm  of  chromosome  5  in  band  q22.2  that  

encodes  a  2843  amino  acid  protein.      The  vast  majority  of  APC  mutations  result  in  a  truncated  
protein,  where  approximately  one  third  of  germline  mutations  in  APC  lie  between  codons  1061  
and  130912.    Whereas  the  germline  mutations  are  scattered  throughout  the  5’  half  of  the  APC  
gene,  the  majority  of  somatic  mutations  in  both  FAP  and  sporadic  forms  of  CRCs  are  clustered  
between  codons  1286  and  1513,  in  the  so-‐‑called  mutation  cluster  region  (MCR)13.  
The  APC  gene  is  a  tumor  suppressor  and  promotes  the  degradation  of  beta-‐‑catenin.    The  
regulation  of  beta-‐‑catenin  by  APC  is  accomplished  by  portions  of  the  gene  sequence  including  
three  15-‐‑amino-‐‑acid  repeats  and  seven  20-‐‑amino-‐‑acid  repeats  that  respectively  bind  and  
downregulate  beta-‐‑catenin  via  ubiquitination14.    Loss  of  APC  results  in  a  constitutive  activation  
of  beta-‐‑catenin,  such  that  beta-‐‑catenin  will  be  translocated  to  the  nucleus  and  will  activate  the  
transcription  of  many  WNT  target  genes,  which  leads  to  cellular  proliferation  among  activation  
of  other  cellular  processes15.    More  than  90%  of  sporadic  CRC  patients  have  functional  APC  
alterations14.    Normally,  for  APC  driven  tumorigenesis,  bi-‐‑allelic  alteration  initiates  disease  
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development.    FAP  patients  have  inherited  only  one  normal  functioning  APC  allele,  which  
increases  their  probability  and  rate  of  disease  development.  
There  are  several  FAP  phenotypes  that  correlate  with  specific  APC  germline  mutations.    
Mutations  between  codon  1250  and  codon  1464  are  associated  with  profuse  polyposis  where  
patients  have  greater  than  5,000  colorectal  polyps16.    Mutations  in  codon  1309  are  associated  
with  early  onset  adenoma  development  (10  years  earlier)  and  earlier  CRC  at  ages  less  than  35  
years  of  age16.    Mutations  at  the  5’  and  3’  ends  of  the  APC  gene  are  associated  with  attenuated  
FAP,  where  patients  are  characterized  by  oligopolyposis,  presenting  with  less  than  100  
colorectal  polyps,  with  later  onset  of  CRC  at  greater  than  50  years  of  age12.  
  
1.1.3

Current  chemopreventive  strategies  
Chemoprevention  delays  or  prevents  the  development  of  cancer  through  the  use  of  

natural  or  pharmaceutical  agents17.    FAP  patients  are  ideal  for  assessing  the  efficacy  of  
chemopreventive  agents  for  adenomatous  polyps  because  FAP  patients  predictably  develop  
polyps  that  are  visible  and  countable  prior  to  their  transformation  to  cancer.    Polyp  counts  in  
these  patients  provide  a  convenient  measure  of  the  effectiveness  of  chemopreventive  agents.    
The  potential  benefits  of  chemoprevention  in  FAP  consist  mainly  of  the  prevention  of  adenomas  
and  the  delay  of  tumor  growth,  thus  giving  FAP  patients  a  longer  and  higher  quality-‐‑of-‐‑life.  
In  the  early  1980’s,  epidemiological  studies  found  that  treatment  with  aspirin,  a  non-‐‑
steroidal  anti-‐‑inflammatory  drug  (NSAID),  was  associated  with  a  reduced  risk  for  CRCs18.    Since  
then,  NSAIDs  have  been  extensively  tested  for  chemoprevention  of  CRC  in  patients  with  
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hereditary  predispositions,  as  well  as  the  general  population.    NSAIDs  inhibit  COX,  a  key  
enzyme  in  the  conversion  of  arachidonic  acid  to  prostaglandins  and  other  eicosanoids.    There  
are  2  isoforms  of  the  COX  enzyme,  COX-‐‑1  and  COX-‐‑2.    COX-‐‑1  is  constitutively  expressed  in  
virtually  all  tissues,  whereas  COX-‐‑2  is  absent  under  physiologic  conditions19.    COX-‐‑2  is  induced  
in  several  clinical  contexts  such  as  inflammation  and  cancer.    Overexpression  of  COX-‐‑2  has  been  
observed  in  colorectal  polyps  and  carcinomas19,20.    The  effectiveness  of  NSAIDs  in  repressing  the  
growth  of  adenomas  appears  to  be  via  inhibition  of  COX-‐‑2,  although  it  has  been  suggested  that  
NSAIDs  may  be  effective  independent  of  COX-‐‑2  suppression21.    
Thus,  NSAIDs  such  as  Sulindac,  Celecoxib,  Rofecoxib  and  others  have  been  developed  as  
chemopreventive  strategies.    In  initial  studies  of  the  NSAID  Sulindac,  a  substantial  activity  
delaying  the  growth  of  polyps  was  observed18.    Later,  Celecoxib,  gained  U.S.  Food  and  Drug  
Administration  (FDA)  approval  for  chemoprevention  of  polyps  in  patients  with  FAP22.    
However,  significant  cardiovascular  toxic  effects  were  observed  during  clinical  trials  in  sporadic  
CRC  populations  and  safety  concerns  led  to  withdrawal  of  the  drug23,24.    Aspirin  has  recently  
been  proposed  for  standard  chemopreventive  treatment  of  CRC  in  individuals  predisposed  to  
CRC  in  addition  to  the  general  population.    Two  Phase  III  clinical  trials  evaluated  aspirin  as  a  
chemopreventive  agent  in  patients  with  FAP  and  Lynch  Syndrome  –  the  CAPP1  and  CAPP2  
studies,  respectively.    These  studies  showed  that  aspirin  reduced  the  number  of  colon  and  
rectum  polyps  in  Lynch  Syndrome  patients  and  to  a  lesser  extent  in  FAP  patients.    Currently,  
the  chemopreventive  agent  of  choice  is  aspirin  in  Lynch  Syndrome  and  Sulindac  in  FAP25,26.    
However,  there  are  currently  no  FDA  approved  chemopreventive  agents  available,  illustrating  
the  need  for  further  development  of  chemopreventive  strategies6.    Further,  the  value  of  these  
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agents  for  the  prevention  of  polyps  in  the  small  intestine  is  unclear  with  yet  no  studies  showing  
statistically  significant  regression  of  duodenal  polyps  in  FAP  patients8.  
  

1.2 Objectives  
Our  long-‐‑term  goal  is  to  develop  more  effective  chemopreventive  therapies  for  the  colon  
and  duodenum  of  FAP  patients.    A  comprehensive  annotation  of  the  genomic  landscape  of  
adenomatous  polyps  in  FAP  patients  has  not  been  previously  attempted  through  next-‐‑generation  
sequencing  (NGS)  studies  and  is  critical  for  enabling  future  targeted  chemopreventive  drug  
identification  and  development.    In  addition,  aside  from  a  single  study  where  the  normal  
mucosa,  an  adenoma  and  an  adenocarcinoma  were  exome  sequenced  from  one  sporadic  CRC  
case27,  adenomas  in  both  the  sporadic  and  hereditary  contexts  have  been  largely  ignored  with  
regards  to  NGS  studies.      Thus,  the  objective  is  first  to  molecularly  characterize  FAP  polyps  at  a  
high-‐‑resolution  by  characterizing  the  exome  and  transcriptome  of  these  lesions.    As  initial  steps  
towards  this  goal,  we  are  sequencing  and  characterizing  the  exomes  of  colon  polyps  and  the  
transcriptomes  of  colon  and  duodenum  polyps  along  with  paired  normal  mucosa  samples.  
With  advances  in  NGS  technologies,  the  whole  genomes  and  exomes  of  colorectal  
adenocarcinomas  have  been  sequenced  and  comprehensive  landscapes  of  genetic  alterations  
and  gene  expression  alterations  have  been  characterized  by  The  Cancer  Genome  Atlas  (TCGA)  
consortium28.      We  will  leverage  these  data  and  compare  our  FAP  polyp  genomic  landscape  
with  those  of  TCGA  CRC  tumors  in  an  effort  to  identify  a  more  comprehensive  set  of  potential  
therapeutic  targets  that  may  be  involved  in  the  early  development  of  CRC.    By  comparing  FAP  
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polyp  somatic  events  to  those  of  CRC  and  identifying  similarities  between  the  two,  we  will  
propose  events  that  occur  early  in  the  development  of  CRCs.      Conversely,  by  identifying  CRC  
events  that  are  absent  in  our  FAP  polyp  data  set,  we  can  propose  events  that  are  involved  in  the  
transformation  of  colorectal  adenomas  to  carcinomas.        
High-‐‑throughput,  high-‐‑resolution  profiling  through  exome  and  RNA-‐‑sequencing  of  FAP  
adenomas  may  provide  insights  into  the  molecular  mechanisms  underlying  the  early  
development  of  CRC  and  may  reveal  genes  or  pathways  that  may  be  targeted  by  
chemoprevention  to  delay  or  halt  the  tumorigenesis  process  in  early  stages.    As  such,  our  
objectives  are  the  following:  
1. To  characterize  the  genomic  landscape  of  FAP  colon  polyps  through  exome  
sequencing  analyses  to  compare  identified  recurrent  somatic  events  to  those  previously  
associated  with  CRC  to  identify  genes  involved  in  early  CRC  development,  which  may  
help  guide  future  chemoprevention  strategies  (see  red  boxes  in  Figure  3).    
2. To  identify  candidate  chemopreventive  drugs  to  target  the  gene  expression  signatures  
of  the  at-‐‑risk  normal  mucosa  of  both  the  colon  and  duodenum    in  FAP  patients,  where  
the  gene  expression  signatures  are  inferred  from  RNA  sequence  of  colon  and  duodenum  
polyps  and  normal  mucosa  (see  blue  boxes  in  Figure  3).    Ideally,  chemoprevention  
strategies  would  include  effective  drugs  or  compounds  that  have  minimal  toxicity  and  
which  are  inexpensive.  
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speciﬁc!tumor!characteris'cs&

  

Figure  3:  Overview  of  samples,  objectives  and  software  developed  for  the  genomic  characterization  of  colon  polyps  
and  the  identification  of  candidate  chemopreventive  drugs  for  FAP  patients.  

  
In  summary,  effective  chemopreventive  strategies  may  reduce  disease  incidence,  delay  
progression  or  lessen  the  severity  of  disease  and  disease-‐‑related  secondary  effects  in  FAP  
patients.    Alternative  benefits  of  chemopreventive  strategies  would  be  to  postpone  the  need  for  
prophylactic  surgery  providing  patients  a  longer  and  better  quality-‐‑of-‐‑life.    
The  research  design,  the  analyses  and  biological  interpretation  of  the  FAP  colon  polyp  
genomes  and  the  colon  and  duodenum  polyp  transcriptomes,  and  identification  of  candidate  
chemopreventive  drugs  is  presented  in  this  dissertation.    In  chapter  2,  I  describe  our  
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experimental  design  and  patient  samples,  then  present  colon  polyp  somatic  profiles  and  
compare  them  to  those  of  CRC  from  TCGA.    In  chapter  3,  I  present  gene  expression  signatures  
representative  of  the  difference  between  the  at-‐‑risk  normal  mucosa  and  polyps  in  both  the  colon  
and  duodenum  of  FAP  patients,  introduce  a  computational  screening  framework  for  candidate  
drug  identification  by  illustrating  its  application  to  FAP,  and  describe  the  setup  for  follow-‐‑up  
drug  testing.    In  chapter  4,  I  discuss  the  significance  of  our  FAP  research  findings,  describe  
future  directions  and  discuss  the  potential  impact  of  the  bioinformatics  tools  that  we  developed  
over  the  course  of  this  project.    “Appendix  A:  Sequencing  analysis  pipelines”  describes  the  
pipelines  created  for  the  analysis  of  our  exome  and  RNA  sequencing  data.    In  addition,  the  
following  new  bioinformatics  methods  were  developed:  (1)  variant  tools  for  more  simple  
annotation  and  analysis  of  identified  NGS  genetic  variants,  (2)  hapLOHseq  for  the  sensitive  
detection  of  chromosomal  allelic  imbalance  events  from  exome  sequencing  data,  and  (3)  the  
Cancer  in  silico  Drug  Discovery  framework  (CiDD)  for  the  identification  of  candidate  
chemopreventive  drugs.    These  three  pieces  of  software  (see  green  boxes  in  Figure  3)  are  
described  in  detail  in  three  subsections  of  “Appendix  B:  Bioinformatics  software”.  
  
  
  

  

  

11  

2 Genomic  characterization  of  FAP  polyps  
In  the  adenoma-‐‑to-‐‑carcinoma  sequence,  it  has  been  described  that  WNT  pathway  activation,  
which  normally  arises  through  bi-‐‑allelic  loss  of  the  APC  gene,  is  the  initiating  event  in  the  
development  of  adenomas,  which  are  pre-‐‑malignant  lesions5.    Further,  KRAS  mutations  are  
often  present  when  an  adenoma  transitions  to  later  stages  (e.g.,  the  development  of  high-‐‑grade  
dysplasia),  and  subsequently,  alterations  in  PIK3CA  and  TP53  or  other  genes  occur  during  the  
progression  into  an  invasive  adenocarcinoma,  or  cancer.    We  sought  to  characterize  the  genome  
of  adenomas  through  exome  sequencing  to  further  refine  the  somatic  alterations  and  genes  that  
might  be  involved  in  adenoma  development  to  identify  candidate  targets  for  chemoprevention.    
In  this  chapter,  I  describe  the  mutation  and  chromosomal  allelic  imbalance  profiles  of  FAP  
polyps  and  compare  them  to  profiles  of  CRC  from  TCGA.    A  special  emphasis  is  placed  on  
identifying  somatic  APC  events  and  alterations  in  WNT  signaling  since  these  events  are  
expected  to  be  key  initiating  events  of  adenoma  formation.    I  conclude  by  proposing  a  list  of  
candidate  genes  that  may  contribute  to  the  initiation  or  development  of  adenomas.  
  

2.1 Methods  
2.1.1

Available  patients  and  samples  
To  characterize  somatic  alterations  in  polyps  of  FAP  patients,  we  conducted  a  genome-‐‑

wide  analysis  of  polyps  from  12  patients.    Samples  for  4  patients  were  collected  at  the  Catalan  
Institute  of  Oncology.    Colon  polyp  and  normal  mucosa  samples  from  these  patients  were  
extracted  after  prophylactic  surgical  resection  of  the  colon.    Colon  polyp  and  normal  mucosa  
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samples  from  8  additional  patients  were  collected  at  MD  Anderson  Cancer  Center  through  
endoscopic  excision.    Germline  DNA  was  extracted  from  peripheral  blood  lymphocytes  using  
the  Blood  &  Cell  Culture  DNA  Mini  Kit  (Qiagen).    Polyp  and  normal  mucosa  DNA  was  extracted  
using  the  QIAmp  DNA  Mini  Kit  (Qiagen).    A  blood  sample  and  one  or  more  polyp  samples  were  
collected  from  each  patient  with  a  total  of  25  polyps  analyzed.    Additionally,  for  11  of  the  12  
patients,  a  normal  mucosa  sample  was  obtained.    
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Person

CATA01

CATA02

CATA03

CATA04

MDAC01

MDAC02

MDAC08

MDAC10

MDAC14

MDAC17

MDAC18

MDAC20

Tissue*Type

Sample*Name

Blood
Normal1Mucosa
Polyp
Polyp
Polyp
Polyp
Blood
Normal1Mucosa
Polyp
Polyp
Polyp
Blood
Normal1Mucosa
Polyp
Blood
Normal1Mucosa
Polyp
Polyp
Polyp
Polyp
Blood
Normal
Polyp
Polyp
Blood
Polyp
Blood
Normal
Polyp
Polyp
Blood
Normal
Polyp
Blood
Normal
Polyp
Polyp
Polyp
Blood
Normal
Polyp
Polyp
Blood
Normal
Polyp
Blood
Normal
Polyp

CATA01_B01_Vilar01
CATA01_N01_Vilar02
CATA01_P01_Vilar13
CATA01_P02_Vilar16
CATA01_P03_Vilar17
CATA01_P04_Vilar18
CATA02_B01_Vilar04
CATA02_N01_Vilar05
CATA02_P01_Vilar14
CATA02_P02_Vilar19
CATA02_P03_Vilar21
CATA03_B01_Vilar07
CATA03_N01_Vilar08
CATA03_P01_Vilar15
CATA04_B01_Vilar10
CATA04_N01_Vilar11
CATA04_P01_Vilar12
CATA04_P02_Vilar22
CATA04_P03_Vilar23
CATA04_P04_Vilar24
MDAC01_B01_Vilar44
MDAC01_N01_Vilar43
MDAC01_P01_Vilar41
MDAC01_P02_Vilar42
MDAC02_B01_Vilar46
MDAC02_P01_Vilar45
MDAC08_B01_Vilar50
MDAC08_N01_Vilar49
MDAC08_P01_Vilar47
MDAC08_P02_Vilar48
MDAC10_B01_Vilar53
MDAC10_N01_Vilar52
MDAC10_P01_Vilar51
MDAC14_B01_Vilar58
MDAC14_N01_Vilar57
MDAC14_P01_Vilar54
MDAC14_P02_Vilar55
MDAC14_P03_Vilar56
MDAC17_B01_Vilar62
MDAC17_N01_Vilar61
MDAC17_P01_Vilar59
MDAC17_P02_Vilar60
MDAC18_B01_Vilar65
MDAC18_N01_Vilar64
MDAC18_P01_Vilar69
MDAC20_B01_Vilar68
MDAC20_N01_Vilar67
MDAC20_P01_Vilar66

APC*Germline*Mutation*(cDNA) APC*Germline*Mutation*(protein)

c.3927_3931delAAAGA1

p.Glu1309Aspfs*4

c.4393_4394delAG

p.Ser1465Trpfs*3

c.1[1958+3G>A(;)c.1959G>A]

HHH

c.1412delG

p.Gly471Aspfs*27

c.1880dupA

p.Ala630*

c.3810T>A

p.Cys1270*

c.622C>T1

p.Gln208*

c.3440dupA

p.Ser1148Thrfs*18

del18H9

HHH

c.1658G>A

p.Trp553*

c.4393_4394delAG

p.Ser1465Trpfs*3

c.477C>G

p.Tyr159*

  

Table  1:  FAP  patients,  samples  collected  for  exome  sequencing  and  their  APC  germline  mutations.  

  
2.1.2

Data  collection  
Exome  DNA  was  captured  using  the  SeqCap  EZ  Human  Exome  library  v3.0  capture  chip  

from  Roche  NimbleGen,  which  has  a  target  capture  region  of  64  Mb.    Samples  were  sequenced  
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on  an  Illumina  HiSeq  2000  sequencer  with  76  base  paired-‐‑end  reads  at  a  mean  depth  of  80  reads  
(or  “80x”)  at  the  MD  Anderson  Cancer  Center  sequencing  core  facility.    Reads  were  aligned  
with  the  Burrows-‐‑Wheeler  Alignment  software  (BWA)29  to  the  reference  human  genome  version  
hg19.    The  initial  alignment  results  were  further  processed  with  local  realignment,  duplicate  
read  marking  and  base  quality  recalibration  by  using  Picard  and  the  Genome  Analysis  Toolkit  
(GATK)30  and  by  applying  recommended  best  practices  for  sequence  analysis  from  the  Broad  
Institute.  For  a  complete  description  of  the  sequence  alignment  pipeline,  see  section  5.1  in  
Appendix  A.    After  filtering  for  only  those  reads  that  map  to  the  target  exome  region,  the  mean  
on-‐‑target  depth  was  64x  (see  Table  2).    
  

  

15  

Sample'Name
Target'Mean'Depth %@10X %@20X %@50X %@100X
CATA01_B01_Vilar01
85.23
0.959
0.923
0.892
0.721
CATA01_N01_Vilar02
85.14
0.959
0.921
0.889
0.714
CATA01_P01_Vilar13
90.7
0.970
0.940
0.916
0.764
CATA01_P02_Vilar16
70.29
0.969
0.930
0.878
0.577
CATA01_P03_Vilar17
71.83
0.970
0.932
0.879
0.582
CATA01_P04_Vilar18
72.39
0.971
0.933
0.884
0.595
CATA02_B01_Vilar04
90.95
0.961
0.927
0.899
0.745
CATA02_N01_Vilar05
84.52
0.962
0.928
0.900
0.723
CATA02_P01_Vilar14
71.19
0.963
0.920
0.880
0.621
CATA02_P02_Vilar19
78.75
0.964
0.929
0.896
0.680
CATA02_P03_Vilar21
74.87
0.964
0.928
0.890
0.642
CATA03_B01_Vilar07
77.54
0.967
0.923
0.870
0.604
CATA03_N01_Vilar08
69.46
0.955
0.901
0.834
0.533
CATA03_P01_Vilar15
63.29
0.960
0.908
0.851
0.535
CATA04_B01_Vilar10
74.76
0.941
0.856
0.788
0.550
CATA04_N01_Vilar11
71.14
0.950
0.888
0.819
0.539
CATA04_P01_Vilar12
81.57
0.975
0.942
0.905
0.666
CATA04_P02_Vilar22
79.26
0.968
0.935
0.896
0.653
CATA04_P03_Vilar23
74.1
0.968
0.932
0.886
0.606
CATA04_P04_Vilar24
66.22
0.967
0.925
0.859
0.528
MDAC01_B01_Vilar44
45.65
0.978
0.921
0.812
0.294
MDAC01_N01_Vilar43
43.32
0.979
0.910
0.771
0.270
MDAC01_P01_Vilar41
45.08
0.985
0.923
0.801
0.289
MDAC01_P02_Vilar42
49.44
0.984
0.923
0.815
0.346
MDAC02_B01_Vilar46
62.46
0.983
0.941
0.881
0.507
MDAC02_P01_Vilar45
58.75
0.981
0.935
0.863
0.464
MDAC08_B01_Vilar50
71.72
0.987
0.949
0.905
0.600
MDAC08_N01_Vilar49
28.69
0.982
0.841
0.536
0.116
MDAC08_P01_Vilar47
29.4
0.979
0.862
0.574
0.109
MDAC08_P02_Vilar48
62.07
0.982
0.938
0.874
0.498
MDAC10_B01_Vilar53
63.4
0.982
0.942
0.889
0.527
MDAC10_N01_Vilar52
69.91
0.983
0.944
0.899
0.588
MDAC10_P01_Vilar51
65.94
0.983
0.942
0.890
0.548
MDAC14_B01_Vilar58
44.69
0.982
0.919
0.800
0.287
MDAC14_N01_Vilar57
42.59
0.984
0.919
0.790
0.256
MDAC14_P01_Vilar54
58.93
0.980
0.938
0.877
0.478
MDAC14_P02_Vilar55
62.26
0.984
0.942
0.885
0.514
MDAC14_P03_Vilar56
65.1
0.984
0.944
0.891
0.544
MDAC17_B01_Vilar62
61.37
0.985
0.940
0.876
0.496
MDAC17_N01_Vilar61
60.33
0.985
0.941
0.875
0.486
MDAC17_P01_Vilar59
45.32
0.985
0.921
0.801
0.294
MDAC17_P02_Vilar60
44.45
0.983
0.923
0.803
0.280
MDAC18_B01_Vilar65
66.48
0.987
0.946
0.891
0.549
MDAC18_N01_Vilar64
58.7
0.985
0.936
0.859
0.463
MDAC18_P01_Vilar69
57.13
0.980
0.910
0.793
0.426
MDAC20_B01_Vilar68
60.81
0.986
0.941
0.876
0.488
MDAC20_N01_Vilar67
60.89
0.987
0.945
0.885
0.493
MDAC20_P01_Vilar66
55.53
0.986
0.939
0.862
0.427

  

Table  2:  Exome  coverage  summary  for  FAP  samples.    The  on-‐‑target  mean  depth  is  64x  with  an  average  of  92.5%  of  
the  target  regions  being  covered  by  at  least  20x.  

  
Each  individual  and  sample  is  characterized  by  a  germline  mutation  in  the  APC  gene  as  
described  in  Table  1.    The  vast  majority  of  FAP  patients  are  characterized  by  nonsense  
mutations  on  the  5’  half  of  APC  as  were  our  samples.    Germline  mutations  were  verified  in  each  
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sample  through  visualization  of  aligned  sequence  reads  in  the  Integrative  Genomics  Viewer  (IGV)  
software31.      
2.1.3

Strategies  for  calling  somatic  events  
We  performed  exome  sequencing  to  identify  somatic  events  in  our  polyp  samples  

including  point  mutations,  insertions,  deletions  and  chromosomal  allelic  imbalance  (AI)  events,  
which  we  define  as  large  amplifications,  deletions  and  loss-‐‑of-‐‑heterozygosity  (LOH)  event  regions  
of  greater  than  10  MB.    Data  not  analyzed  include  small  copy  number  variants  (CNV)  less  than  10  
MB  and  structural  variations  such  as  translocations  and  inversions.    These  data  are  typically  
analyzed  using  SNP  arrays  and  whole  genome  sequencing,  respectively.    With  the  exception  of  
the  verification  of  APC  germline  mutations  in  the  blood  and  normal  mucosa  samples,  the  
current  focus  of  our  project  is  on  somatic  variation.    Thus,  blood  and  normal  samples  were  
simply  used  as  reference  samples  to  allow  for  the  characterization  of  polyp  events  as  somatic  
(versus  germline).    Inspecting  somatic  variation  in  normal  mucosa  samples  is  the  subject  of  
future  work  and  is  out  of  scope  of  this  dissertation.    Figure  4  illustrates  three  general  pipelines  
and  the  associated  software  that  have  been  implemented  for  the  genomic  characterization  of  
FAP  polyps,  which  are  the  following:  (1)  alignment  and  quality  control  of  sequencing  reads  (in  
black)  as  described  previously,  (2)  calling  and  controlling  of  false  positives  for  somatic  point  
mutations  and  indels  (in  red),  and  (3)  calling  of  chromosomal  allelic  imbalance  events  (in  blue).    
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Exome&sequencing&for&12&FAP&pa7ents&
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Figure  4:  Simplified  pipelines  for  the  alignment  of  sequencing  reads  (black),  calling  of  somatic  point  mutations,  and  
indels  (red)  and  identification  of  chromosomal  allelic  imbalance  events  (blue)  from  exome  sequencing  data.  

  
Mutect32  was  run  for  calling  point  mutations  and  Indelocator30  was  executed  for  calling  
small  insertions  and  deletions  (see  Figure  4).    Mutect  and  Indelocator  were  designed  for  calling  
mutations  and  indels  in  the  context  of  low  tumor  purity  and  for  identifying  subclonal  events  
making  them  suitable  in  the  context  of  pre-‐‑cancerous  lesions.    To  control  for  false  positives,  we  
annotated  mutations  with  public  databases  and  applied  a  filtering  strategy  to  remove  putative  
mutations  that  were  likely  to  be  common  polymorphisms.    Specifically,  any  somatic  mutation  
that  has  been  identified  as  a  germline  variant  in  a  public  sequencing  project  is  likely  to  be  a  false  
positive  mutation  call.    This  “mutation”  is  likely  a  germline  variant  that  was  correctly  identified  
in  a  polyp  sample  but  failed  detection  in  the  paired  blood  sample.      
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To  support  this  part  of  the  event  calling  pipeline,  we  developed  variant  tools  (vtools),  a  
flexible  annotation  and  analysis  toolset  that  greatly  simplifies  the  storage,  annotation  and  
filtering  of  variants  and  the  analysis  of  the  underlying  samples33.    Storing,  annotating  and  
analyzing  variants  from  NGS  projects  can  be  difficult  due  to  the  availability  of  a  wide  array  of  
data  formats,  tools  and  annotation  sources,  as  well  as  the  sheer  size  of  the  data.    Useful  tools,  
including  the  GATK30,  ANNOVAR34  and  BEDTools35,  can  be  integrated  into  custom  pipelines  for  
annotating  and  analyzing  sequence  variants.    However,  building  flexible  pipelines  that  support  
the  tracking  of  variants  alongside  their  samples,  while  enabling  updated  annotation  and  re-‐‑
analyses  is  not  a  simple  task.    Using  a  command-‐‑line  driven  reporting  structure,  variant  tools  can  
be  used  to  manage  and  analyze  genetic  variants  obtained  from  sequence  alignments,  and  the  
toolset  could  be  used  as  a  foundation  for  building  more  sophisticated  analytical  pipelines.    The  
variant  tools  concept  is  illustrated  in  Figure  5  and  its  functions  are  described  in  more  detail  in  
Appendix  B  section  6.1.  
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Figure  5:  Overview  of  variant  tools33.    This  software  facilitates  the  management,  annotation  and  analysis  of  genetic  
variants  from  NGS  studies.  

Somatic  events  called  by  Mutect  and  Indelocator  were  annotated  through  variant  tools  
with  population  allele  frequencies  of  the  1000  Genomes  Project36  and  the  Exome  Sequencing  Project  
(version  with  6,500  exomes)  a  for  subsequent  filtering  of  likely  common  polymorphisms  and  
false  positives.    We  excluded  any  candidate  somatic  mutations  seen  at  1%  or  greater  population  
allele  frequency  in  either  of  these  projects.  
In  order  to  further  limit  false  positive  calls  after  filtering  based  on  annotations,  we  
developed  a  simple  sequencing  read  verification  pipeline  to  help  control  for  systematic  sequencing  
errors.    The  pipeline  identifies  potential  errors  by  looking  for  evidence  of  variant  reads  in  
normal  samples  at  all  sites  where  somatic  events  were  called.    The  verification  pipeline  
implements  the  following  workflow:  
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1. Create  a  master  list  of  all  the  putative  somatic  mutations  identified  in  all  polyps.  
2. Obtain  a  genotype  call  (from  the  UnifiedGenotyper  of  the  GATK)  and  the  variant  allele  
fraction  at  all  of  the  sites  in  the  master  list  for  all  FAP  samples  including  blood,  normal  
mucosa  and  polyp  samples.    A  variant  allele  fraction  for  a  site  is  the  number  of  reads  
harboring  the  variant  allele  divided  by  the  total  number  of  reads  covering  that  site.  
3. For  each  putative  somatic  mutation,  mark  it  as  “failed  verification”  if  any  of  the  
following  are  true:  
a. a  germline  genotype  call  in  any  blood  or  normal  mucosa  sample  in  our  project  
contains  the  variant  allele  (with  the  exception  of  APC  germline  mutations  which  
may  also  be  seen  as  a  somatic  mutation  in  a  polyp),  
b. the  variant  allele  fraction  is  2%  or  greater  in  the  paired  blood  sample,  or  
c. the  variant  allele  fraction  is  5%  or  greater  in  the  paired  normal  mucosa  sample.  
Finally,  we  visually  verified  point  mutations  and  insertions  and  deletions  using  IGV.    In  
total,  through  our  filtering  process  we  reduced  the  3,454  original  point  mutation  calls  to  1,943  
visually  verified  point  mutations.    For  insertions  and  deletions,  we  reduced  the  454  original  
calls  to  199  visually  verified  calls.  
A  description  of  the  pipeline  for  calling  chromosomal  allelic  imbalance  (AI)  events  is  
described  in  Appendix  A,  section  5.4.    This  pipeline  prepares  data  and  runs  hapLOHseq,  
software  that  we  developed,  for  identifying  regions  of  chromosomal  AI,  which  I  describe  in  
Appendix  B,  section  6.2.  
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2.1.4

Prioritizing  and  validating  mutations  
For  prioritization  of  events,  mutations  were  annotated  using  variant  tools  with  functional  

prediction  statuses  as  determined  by  PolyPhen237,  LRT38,  SIFT39  and  MutationTaster40.    These  
predictions  were  pre-‐‑calculated  by  dbNSFP41.    In  addition,  driver  prediction  statuses  for  each  
point  mutation  were  obtained  by  running  CHASM42.    Finally,  recurrence  of  events  in  existing  
cancer  data  sets  was  assessed  by  annotating  mutations  with  the  COSMIC  database43  through  
variant  tools.  
A  strategy  for  categorizing  mutations  into  functional  tiers  was  then  applied  to  all  somatic  
events.    First,  indels  and  stop  gain  (or  nonsense)  and  loss  mutations  were  separated  into  their  
own  tiers.    Then  the  remaining  mutations  were  prioritized  using  the  following  tier  definitions  
where  lower  tier  numbers  correspond  to  higher  priorities.  
•

Tier  1:  Driver  mutations  –  classified  as  a  driver  mutation  (based  on  an  empirical  p-‐‑value  
≤  0.05  from  CHASM)  and  seen  in  multiple  (2  or  more)  other  tumors  in  the  COSMIC  
database  

•

Tier  2:  Damaging  recurrent  mutations  –  predicted  to  be  damaging  by  2  or  more  
algorithms  and  seen  in  multiple  (2  or  more)  other  tumors  in  the  COSMIC  database  

•

Tier  3:  Damaging  mutations  –  predicted  to  be  damaging  by  2  or  more  algorithms    

•

Tier  4:  Potentially  damaging  mutations  –  predicted  to  be  damaging  by  1  algorithm  

•

Tier  5:  Passenger  mutations  –  remaining  point  mutations  that  are  not  stop  gains  or  stop  
losses  
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Stop  gains  and  losses  –  any  mutation  that  results  in  a  nonsense  mutation,  such  that  the  

•

gene  is  prematurely  truncated,  or  any  mutation  that  alters  an  existing  stop  codon,  such  
that  the  gene  is  elongated  
Functional  insertions  and  deletions  –  any  insertion  or  deletion  in  the  coding  region  of  a  

•

gene.  
  
Tier
Number)of)events
Tier%1:%Driver%mutations
52
Tier%2:%Damaging%recurrent%mutations
22
Tier%3:%Damaging%mutations
214
Tier%4:%Potentially%damaging%mutations
170
Tier%5:%Passenger%mutations
1434
Stop%gains%and%losses
51
Functional%insertions%and%deletions
18
  
Table  3:  Number  of  somatic  events  per  tier  definition  

  
Mutations  identified  in  APC  or  in  known  colorectal  cancer  genes  or  those  predicted  to  be  
driver  mutations  in  Tier  1  have  been  validated  with  Sanger  sequencing  in  cases  where  we  have  
enough  DNA  to  perform  the  sequencing.      Primers  for  amplification  and  sanger  sequencing  
validation  were  designed  by  using  a  custom  pipeline  that  incorporates  Primer344  that  targeted  
mutations  with  50  bases  of  flanking  DNA  sequence  on  the  5’  and  3’  ends  of  the  mutation.    
Sanger  sequencing  was  performed  on  an  ABI  3730  Capillary  DNA  Analyzer.    Sequence  trace  
files  were  manually  inspected  for  the  verification  of  point  mutations,  insertions  and  deletions.    
(Table  for  validated/failed  mutations?)  
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2.1.5

Strategy  for  identifying  candidate  genes  involved  in  early  CRC  development  
Our  strategy  for  identifying  important  candidate  genes  involved  in  the  early  development  

of  CRC  was  to  find  recurrently  mutated  genes  in  our  data  set  that  have  been  previously  
identified  as  CRC  genes.    We  identified  CRC  genes  from  3  large-‐‑scale  projects:  TCGA  colorectal  
project28,  Vogelstein  et  al45  and  Seshagiri  et  al46.    We  also  interrogated  pathways  known  to  be  
deregulated  in  CRC:  most  importantly,  the  WNT,  MAPK  and  ERBB  signaling  pathway.    We  
identified  the  genes  for  these  pathways  using  the  Molecular  Signatures  Database  (MSigDB)47.    If  a  
sample  had  a  nonsynonymous  mutation  on  any  gene  in  a  given  pathway,  that  sample  was  
labeled  as  having  an  alteration  in  that  pathway.  
  

2.2 FAP  polyp  genomic  profiles  
Here,  I  present  a  characterization  of  the  genomic  landscape  of  FAP  adenomas  based  on  
the  exome  sequence  data.    I  compare  mutation  rates  and  base  substitution  profiles  between  FAP  
polyps  and  CRC  tumors.    Somatic  alterations  in  APC  and  other  previously  identified  CRC  genes  
are  characterized.    Additionally,  recurrent  chromosomal  allelic  imbalance  events,  which  we  
define  as  amplifications,  deletions  and  copy-‐‑neutral  loss-‐‑of-‐‑heterozygosity  (cn-‐‑LOH)  events  are  
identified  and  interpreted  in  the  context  of  the  adenoma-‐‑to-‐‑carcinoma  sequence.    In  total,  52  
genes  that  have  previously  been  associated  with  CRC  and  that  are  recurrently  altered  in  our  
adenomas  are  proposed  as  candidate  genes  involved  in  the  early  development  of  CRC.    These  
genes  will  be  followed  up  with  functional  studies  in  future  projects.      
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2.2.1

Mutation  profiling  
To  minimize  batch  effects  in  our  comparisons  between  our  FAP  polyps  and  TCGA  CRC  

samples,  we  downloaded  107  tumor/normal  pairs  of  exomes  from  the  TCGA  project  where  the  
samples  were  sequenced  on  the  Illumina  Hiseq  machine  (the  same  sequencing  technology  used  
for  our  FAP  polyps)  and  we  ran  these  samples  through  the  same  bioinformatics  pipelines  on  
which  we  ran  our  FAP  samples.    Of  the  107  CRC  tumor  exomes  downloaded,  22.4%  (24  of  107)  
of  the  tumors  were  stage  I,  42.1%  (45  of  107)  were  stage  II,  21.5%  (23  of  107)  were  stage  III  and  
11.2%  (12  of  107)  were  stage  IV  tumors.    Three  samples  lacked  tumor  stage  classifications.    The  
same  pipelines  that  were  used  with  our  FAP  polyps  to  identify  somatic  point  mutations  and  
generate  mutation  reports  were  applied  to  the  CRC  exomes.  
2.2.1.1

Mutation  rates  

We  assessed  the  similarity  of  mutation  rates  and  base  substitution  profiles  from  TCGA  
CRC  samples  and  FAP  polyps.    In  the  TCGA  CRC  publication28,  the  authors  identified  2  classes  
of  samples  based  on  mutation  rates:  hypermutators  (samples  with  greater  than  10  mutations/Mb)  
and  nonhypermutators  (samples  with  less  than  10  mutations/Mb).      The  samples  that  we  
downloaded  from  the  TCGA  were  not  included  as  part  of  the  results  in  the  TCGA  CRC  
manuscript  because  they  are  newer  samples,  sequenced  after  the  manuscript  was  published.    
We  identified  the  mutation  rates  for  the  TCGA  CRC  samples  and  recapitulated  the  
hypermutator  and  nonhypermutator  findings  of  the  TCGA  in  these  newer  samples  and  
subsequently  treated  these  two  classes  of  samples  separately  (see  Figure  7).    Mutation  rates  are  
represented  as  the  number  of  mutations  per  megabase  for  each  sample.  
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(1)  

  
For  a  base,  or  a  specific  nucleotide  position  in  a  polyp  genome,  to  be  callable,  a  minimum  
coverage  of  12x  in  the  polyp  sample  and  a  minimum  coverage  of  8x  in  the  corresponding  blood  
sample  from  the  same  patient  is  required.    These  minimum  coverage  requirements  result  in  80%  
power  to  identify  mutations  by  the  Mutect  software32.    The  total  number  of  callable  bases  is  then  
the  denominator  in  the  mutation  rate  calculation.  
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Figure  6:  TCGA  CRC  tumors  can  be  classified  into  one  of  two  groups  based  on  mutation  rate:  hypermutated  for  
mutation  rates  greater  than  10  mutations  per  megabase  or  nonhypermutated  otherwise  

  
Mutation  rates  of  FAP  polyps  (mean  mutation  rate  =  1.74  mutations/Mb)  are  lower  than  
that  of  nonhypermutated  CRCs  (mean  mutation  rate  =  4.26  mutations/Mb;  T-‐‑Test  p-‐‑value  =  
8.92e-‐‑13)  as  expected  since  adenomas  are  in  an  earlier  stage  of  tumorigenesis  compared  to  
carcinomas.    The  mutation  rates  identified  in  the  FAP  polyps  overlapped  those  of  TCGA  CRC  
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nonhypermutated  samples  (see  the  mutation  rate  boxplot  of  Figure  7).    The  polyp  mutation  rate  
is  an  order  of  magnitude  smaller  than  that  of  hypermutated  CRCs  (mean  mutation  rate  =  50.88  
mutations/Mb).    We  expect  this  because  FAP  polyps  are  not  characterized  by  alterations  in  
mismatch  repair  genes,  which  generally  typify  microsatellite  instable  and  hypermutated  
carcinomas.    A  contributing  factor  of  the  mutation  rate  difference  between  polyps  and  
nonhypermutated  CRCs  could  be  due  to  a  lower  power  to  detect  mutations  in  polyps  because  
of  potentially  higher  normal  mucosa  contamination  as  compared  to  TCGA  CRC  samples.      
  

  
Figure  7:  FAP  polyp  mutation  rates  compared  to  TCGA  hypermutated  and  nonhypermutated  CRCs  
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2.2.1.2

Mutation  base  substitution  signatures  

One  strategy  for  identifying  candidate  mechanisms  that  drive  tumor  mutational  processes  
is  to  evaluate  mutation  base  substitution  signatures.    Figure  8  illustrates  mutation  base  
substitution  signatures  across  several  cancer  types.    In  each  signature  plot  at  the  bottom  of  
Figure  8,  vertical  bars  represent  the  base  substitution  frequencies  for  individual  tumor  samples  
of  the  corresponding  cancer  type.    Based  on  these  profiles,  we  can  attempt  to  infer  mutational  
processes  that  are  the  source  of  the  base  substitution  signatures.      For  example,  the  high  C-‐‑>T  
substitutions  in  melanoma  samples  can  be  attributed  to  UV  exposure.    The  high  C-‐‑>A  
substitutions  in  lung  cancer  samples  are  thought  to  be  attributed  to  tobacco  smoke  exposure48.  
  

  
Figure  8:  Mutational  signatures  across  cancer  types  49.  

  
To  refine  the  mutation  signatures  of  Figure  8,  Alexandrov  et  al  identified  base  substitution  
profiles  at  a  higher  resolution  by  incorporating  flanking  bases  for  each  base  substitution48.    For  
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example,  instead  of  identifying  the  numbers  of  C-‐‑>T  substitutions,  they  incorporated  all  
possible  combinations  of  flanking  bases  around  the  C  and  T  (e.g.,  ACG  -‐‑>  ATG,  ACC  -‐‑>  ATC,  
….).    After  doing  this,  they  associated  their  refined  base  substitution  signatures  with  mutational  
mechanisms  for  several  cancers.    They  associated  CRC  mutation  signatures  with  3  distinct  
mutational  processes:  (1)  a  strand-‐‑specific  mutational  process  due  to  POLE  mutations,  (2)  DNA  
mismatch  repair  deficiency  and  (3)  aging  mechanisms48.    Using  this  flanking-‐‑base  strategy,  there  
are  96  possible  base  substitutions  comprising  their  mutation  signatures.    Many  of  our  samples  
have  fewer  than  96  mutations,  thus  we  are  not  reliably  able  to  perform  a  similar  analysis  on  our  
polyp  data.    So  we  make  a  more  qualitative  comparison  between  sample  types  by  comparing  
the  base  substitution  profiles  of  Figure  9.  
  

  
Figure  9:  Base  substitution  profiles  of  FAP  polyps  versus  TCGA  hypermutated  and  nonhypermutated  CRCs  suggest  
that  the  FAP  polyps  have  similar  mutation  processes  underlying  them  compared  to  TCGA  CRC  nonhypermutated  
tumors  
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Based  on  base  substitution  profiles,  the  mutation  signature  of  FAP  polyps  resemble  that  of  
nonhypermutated  CRCs,  suggesting  that  the  mutational  processes  behind  nonhypermutated  
CRCs  are  the  same  as  those  for  FAP  polyps.    Hypermutators  are  largely  microsatellite-‐‑high  
tumors  with  one  or  more  mutations  in  DNA  mismatch  repair  genes  or  mutations  in  POLE28.    
Neither  of  these  genes  was  identified  as  mutated  in  analyses  of  our  FAP  polyps,  leaving  aging  
or  an  unidentified  mutational  process  as  the  likely  source  of  mutations  in  FAP  adenomas.  
  
2.2.1.3

Variant  allele  fraction  profiling  

Another  strategy  for  mutation  profiling  is  in  the  analysis  of  variant  allele  fractions  (VAFs).  
Analysis  of  VAFs  can  provide  insights  into  the  purity  and  clonality  of  samples.    The  variant  (or  
mutation)  allele  fraction,  f  for  a  particular  somatic  mutation  m  is:  
  
  

𝑓! =   

𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑣𝑎𝑟𝑖𝑎𝑛𝑡  𝑟𝑒𝑎𝑑𝑠!
  
𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑟𝑒𝑎𝑑𝑠!

(2)  

  
VAFs  for  mutations  in  chromosomal  allelic  imbalance  regions  (see  section  2.2.2)  were  
ignored  in  addition  to  mutations  on  chromosomes  X  and  Y.    In  this  way,  only  somatic  
mutations  in  copy  neutral  autosomal  regions  were  included  in  the  VAF  profiling  analyses.    The  
resulting  VAF  distributions  of  the  somatic  mutations  identified  in  2  polyps  are  illustrated  in  
Figure  10.    In  the  CATA01_P04_Vilar18  sample,  the  VAF  distribution  is  shifted  close  to  0  with  a  
mean  VAF  of  around  0.08.      All  the  VAF  values  CATA01_P04_Vilar18  are  smaller  than  0.2  
reflecting  that  these  mutations  all  occur  in  a  small  proportion  of  the  cells  sequenced.    Thus,  we  
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infer  that  this  sample  has  low  polyp  purity.    In  contrast,  the  VAF  distribution  for  
CATA04_P01_Vilar12  has  two  peaks,  which  represents  VAFs  for  multiple  clones.    The  founding  
clone  has  a  mean  VAF  at  around  0.35.    To  get  a  simple  estimate  of  purity,  we  can  multiply  this  
VAF  by  2  because  these  variants  are  all  heterozygous  genotypes,  and  we  would  expect  to  see  
the  variant  alleles  in  the  founding  clone  in  approximately  one-‐‑half  of  these  reads  (assuming  no  
copy  number  alterations).    This  would  indicate  that  this  sample  has  good  polyp  purity,  with  a  
purity  estimate  of  0.7  (purity  =  0.35  *  2  =  0.7).    
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Figure  10:  The  distributions  of  variant  allele  fractions  can  be  interpreted  to  identify  samples  of  low  polyp  purity  or  to  
characterize  samples  exhibiting  patterns  of  multi-‐‑clonality.  

  
If  we  generate  VAF  distribution  plots  for  all  polyps  and  assess  multi-‐‑clonality,  we  can  
easily  identify  5  polyps  that  show  evidence  of  being  comprised  of  at  least  2  major  clones  (see  
Figure  11).    In  addition,  several  polyps  have  VAF  distributions  tightly  shifted  near  0,  indicating  
as  we  expected,  that  these  polyps  have  low  purity  and  are  challenging  to  genomically  
characterize.      
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Figure  11:  Distributions  of  variant  allele  fractions  for  all  25  polyps.    Several  polyps  show  evidence  of  multi-‐‑clonality  
(with  their  variant  allele  fraction  plots  boxed  in  red)  suggesting  that  they  are  acquiring  driver  mutations  and  
evolving  and  potentially  progressing  to  carcinomas.  

  
Figure  12  illustrates  VAFs  for  all  of  the  mutations  identified  in  each  FAP  polyp  using  
boxplots.    In  addition,  the  boxplots  indicate  whether  or  not  each  polyp  had  a  somatic  mutation  
in  APC,  and  if  so,  a  red  dot  indicates  the  VAF  of  that  APC  mutation.    We  identified  somatic  APC  
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mutations  in  52%  (13  of  25)  of  polyps.    For  those  samples  with  APC  mutations,  the  APC  
mutations  generally  have  a  higher  mutation  allele  fraction  compared  to  other  polyp  mutations  
suggesting  that  somatic  APC  mutations  are  initiating  events  and  reside  in  the  founding  clone  of  
polyps.      
  

  
Figure  12:  Mutation  allele  fractions  for  APC  somatic  events  relative  to  those  of  other  somatic  events  in  the  25  FAP  
polyps.      Samples  are  ordered  and  grouped  by  patient  IDs,  where  this  illuminates  a  potential  batch  effect  with  
regards  to  polyp  purity.    For  example,  CATA01  and  CATA02  samples  appear  to  have  lower  allele  fractions  and  purity  
relative  to  CATA03,  CATA04,  MDAC01  and  others,  indicating  that  fluctuations  in  purity  levels  may  be  influenced  by  
the  persons  and  processes  used  to  obtain  the  polyp  samples.  
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Several  of  the  samples  without  an  APC  somatic  event  exhibit  lower  mutation  allele  
fractions,  reflecting  lower  purity  in  these  samples  and  suggesting  a  lower  power  to  detect  APC  
mutations.    Another  possibility  is  that  a  chromosomal  allelic  imbalance  event,  such  as  a  deletion  
or  copy-‐‑neutral  LOH  event  may  be  the  source  of  inactivation  of  the  second  APC  allele.  
  
2.2.2

Chromosomal  allelic  imbalances  
A  well-‐‑studied  mechanism  by  which  cancer  cells  alter  the  activity  of  tumor  suppressor  

genes  and  oncogenes  is  through  fluctuations  in  gene  dosage.    For  FAP,  deletion  or  LOH  of  
chromosome  5q,  where  APC  resides,  is  a  known  mechanism  of  APC  loss50.    In  this  project,  we  
searched  for  such  chromosomal  allelic  imbalance  (AI)  events  in  exome  sequencing  data.    We  define  
these  AI  events  as  genomic  aberrations  of  greater  than  10MB  due  to  amplifications,  deletions  
and  cn-‐‑LOH  events.      
  
2.2.2.1

Identifying  chromosomal  AI  events  from  exome  sequencing  data  with  hapLOHseq  

Typically,  data  from  array  comparative  genomic  hybridization  (aCGH)  or  single  nucleotide  
polymorphism  (SNP)  arrays  are  analyzed  for  the  identification  of  copy  number  and  AI  events.    
Often  these  experiments  are  performed  in  addition  to  exome  or  whole  genome  sequencing  on  
tumor  samples28.    However,  due  to  limitations  in  sample  DNA,  we  were  not  able  to  run  such  
experiments  on  the  same  polyps  from  which  exome  sequencing  was  performed.    For  this  
reason,  we  interpreted  chromosomal  AI  events  from  exome  sequencing  data  through  the  
development  of  new  software  called  hapLOHseq.    
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The  traditional  strategy  behind  identification  of  AI  events  is  finding  bands  of  separation  as  
illustrated  in  the  simulated  VAF  band  plots  of  Figure  13.      These  plots  show  the  VAFs  for  
heterozygous  sites  across  a  region  of  the  genome.    In  “normal”  regions  of  the  genome,  we  
would  expect  that  at  heterozygous  sites,  50%  of  reads  would  harbor  the  variant  allele  and  the  
other  50%  would  harbor  the  reference  allele.    Thus,  in  “normal”  regions  we  would  expect  to  see  
a  VAF  band  at  0.5.    This  is  illustrated  with  the  normal  sample  of  Figure  13.    In  the  100%  tumor  
sample,  there  is  an  AI  event,  which  results  in  the  frequencies  of  the  alleles  of  one  haplotype  (e.g.,  
a  configuration  of  alleles  on  one  chromosome)  to  elevate  in  excess  of  the  second  haplotype  
where  the  allele  frequencies  decreased,  resulting  in  2  separate  bands  showing  the  deviation  of  
the  VAFs  from  0.5.    Thus  these  haplotypes,  or  alleles,  are  not  in  a  50/50  balance,  rather,  this  is  an  
allelic  imbalance  event.      
The  band  separation  in  the  100%  tumor  sample  is  obvious,  so  the  event  can  be  identified  
visually  in  these  plots  or  via  a  simple  algorithm.    However,  as  the  tumor  purity  decreases,  such  
as  in  the  30%  tumor  and  15%  tumor  samples,  it  becomes  harder  to  visually  identify  this  event.    
We  developed  a  method  for  exome  sequencing  data  that  addresses  issues  in  detection  of  subtle  
allelic  imbalances  in  the  context  of  lower  tumor  purities.    Our  method,  hapLOHseq,  is  a  next-‐‑
generation  sequencing  based  extension  of  hapLOH51,  which  is  an  allelic-‐‑imbalance  detection  
method  that  is  designed  for  SNP  microarray  data.  
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Figure  13:  Methods  that  detect  chromosomal  allelic  imbalance  are  dependent  on  either  coverage  fluctuations  (not  
shown  here)  or  identifying  separation  of  allele  frequency  bands  away  from  0.5.  

  
hapLOHseq  extends  the  idea  of  searching  for  heterozygous  sites  with  VAFs  that  deviate  
from  0.5  to  instead  look  for  deviation  of  haplotype  allele  frequencies  deviating  from  0.5,  improving  
the  sensitivity  of  identifying  such  events.    In  the  simulated  VAF  data  of  Figure  14,  at  10%  tumor  
purity,  it  is  difficult  to  see  any  deviation  of  VAFs  from  0.5  because  the  two  bands  overlap  each  
other  and  there  is  no  visual  separation  between  them.    But  if  we  knew  the  haplotypes,  and  then  
looked  for  allelic  imbalance  between  the  haplotypes,  the  event  becomes  easier  to  discern.    This  
is  the  intuition  behind  the  method  of  hapLOHseq,  i.e.,  to  first  estimate  haplotypes  and  then  check  
if  there  is  allelic  imbalance  between  the  2  haplotypes.    The  method  is  described  in  Appendix  B  
section  6.2.  

  

36  

  

10%$tumor$
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Figure  14:  The  intuition  behind  hapLOH  and  hapLOHseq  is  that  these  methods  look  for  allelic  imbalance  of  haplotypes  
rather  than  band  separation  of  individual  VAFs.    Haplotype  imbalances  are  easier  to  identify  when  the  events  are  
subtle  compared  to  visually  identifying  VAF  band  separation.  

  
2.2.2.2

Chromosomal  AI  profiling  

We  executed  hapLOHseq  with  default  parameters  on  all  samples  in  the  FAP  project.  
hapLOHseq  plots  for  4  samples  from  the  patient  CATA01  are  shown  in  Figure  15.    For  the  blood,  
normal  mucosa  and  2  polyp  samples,  each  hapLOHseq  plot  illustrates  the  VAFs  for  the  
corresponding  sample  at  all  genomic  markers  that  are  heterozygous  in  the  germline  (blood)  
sample  for  CATA01.    Thus,  hapLOHseq  characterizes  and  identifies  allelic  imbalances  of  
germline  haplotypes  in  the  polyp  samples.    The  blue  and  red  lines  of  hapLOHseq  plots  show  the  
probabilities  of  chromosomal  AI  events  across  the  normal  and  polyp  genomes,  respectively.      
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*Very&low&muta.on&rate&(only&12&muta.ons&across&exome)&
Figure  15:  hapLOHseq  plots  for  4  samples  from  the  CATA01  patient.    The  flat  blue  lines  for  the  blood  and  normal  
mucosa  samples  reflect  probabilities  near  0  for  AI  events  across  these  samples.    The  red  lines  represent  the  
probabilities  of  events  (ranging  from  0  at  the  bottom  of  the  plot  to  1  at  the  top  of  the  plot)  across  the  polyps.  

  
For  the  CATA01  blood  and  normal  mucosa  samples  in  Figure  15,  the  probabilities  of  AI  
events  are  virtually  0  across  these  genomes.    For  polyp  1,  an  AI  event  was  identified  with  a  
probability  near  1  at  chromosome  5q.    The  band  separation  at  the  hapLOHseq  identified  AI  
region  can  be  visually  verified.    Polyp  2  is  suspected  of  having  very  low  polyp  purity  due  to  its  
very  low  mutation  rate  of  0.246  mutations  per  megabase.    Illustrating  the  capabilities  of  
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identifying  subtle  AI  at  low  purities,  AI  events  were  also  identified  in  polyp  2  at  chromosomes  5  
and  19.    
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Figure  16:  Summary  of  FAP  polyp  chromosomal  allelic  imbalance  events  identified  by  hapLOHseq  compared  to  
recurrent  amplifications  and  deletions  inferred  from  SNP  arrays  from  the  TCGA  CRC  project.  

  
Similarly,  hapLOHseq  was  applied  to  all  of  the  FAP  patient  samples  and  then  the  results  
were  summarized  and  compared  with  CRC  AI  profiles.    For  CRC  AI  events,  copy  number  
profiles  inferred  from  SNP  arrays  were  downloaded  for  70  stage  I  microsatellite  stable  tumors.    
Figure  16  summarizes  AI  events  for  FAP  and  TCGA  CRC  samples  across  the  genome.    AI  
events  in  the  polyps  are  illustrated  with  black  bars  in  the  top  section.    TCGA  CRC  stage  I  tumor  
events  are  illustrated  with  red  and  blue  bars  (amplifications  and  deletions  respectively)  below  
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the  FAP  polyp  AI  events.    A  summary  histogram  for  both  the  polyp  and  CRC  events  are  shown  
at  the  tops  of  both  sections.      
For  polyp  AI  events,  we  did  not  distinguish  among  amplifications,  deletions  and  copy-‐‑
neutral  LOH  events  in  Figure  16.    Some  of  these  events  were  characterized  visually  by  
comparing  the  coverage  profiles  of  tumor  samples  (at  these  AI  events)  to  their  paired  normal  
samples.    Amplifications,  deletions  and  cn-‐‑LOH  classifications  for  recurrently  aberrant  genes  
within  these  regions  are  depicted  in  Figure  19.    However,  many  of  the  polyp  AI  events  are  too  
subtle  to  confidently  determine  the  event  type.    In  these  cases,  we  classified  the  events  as  subtle  
AI.    For  consistency  in  the  current  comparison  of  these  polyp  AI  events  to  CRC  copy  number  
alterations,  we  treat  the  hapLOHseq  event  calls  as  generic  allelic  imbalance  events.  
By  comparing  FAP  polyp  AI  events  to  chromosomal  copy  number  aberrations  in  stage  1  
CRC,  we  can  identify  regions  of  the  genome  that  have  events  in  both  polyps  and  stage  1  CRCs.    
Regions  that  are  aberrant  in  both  data  sets  are  suggestive  of  events  occurring  early  in  the  
development  of  CRCs.    Common  aberrant  regions  in  both  data  sets  are  loss  of  5q  (through  
deletion  or  cn-‐‑LOH)  and  amplification  of  chromosome  7,  13  and  20.    Loss  of  5q  is  a  common  
mechanism  of  losing  one  copy  of  an  APC  gene  and  was  observed  in  25%  (5  of  25)  of  polyps.    
Gains  of  chromosomes  7,  13  and  20  have  been  associated  with  the  early  development  of  
carcinomas  in  previous  studies52.    Chromosome  7  increases  are  thought  to  be  mechanisms  of  
EGFR  and  MET  oncogene  amplification53.    Chromosome  13  amplification  has  been  associated  
with  gains  in  the  oncogene  CDX253.    Genes  associated  with  the  colon  adenoma  to  carcinoma  
progression  as  a  result  of  gains  in  chromosome  20  include:  C20orf24,  AURKA,  RNPC1,  TH1L,  
ADRM1,  C20orf20  and  TCFL554.    Gain  of  20q  has  also  been  associated  with  a  progression  
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towards  invasiveness54.    The  mutation  rate  of  polyps  with  allelic  imbalance  of  20q  is  3.235  
mutations  per  megabase,  which  is  higher  than  the  overall  mean  mutation  rate  of  our  polyps,  
which  is  1.75  mutations  per  megabase  (t-‐‑test  p-‐‑value  =  8.575e-‐‑4).    Further,  the  mutation  rate  of  
polyps  with  allelic  imbalances  on  chromosome  20  approach  the  mutation  rate  of  3.95  mutations  
per  megabase  of  the  TCGC  non-‐‑hypermutated  CRCs,  supporting  the  idea  that  these  polyps  
have  progressed  further  along  the  adenoma-‐‑to-‐‑carcinoma  sequence.    
Recurrent  amplification  and  deletion  regions  in  the  CRC  data  set  that  are  absent  in  the  
polyp  AI  data  are  representative  of  events  associated  with  later  adenoma  development,  
potentially  representing  events  necessary  for  transforming  a  polyp  into  a  carcinoma.    Deletions  
of  17p  and  18q  are  seen  in  a  high  proportion  of  stage  1  CRCs  in  TCGA,  60%  and  70%  
respectively.    Deletion  of  17p  has  been  associated  with  loss  of  TP53  and  deletion  of  18q  is  
associated  with  the  loss  of  SMAD2  and  SMAD4  (see  Figure  16).    These  genes  have  been  
associated  with  carcinoma  initiation  in  the  adenoma-‐‑to-‐‑carcinoma  sequence,  reflecting  the  
utility  of  our  FAP  polyp  and  CRC  comparative  approach.  
  
2.2.3

Patterns  of  APC  somatic  events  
In  general,  events  characterizing  FAP  polyps  in  our  data  set  were  also  prevalent  in  CRC  

tumors.    Consistent  with  current  knowledge  of  FAP  polyps,  recurrent  LOH  of  5q  was  observed  
across  polyps  and  most  other  identified  somatic  APC  events  were  truncating  mutations.    Bi-‐‑
allelic  loss  of  APC  was  widespread  and  was  detected  in  72%  (17  of  25)  of  polyps.    Five  of  the  7  
polyps  lacking  a  somatic  alteration  of  APC  also  lacked  any  WNT  signaling  pathway  alterations  
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(see  section  2.2.4).    These  samples  appeared  to  have  lower  polyp  purity  compared  to  the  80%  
where  somatic  WNT  pathway  alterations  were  identified,  which  results  in  a  lower  power  to  
detect  somatic  events  in  these  samples.    This  lower  purity  is  reflected  in  the  lower  detectable  
mutation  rate  in  these  samples  (0.629  mutations/Mb)  versus  that  in  WNT  altered  samples  (2.035  
mutations/Mb;  t-‐‑test  p-‐‑value  =  0.005).    As  such,  we  believe  that  72%  to  100%  of  the  FAP  polyps  
have  bi-‐‑allelic  loss  of  APC.    One  truncating  mutation  at  codon  564  was  seen  in  2  polyps  from  
different  patients:  CATA02_P03_Vilar21  and  MDAC20_P01_Vilar66.    This  recurrent  mutation  has  
been  documented  in  21  large  intestine  samples  in  the  COSMIC  database43.    In  all,  putative  
results  show  that  5  of  the  somatic  APC  events  were  due  to  deletion  or  LOH  of  5q,  2  were  single  
base  frameshift  deletions,  2  were  missense  mutations  (identified  in  the  same  patient)  and  10  
were  nonsense  mutations.  Of  the  10  nonsense  mutations,  5  (50%)  were  C-‐‑>T  transitions,  4  (40%)  
were  G-‐‑>T  transversions  and  1  (10%)  was  a  C-‐‑>A  transversion.    
  
APC_germline_mutations APC_germline_mutations 820;amino;acid8repeats
820;amino;acid WNT8Pathway Multiple
Non;APC8
Mutation8Rate8
APC8Somatic8Alteration
(cDNA)
(protein)
in8germline8mutant8allele
repeats8in8total 8Gene8Alteration Clones Putative8Driver8Events (mutations/Mb)
CATA01_P01_Vilar13
c.3927_3931delAAAGA
p.Glu1309Aspfs*4
1
5q>loss
1
APC>@>5q>loss
@@@
KRAS>G12C
1.095
CATA01_P02_Vilar16
c.3927_3931delAAAGA
p.Glu1309Aspfs*4
1
5q>loss
1
APC>@>5q>loss
@@@
@@@
0.246
CATA01_P03_Vilar17
c.3927_3931delAAAGA
p.Glu1309Aspfs*4
1
5q>loss
1
APC>@>5q>loss
@@@
BRCA2>S1733P
0.944
CATA01_P04_Vilar18
c.3927_3931delAAAGA
p.Glu1309Aspfs*4
1
R805X
1
APC>@>nonsense
@@@
@@@
0.839
CATA02_P01_Vilar14
c.4393_4394delAG
p.Ser1465Trpfs*3
2
@@@
@@@
@@@
@@@
@@@
0.185
CATA02_P02_Vilar19
c.4393_4394delAG
p.Ser1465Trpfs*3
2
@@@
@@@
@@@
@@@
@@@
0.630
CATA02_P03_Vilar21
c.4393_4394delAG
p.Ser1465Trpfs*3
2
R564X
2
APC>@>nonsense
@@@
KRAS>G12D
2.443
CATA03_P01_Vilar15 c.>[1958+3G>A(;)c.1959G>A]
@@@
0
Frameshift>deletion>(at>codon>1309)
1
APC>@>frameshift
yes
@@@
2.695
CATA04_P01_Vilar12
c.1412delG
p.Gly471Aspfs*27
0
5q>loss
0
APC>@>5q>loss
yes
FBXW7>G557R
3.131
CATA04_P02_Vilar22
c.1412delG
p.Gly471Aspfs*27
0
@@@
@@@
FZD7>@>missense
yes
@@@
2.826
CATA04_P03_Vilar23
c.1412delG
p.Gly471Aspfs*27
0
E1306X
1
APC>@>nonsense
@@@
@@@
3.556
CATA04_P04_Vilar24
c.1412delG
p.Gly471Aspfs*27
0
E1374X
1
APC>@>nonsense
@@@
@@@
4.104
MDAC01_P01_Vilar41
c.1880dupA
p.Ala630*
0
Frameshift>deletion>(at>codon>1541)
2
APC>@>frameshift
yes
FBXW7>R465C
1.894
MDAC01_P02_Vilar42
c.1880dupA
p.Ala630*
0
E1397X
2
APC>@>nonsense
@@@
@@@
2.158
MDAC02_P01_Vilar45
c.3810T>A
p.Cys1270*
0
@@@
@@@
@@@
@@@
@@@
1.101
MDAC08_P01_Vilar47
c.622C>T
p.Gln208*
0
@@@
@@@
TCF7L2>@>missense
@@@
@@@
1.822
MDAC08_P02_Vilar48
c.622C>T
p.Gln208*
0
S1315X
1
APC>@>nonsense
@@@
@@@
2.388
MDAC10_P01_Vilar51
c.3440dupA
p.Ser1148Thrfs*18
0
@@@
@@@
@@@
@@@
@@@
0.665
MDAC14_P01_Vilar54
del>8@9
@@@
0
E1408X
2
APC>@>nonsense
@@@
@@@
1.610
MDAC14_P02_Vilar55
del>8@9
@@@
0
L645F,>I646R
more>than>2
APC>@>missense
@@@
@@@
1.808
MDAC14_P03_Vilar56
del>8@9
@@@
0
5q>loss
0
APC>@>5q>loss
@@@
@@@
1.662
MDAC17_P01_Vilar59
c.1658G>A
p.Trp553*
0
R1450X
2
APC>@>nonsense
@@@
@@@
0.882
MDAC17_P02_Vilar60
c.1658G>A
p.Trp553*
0
@@@
@@@
@@@
@@@
@@@
0.566
MDAC18_P01_Vilar69
c.4393_4394delAG
p.Ser1465Trpfs*3
2
R554X
2
APC>@>nonsense
yes
@@@
1.713
MDAC20_P01_Vilar66
c.477C>G
p.Tyr159*
0
R564X
0
APC>@>nonsense
@@@
@@@
2.890
Sample

  

Table  4:  Summary  of  polyp  somatic  events  in  APC  and  the  WNT  signaling  pathway.  
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Literature  has  suggested  that  given  the  location  within  the  first  altered  APC  allele,  one  can  
loosely  predict  the  location  and  type  of  the  somatic  alteration  in  the  second  APC  allele.    In  a  
proposed  first-‐‑hit-‐‑second-‐‑hit  model,  APC  germline  mutations  near  codon  1300,  specifically  
between  codons  1285  and  1378,  are  associated  with  somatic  chromosome  5q  loss55.    CATA01  is  
the  only  patient  in  our  data  set  with  such  a  germline  mutation.    Consistent  with  this  first-‐‑hit-‐‑
second-‐‑hit  model,  75%  (3  of  4)  of  CATA01  polyps  had  loss  of  chromosome  5q,  but  this  event  was  
seen  in  only  9.5%  (2  of  21)  of  the  remaining  samples  where  a  somatic  APC  event  was  identified.    
Thus  an  association  exists  (p-‐‑value  =  0.016,  Fisher’s  exact  test)  between  germline  mutations  
(between  codons  1285  and  1378)  and  chromosome  5q  loss  in  our  data  set.    
Further,  the  first-‐‑hit-‐‑second-‐‑hit  model  proposes  that  for  patients  with  APC  truncating  
germline  mutations  before  codon  1264,  the  first  repeat  region  of  the  beta-‐‑catenin  binding  and  
degradation  portion  of  APC,  LOH  or  deletion  of  chromosome  5q  is  very  rare55.    Although  not  at  
statistical  significance  our  data  set  also  suggests  that  this  pattern  is  valid.    Four  of  our  FAP  
patients  have  germline  mutations  located  prior  to  the  first  20  amino-‐‑acid  repeat  region.    Only  1  
in  9  of  their  polyps  had  a  somatic  loss  of  5q.    Alternatively,  25%  (4  of  16)  of  the  remaining  
samples  had  5q  AI  events.  
  

The  20-‐‑amino-‐‑acid  repeat  regions  of  APC  are  involved  in  beta-‐‑catenin  binding  and  

degradation.    It  has  been  proposed  that  between  the  2  APC  alleles  of  cells  there  is  an  optimal  
number  of  beta-‐‑catenin  repeats  for  cellular  proliferation,  where  this  theory  motivates  the  first-‐‑
hit-‐‑second-‐‑hit-‐‑model  of  APC  somatic  mutation  in  patients  with  FAP  such  that  a  polyp  cell  ends  up  
with  an  optimal  number  of  1  beta-‐‑catenin  repeat  in  the  so-‐‑called  just-‐‑right  signaling  model50.    
Thus,  where  a  person  has  a  truncating  mutation  that  leaves  APC  with  1  beta-‐‑catenin  repeat,  
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they  are  more  likely  to  have  loss  of  APC  (or  loss  of  5q)  as  a  somatic  event,  leaving  them  with  1  
beta-‐‑catenin  repeat  in  total.    This  pattern  is  observed  in  our  dataset.    Eighteen  polyps  exhibited  
bi-‐‑allelic  loss  of  APC  and  most  commonly,  adenoma  cells  were  left  with  1  beta-‐‑catenin  repeat.    
As  depicted  in  Table  4,  1  polyp  had  more  than  2  of  the  20  amino-‐‑acid  repeats  within  its  2  APC  
alleles,  6  polyps  had  2  of  the  20  amino-‐‑acid  repeat  regions,  8  had  1  repeat  region  and  3  polyps  
had  0  repeat  regions.    In  summary,  our  data  suggests  that  APC  germline  mutations  may  be  used  
as  a  predictor  of  future  somatic  events  based  on  the  first-‐‑hit-‐‑second-‐‑hit  model  50  proposed  for  
adenoma  development.  
  
2.2.4

Alterations  in  WNT  signaling  genes  are  pervasive  
Activation  of  the  WNT  signaling  pathway  causes  an  accumulation  of  beta-‐‑catenin  in  the  

cytoplasm,  leading  to  its  eventual  translocation  into  the  nucleus  where  it  acts  as  a  
transcriptional  coactivator  of  MYC  and  other  genes  resulting  in  cellular  proliferation.    Without  
WNT  signaling,  a  destruction  complex  would  normally  degrade  beta-‐‑catenin.    WNT  pathway  
genes  were  identified  as  altered  in  92%  of  TCGA  CRCs28.    Specific  genes  that  have  been  
identified  as  significantly  mutated  in  TCGA  CRCs  are  included  in  a  simplified  representation  of  
the  WNT  signaling  pathway  in  Figure  17.      
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Figure  17:  Significantly  mutated  TCGA  CRC  genes  involved  in  the  canonical  WNT  signaling  pathway.    Several  beta-‐‑
catenin  inhibitors  are  mutated  in  both  TCGA  CRC  and  FAP  polyps  including:  APC,  TCF7L2,  and  FBXW7,  suggesting  
these  are  key  events  in  the  early  development  of  CRC.    

  
Similarly,  somatic  alterations  of  WNT  signaling  pathway  genes  were  seen  in  80%  (20  of  
25)  of  FAP  adenomas.    APC  is  the  predominantly  mutated  gene.    Mutations  resulting  in  
inactivation  of  APC,  TCF7L2  and  FBXW7  appear  to  contribute  to  the  proliferation  of  beta-‐‑
catenin  and  the  growth  of  polyps.    Further,  nonsense  mutations  of  ARID1A  may  contribute  to  
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MYC  over-‐‑expression.    Overexpression  of  both  beta-‐‑catenin  and  MYC  contribute  to  cellular  
proliferation.    Additionally,  putative  key  genes  with  non-‐‑coding  alterations  in  FAP  adenomas  
include  AXIN2  and  SOX9,  which  harbored  a  synonymous  and  a  5’  UTR  base  substitution,  
respectively.      
We  did  not  detect  an  alteration  of  WNT  signaling  pathway  genes  in  5  polyps  represented  
with  rows  shaded  in  gray  in  Table  4.    However,  these  5  polyps  had  low  mutation  rates  (0.629  
mutations/Mb)  compared  to  the  rest  of  the  polyps  (2.035  mutations/Mb)  suggesting  that  we  may  
have  missed  important  mutations  in  these  polyps  due  to  a  lack  of  power  to  detect  them.    In  
addition,  Obrador-‐‑Hevia  et  al  profiled  60  adenomas  and  identified  WNT  pathway  gene  
aberrations  at  either  the  DNA  and/or  RNA  level  in  all  adenomas56,  suggesting  that  another  
source  of  WNT  aberrations  that  we  are  missing  may  be  hidden  in  the  mRNA  transcripts  of  these  
polyps.    Additionally,  TCGA  identified  over-‐‑expression  of  FZD10  in  19%  of  CRCs  (Figure  17).    
Without  RNA  sequencing  of  these  25  polyps,  we  lack  the  ability  to  identify  transcript  level  
WNT  pathway  aberrations.  
Looking  specifically  at  the  WNT,  MAPK  and  ERBB  signaling  pathways,  which  are  known  
to  be  aberrant  in  CRC,  Table  5  indicates  the  gene  and  type  of  mutation  observed  in  each  sample  
for  each  of  these  pathways.    The  genes  for  each  of  these  pathways  were  obtained  from  the  
Molecular  Signatures  Database  (MSigDB)47  using  the  KEGG  pathway  names  indicated  on  the  
table.    The  table  excludes  AI  events  and  only  lists  somatic  point  mutations  and  small  insertions  
and  deletions.    Samples  with  alterations  in  the  WNT  signaling  pathway  in  addition  to  the  
MAPK  and/or  ERBB  pathways  are  shaded  in  gray.    We  expect  that  these  samples  have  
progressed  further  along  the  adenoma-‐‑to-‐‑carcinoma  sequence  as  compared  to  the  other  
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samples.    This  is  supported  by  the  difference  in  mutation  rates  between  these  samples  (2.565  
mutations/Mb)  as  compared  to  the  remaining  samples  (1.552  mutations/Mb)  through  a  T-‐‑test  (p-‐‑
value  =  0.030).  
  
sample'name
KEGG_WNT_SIGNALING_PATHWAY
KEGG_MAPK_SIGNALING_PATHWAY KEGG_ERBB_SIGNALING_PATHWAY mutation'rate'(mutations/Mb)
CATA01_P01_Vilar13
...
KRAS:MISSENSE
KRAS:MISSENSE
1.095
CATA01_P02_Vilar16
...
...
...
0.246
CATA01_P03_Vilar17
...
...
...
0.944
CATA01_P04_Vilar18
APC:NONSENSE;TCF7L2:MISSENSE
...
...
0.839
CATA02_P01_Vilar14
...
...
...
0.185
CATA02_P02_Vilar19
...
...
...
0.630
CATA02_P03_Vilar21
APC:NONSENSE
KRAS:MISSENSE
KRAS:MISSENSE
2.443
CATA03_P01_Vilar15 CREBBP:NONSENSE;CSNK1A1:MISSENSE;APC:FRAMESHIFT
...
...
2.695
CATA04_P01_Vilar12
...
...
STAT5A:NONSENSE
3.131
CATA04_P02_Vilar22
FZD7:MISSENSE;PPP3CB:NONSENSE
PPP3CB:NONSENSE
...
2.826
CATA04_P03_Vilar23
APC:NONSENSE;TCF7L2:NONSENSE
MAP2K7:NONSENSE
MAP2K7:NONSENSE
3.556
CATA04_P04_Vilar24
APC:NONSENSE
...
...
4.104
MDAC01_P01_Vilar41
APC:FRAMESHIFT
...
...
1.894
MDAC01_P02_Vilar42
APC:NONSENSE
...
...
2.158
MDAC02_P01_Vilar45
...
...
...
1.101
MDAC08_P01_Vilar47
TCF7L2:MISSENSE
...
...
1.822
MDAC08_P02_Vilar48
APC:NONSENSE
FGFR4:MISSENSE
...
2.388
MDAC10_P01_Vilar51
...
...
...
0.665
MDAC14_P01_Vilar54
APC:NONSENSE
DUSP10:MISSENSE
...
1.610
MDAC14_P02_Vilar55
APC:MISSENSE
...
...
1.808
MDAC14_P03_Vilar56
...
...
...
1.662
MDAC17_P01_Vilar59
APC:NONSENSE
...
...
0.882
MDAC17_P02_Vilar60
...
...
...
0.566
MDAC18_P01_Vilar69
APC:NONSENSE
...
...
1.713
MDAC20_P01_Vilar66
APC:NONSENSE
...
...
2.890

  

Table  5:  Genes  aberrant  in  the  WNT,  MAPK  and  ERBB  signaling  pathways.    Note  that  some  genes  are  members  of  
both  the  MAPK  and  ERBB  signaling  pathways.    Samples  are  ordered  by  patient  IDs.    Those  samples  with  alterations  
in  WNT  signaling  pathway  in  addition  to  the  MAPK  and/or  ERBB  signaling  pathway  are  shaded  in  gray.  

  
2.2.5

Candidate  genes  of  early  CRC  development  
Consistency  in  our  findings  with  current  knowledge  of  FAP  polyps  provides  some  

confidence  in  our  results  and  suggests  that  our  candidate  gene  list  (shown  on  the  left  side  of  
Figure  19)  identified  for  further  functional  studies  may  indeed  contain  true  genes  involved  in  
the  development  of  adenomas.    In  addition  to  APC  somatic  events  being  identified  in  72%  (18  of  
25)  of  polyps,  activating  mutations  in  KRAS  were  detected  in  8%  (2  of  25)  of  the  polyps.    Events  
in  the  tumor  suppressors  SMAD2/4  and  TP53  which  are  prevalent  in  CRC  and  thought  to  be  
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events  that  transform  adenomas  to  carcinomas  were  not  seen  in  the  FAP  polyps  as  expected  
since  our  samples  are  pre-‐‑malignant  lesions.  
Through  application  of  MutSig49,  the  only  identified  significantly  mutated  gene  in  our  
data  set  is  APC  (p-‐‑value  =  1.15e-‐‑07  and  q-‐‑value  =  2.18e-‐‑03).    The  lack  of  statistical  significance  in  
our  candidate  gene  findings  is  likely  due  to  our  small  sample  size.    As  an  alternative  approach  
to  MutSig  for  identifying  mutated  genes  associated  with  adenoma  development,  we  looked  for  
recurrently  altered  genes  in  our  data  set  that  have  previously  been  associated  with  CRC.    The  
motivation  behind  this  is  that  we  would  expect  that  mutated  genes  associated  with  polyp  
development  are  significantly  mutated  in  CRCs.    Using  this  strategy,  the  candidate  genes  listed  
on  the  left  of  Figure  18  were  identified.    Excluding  APC  and  KRAS,  which  are  known  to  play  
important  roles  in  adenoma  development,  17  additional  candidate  genes  have  been  identified.  
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Figure  18:  Map  of  candidate  genes  of  early  CRC  development  based  on  somatic  mutation  characterization.  

  
The  specific  criteria  for  including  these  candidate  genes  are  the  following.  
1. A  candidate  gene  must  be  recurrently  altered  in  at  least  2  FAP  adenomas.  
2. That  gene  must  harbor  at  least  one  mutation  categorized  as  tier  1  and  2  or  the  mutation  
must  be  a  nonsense  mutation  (see  section  2.1.4  for  more  details  on  tier  definitions  and  
for  details  on  incorporating  previously  identified  CRC  genes  into  our  mutation  
prioritization).  
  
Figure  18  is  a  summary  characterization  of  our  polyps  and  a  map  of  our  candidate  genes  of  
early  CRC  development.    The  figure  shows  candidate  genes  as  rows  in  a  categorical  map,  where  
each  color  corresponds  to  a  specific  type  of  mutation  observed  in  each  adenoma  sample.    The  
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blue  bar  plot  on  the  right  shows  the  frequency  at  which  each  gene  is  altered  in  the  FAP  polyp  
samples  broken  down  by  insertions  and  deletions  (indels)  or  single  nucleotide  substitutions  (SNS).    
The  columns  of  the  figure  correspond  to  the  FAP  polyps  where  the  red  bar  plot  at  the  top  
illustrates  the  mutation  rate  for  each  sample  broken  down  by  noncoding,  silent  and  nonsilent  
alterations.    Genes  and  samples  are  ordered  in  such  a  way  to  capture  potential  mutual  
exclusivity  patterns  in  the  data.    For  example,  APC  is  the  most  frequently  altered  gene  and  
CDC27  is  the  next  most  altered  gene  exclusive  of  the  APC  mutated  samples.    Interestingly,  Yu  et  
al  recently  performed  population  and  single-‐‑cell  sequencing  analyses  of  a  bi-‐‑clonal  colon  cancer  
case  and  discovered  that  mutated  CDC27  occurs  exclusively  from  mutated  APC  in  each  clone,  
supporting  the  hypotheses  that  each  of  these  mutations  may  provide  unique  mechanisms  of  
colon  cancer  initiation57.    Most  importantly,  Figure  18  lists  17  genes  (excluding  APC  and  KRAS  
which  are  known  genes  involved  in  the  early  development  of  CRC)  that  meet  the  criteria  for  
being  candidate  genes  of  early  CRC  development.      
Figure  19  extends  the  analysis  portrayed  in  Figure  18  to  include  chromosomal  AI  events,  
which  we  believe  characterizes  FAP  polyps  with  somatic  APC  alterations  more  accurately.    For  
Figure  19,  the  candidate  gene  criteria  were  altered  such  that:  
1. A  candidate  gene  must  be  recurrently  altered  in  at  least  2  FAP  adenomas,  where  these  
alterations  can  include  chromosomal  AI.  
2. That  gene  must  harbor  at  least  one  mutation  categorized  as  tier  1  and  2  or  the  mutation  
must  be  a  nonsense  mutation  (see  section  2.1.4  for  more  details  on  tier  definitions  and  
for  details  on  incorporating  previously  identified  CRC  genes  into  our  mutation  
prioritization).      
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In  this  way,  even  if  a  gene  has  been  altered  through  multiple  AI  events  in  the  polyps,  it  is  not  a  
candidate  gene  unless  it  harbors  at  least  one  highly  prioritized  mutation,  where  this  
prioritization  is  highly  influenced  by  the  mutation  being  predicted  to  be  a  driver  event,  by  being  
recurrently  altered  in  the  COSMIC  database43,  or  by  residing  in  a  previously  associated  CRC  
gene  (see  section  2.1.4  for  more  details).  
  

  
Figure  19:  Map  of  candidate  genes  of  early  CRC  development  based  on  somatic  mutation  characterization  
considering  AI  events.  
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The  aberration  summary  of  Figure  19  now  includes  5  additional  APC  alterations  due  to  

chromosomal  AI  events,  resulting  in  72%  (18  of  25)  polyps  having  a  somatic  APC  alteration.    
Fifty-‐‑one  candidate  genes  (32  additional  candidate  genes  compared  to  those  listed  in  Figure  18)  
were  also  identified  as  potentially  contributing  to  early  CRC  development.    The  blue  bar  plot  on  
the  right  side  of  Figure  19  now  accounts  for  chromosomal  AI  events.    In  cases,  where  AI  events  
could  visually  be  categorized  as  amplifications,  deletions  or  copy-‐‑neutral  LOH  by  inspecting  
read  coverage  profiles  across  the  genomes  of  these  polyp  samples  and  comparing  them  to  
coverage  profiles  of  their  paired  blood  samples,  the  events  are  colored  accordingly.    In  cases  of  
subtle  AI  (or  AI  events  at  very  low  cellular  proportions)  it  is  difficult  to  visually  distinguish  
between  amplifications,  deletions  or  LOH  events  and  the  events  are  left  as  subtle  AI,  although  in  
each  of  these  cases  in  our  FAP  data  set,  it  appears  that  these  events  are  either  deletions  or  copy-‐‑
neutral  LOH  events.  
  

2.3 Discussion  
2.3.1

Challenges  of  molecularly  profiling  polyps  

In  this  chapter  we  have  characterized  the  genomes  of  polyp  samples,  which  can  be  more  
difficult  to  characterize  compared  to  tumor  samples  due  to  problems  of  limited  amounts  sample  
and  low  purity.    With  the  goals  of  performing  mutation  and  chromosomal  AI  profiling  of  these  
pre-‐‑malignant  lesions,  our  project  presented  2  primary  challenges  as  compared  to  tumor  
sequencing  projects:  
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1. The  polyps  obtained  for  experimentation  were  small  and  therefore  we  had  limited  
genetic  material  to  perform  additional  experiments  beyond  exome  sequencing.    We  
would  have  liked  to  run  comparative  genomic  hybridization  (CGH)  or  single  nucleotide  
polymorphism  (SNP)  arrays  for  higher-‐‑resolution  identification  of  copy  number  events  for  
the  same  polyps  that  we  performed  exome  sequencing  on,  however  this  was  not  
possible  due  to  a  limited  amount  of  quality  polyp  DNA.    The  DNA  remaining  after  
exome  sequencing  was  conserved  for  Sanger  sequencing  validation  of  important  
identified  mutations.    
2. Adenomas  inherently  have  high  stromal  contamination  due  to  the  fact  that  they  develop  
earlier  in  the  adenoma-‐‑to-‐‑carcinoma  sequence  and  more  closely  resemble  “normal  
epithelium”  cells  in  biological  state  as  compared  to  carcinomas.  
  
To  overcome  these  challenges  for  the  genomic  characterization  from  limited,  low-‐‑purity  
samples,  we  performed  analyses  on  the  exome  sequencing  data  using  Mutect  for  the  sensitive  
detection  of  point  mutations  and  we  developed  our  own  software,  hapLOHseq,  for  the  detection  
of  subtle  chromosomal  AI  events.      hapLOHseq  was  applied  to  the  FAP  exome  sequencing  data  
in  section  2.2.2  and  the  method  is  described  in  detail  in  Appendix  B  in  section  6.2.  
  
2.3.2

Significance  of  findings  

In  this  chapter,  we  presented  the  first  genomic  characterization  of  FAP  adenomas  
performed  through  NGS.    Through  mutation  profiling,  we  showed  that  FAP  polyp  mutation  
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rates  are  lower  compared  to  CRC  mutation  rates  indicating  that  FAP  adenomas  are  in  an  earlier  
stage  of  tumorigenesis  compared  to  CRC  as  expected.    In  addition,  mutational  base  substitution  
signatures  of  polyps  appear  to  be  identical  to  those  of  nonhypermutated  CRCs,  suggesting  that  
these  two  types  of  samples  have  the  same  mutational  processes  driving  them.    These  processes  
appear  to  be  related  to  aging  or  other  currently  unidentified  processes49.    Several  of  the  polyps  
also  appear  to  be  multi-‐‑clonal,  supporting  the  idea  that  they  are  evolving  towards  carcinomas  
and  acquiring  driver  mutations  such  as  those  on  KRAS.    More  fundamentally,  most  of  the  
polyps  (72%)  exhibited  second  hits  of  the  tumor  suppressor  gene  APC,  of  which,  bi-‐‑allelic  loss  is  
thought  to  be  the  initiating  event  in  the  development  of  adenomas  according  to  the  adenoma-‐‑
to-‐‑carcinoma  sequence  model.    For  those  adenomas  lacking  APC  somatic  events,  this  could  be  
due  to  lower  power  to  detect  APC  events  because  of  low  polyp  purities  that  these  samples  
appear  to  have,  or  they  could  have  alterations  not  detectable  through  exome  sequencing,  such  
as  transcript  level  alterations  or  epigenetic  alterations.    Alternatively,  these  samples  could  be  
harboring  other  important  mutations  exclusive  of  APC.    Eighty  percent  of  the  adenomas  
harbored  alterations  in  WNT  signaling.    Additional  WNT  signaling  genes  besides  APC  that  are  
altered  include  AXIN2,  TCF7L2,  FBXW7,  SOX9  and  ARID1A.    In  total,  50  candidate  genes  were  
identified  (excluding  APC  and  KRAS)  that  are  putatively  involved  in  the  early  development  of  
CRC.    These  genes  are  currently  being  functionally  tested  in  vitro  through  cell-‐‑line  and  animal  
model  experiments  by  the  lab  of  Eduardo  Vilar.  
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3 Identification  of  candidate  chemopreventive  drugs  for  FAP  
In  this  chapter,  I  present  a  separate  but  complementary  phase  of  our  project  for  the  
identification  of  candidate  chemopreventive  drugs  for  FAP  patients  (see  Figure  3  for  a  high-‐‑
level  overview  of  the  2  phases  of  our  FAP  project).    In  the  longer-‐‑term  vision  of  this  project,  
knowledge  gained  and  candidate  gene  targets  identified  from  the  genomic  characterization  of  
FAP  polyps  (see  chapter  2)  will  be  used  to  inform  the  identification  of  candidate  
chemopreventive  drugs.    Indeed,  that  is  our  hope  as  functional  studies  are  currently  being  
performed  to  validate  the  candidate  genes  identified  in  the  genomic  characterization  of  colon  
adenomas.    However,  at  the  present  time,  we  are  taking  what  could  be  viewed  as  a  more  direct  
approach  for  identifying  candidate  drugs.    We  have  performed  RNA  sequencing  of  colon  and  
duodenum  samples  in  FAP  patients,  defined  gene  expression  signatures  representative  of  the  
differences  between  FAP  at-‐‑risk  normal  mucosa  and  polyps,  and  then  identified  candidate  
drugs  to  directly  target  these  gene  expression  signatures.      
Ideally,  chemoprevention  strategies  would  incorporate  drugs  or  compounds  that  have  
minimal  toxicity  that  are  inexpensive  and  effective.    So  we  take  a  drug  repurposing  approach,  
by  screening  for  candidate  drug  compounds  that  include  U.S.  Food  and  Drug  Administration  
(FDA)-‐‑approved  drugs  and  nondrug  bioactive  compounds,  which  are  generally  considered  to  
be  safe  but  which  may  not  have  been  shown  to  be  effective  in  their  originally  intended  purposes  
in  addition  to  drugs  that  have  been  shown  to  be  effective  for  various  uses58.    In  this  chapter,  we  
describe  this  computational  screening  approach,  apply  it  to  FAP  polyps,  and  propose  candidate  
drugs  for  FAP  patient  chemoprevention.      
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3.1 Methods  
3.1.1

Available  patients  and  samples  
Samples  from  2  FAP  patients  followed  at  MD  Anderson  Cancer  Center  were  collected  

through  endoscopic  biopsy  (see  Table  6).    From  each  patient,  normal  mucosa  samples  from  both  
the  colon  and  duodenum  were  obtained.    From  patient  FAP1,  3  colon  polyps  and  1  duodenum  
polyp  were  collected,  and  from  FAP6,  2  colon  polyps  and  2  duodenum  polyps  were  obtained.    
RNA  from  polyp  and  normal  mucosa  samples  were  isolated  using  a  combined  protocol  with  
TRIzol  reagent  (Life  Technologies)  and  the  RNeasy  Mini  Kit  (Qiagen).  
  
Sample
Patient Type Localization
FAP1_B1_NORMAL_COLON
FAP1 NORMAL
COLON
FAP1_M1_POLYP_COLON
FAP1
POLYP
COLON
FAP1_F1_POLYP_COLON
FAP1
POLYP
COLON
FAP1_DA1_POLYP_COLON
FAP1
POLYP
COLON
FAP1_DG1_NORMAL_DUODENUM FAP1 NORMAL DUODENUM
FAP1_DB1_POLYP_DUODENUM
FAP1
POLYP DUODENUM
FAP6_F6_NORMAL_COLON
FAP6 NORMAL
COLON
FAP6_B6_POLYP_COLON
FAP6
POLYP
COLON
FAP6_D6_POLYP_COLON
FAP6
POLYP
COLON
FAP6_DH6_NORMAL_DUODENUM FAP6 NORMAL DUODENUM
FAP6_DC6_POLYP_DUODENUM
FAP6
POLYP DUODENUM
FAP6_DD6_POLYP_DUODENUM
FAP6
POLYP DUODENUM

  

Table  6:  Four  normal  mucosa  and  8  polyps  were  RNA  sequenced  from  the  colon  and  duodenum  of  2  FAP  patients.  

  
3.1.2

Data  collection  
RNA  from  the  FAP  samples  was  sequenced  on  an  Illumina  Hiseq  2000  sequencer  with  76  

base  paired-‐‑end  reads  at  the  MD  Anderson  Cancer  Center  sequencing  core  facility.  Reads  were  
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aligned  and  analyzed  using  the  Tuxedo  protocol  for  differential  gene  expression  analyses  of  
RNA  sequence  data59.    Briefly,  TopHat60  is  used  for  alignment  of  initial  reads  to  the  human  
reference  genome  hg19.    Sequence  run  summaries  are  provided  in  Table  7  and  based  on  the  
proportion  of  read  pairs  aligned  (the  Tuxedo  protocol  specifies  0.7  as  being  representative  of  
quality  samples),  our  samples  all  appear  to  have  provided  high-‐‑quality  sequencing  reads.    
Cufflinks61  then  assembles  and  quantifies  transcripts.    Subsequently,  the  software  package  
Cuffdiff62  is  used  to  identify  differentially  expressed  genes.    In  a  separate  analysis,  Tophat-‐‑fusion63  
is  used  to  identify  gene  fusions.    See  Appendix  A  sections  5.5  and  5.6,  for  more  details.  
  
Sample
FAP1_B1_NORMAL_COLON
FAP1_M1_POLYP_COLON
FAP1_F1_POLYP_COLON
FAP1_DA1_POLYP_COLON
FAP1_DG1_NORMAL_DUODENUM
FAP1_DB1_POLYP_DUODENUM
FAP6_F6_NORMAL_COLON
FAP6_B6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_DH6_NORMAL_DUODENUM
FAP6_DC6_POLYP_DUODENUM
FAP6_DD6_POLYP_DUODENUM

Num)reads Prop)reads)aligned Prop)read)pairs)aligned
68,011,372
0.927
0.832
72,371,340
0.947
0.865
73,153,262
0.939
0.792
66,278,382
0.947
0.853
59,764,764
0.938
0.845
66,912,666
0.947
0.848
53,043,824
0.927
0.834
61,821,220
0.943
0.853
70,576,352
0.933
0.841
77,840,378
0.935
0.839
73,758,696
0.943
0.855
78,367,938
0.941
0.851

  

Table  7:  RNA  sequencing  mapping  statistics  indicate  that  the  sequencing  quality  of  each  of  these  samples  is  optimal.    
A  "ʺ%  read  pairs  aligned"ʺ  >  0.70  indicates  a  good  quality  sequencing  run59.  

  
3.1.3

Defining  FAP  colon  and  duodenum  gene  expression  signatures  
In  our  project,  a  gene  expression  signature  is  a  set  of  up-‐‑regulated  and  down-‐‑regulated  

genes  identified  by  comparing  at-‐‑risk  normal  mucosa  to  polyp  samples  of  FAP  patients.  These  
signatures  are  representative  of  the  molecular  alterations  that  differentiate  at-‐‑risk  normal-‐‑
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mucosa  and  adenomas.    The  normal  mucosa  samples  of  FAP  patients  are  at-‐‑risk  because  they  
harbor  aberrant  copies  of  the  APC  gene.    Given  the  quantified  transcripts  reported  by  Cufflinks,  
the  software  package  Cuffdiff  is  used  to  identify  differentially  expressed  genes  between  2  sets  of  
samples,  such  as  colon  polyps  versus  colon  normal  mucosa  samples.    To  label  a  gene  as  
differentially  expressed  (e.g.,  up-‐‑regulated  or  down-‐‑regulated)  for  inclusion  into  the  gene  
signature,  we  require  that  Cuffdiff  adjusted  Benjamini-‐‑Hochberg  p-‐‑values  be  less  than  0.05.    For  
up-‐‑regulated  signature  genes,  we  require  a  log2  fold-‐‑change  >=  1.    For  down-‐‑regulated  genes,  
we  require  a  log2  fold-‐‑change  <=  -‐‑1.      When  applied  to  our  computational  drug-‐‑screening  
experiments,  this  gene  expression  signature  is  called  a  query  signature.  
  
3.1.4

Identifying  candidate  drugs  to  target  FAP  gene  expression  signatures  
The  query  signature  is  then  fed  into  a  software  application  that  we  have  developed  called  

the  Cancer  in  silico  Drug  Discovery  framework  (CiDD),  where  CiDD  produces  a  report  for  
connections  (or  negative  correlations)  between  the  query  signature  and  gene  expression  signatures  
induced  by  candidate  drug  compounds.    CiDD  screens  the  FAP  at-‐‑risk  normal  mucosa  gene  
expression  signatures  against  those  induced  by  drug  compounds  in  the  Connectivity  Map  
(CMap)58  to  identify  candidate  drugs  that  may  target  the  FAP  signatures.      
The  CMap  is  a  collection  of  gene  expression  data  for  cell  lines  treated  with  bioactive  small  
molecules  paired  with  pattern  matching  algorithms  that  attempt  to  identify  biologically  
functional  connections  between  drugs  and  gene  expression  profiles.    Thus,  the  CMap  can  be  
used  as  a  database  of  drug-‐‑induced  gene  expression  signatures.    The  CMap  was  designed  for  
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identifying  candidate  drugs  for  query  signatures  represented  as  Affymetrix  HG-‐‑U133A  gene  
expression  microarrays  because  its  underlying  drug  expression  signatures  are  represented  
using  Affymetrix  HG-‐‑U133A  data.    CiDD  transforms  this  underlying  probe-‐‑based  gene  
expression  data  to  more  generic  gene-‐‑based  data  so  that  researchers  can  use  signatures  
generated  from  RNA  sequencing  or  other  microarrays  to  identify  candidate  compounds  using  
the  CMap  drug  experiments.    Statistical  procedures  provided  by  the  CMap  for  computational  
screening  of  Affymetrix  HG-‐‑U133A  query  signatures  against  drug-‐‑induced  gene  expression  
signatures  are  implemented  in  CiDD  for  generic  gene-‐‑based  query  signatures.    These  
procedures  are  rank-‐‑based  and  built  upon  Kolmogorov-‐‑Smirnov  statistical  tests.    This  makes  
these  tests  more  robust  to  technology  biases  and  batch  effects,  which  is  important  in  our  case  
because  our  data  were  generated  from  RNA  sequencing  and  not  HG-‐‑U133A  microarrays.    
Details  of  CMap  methods  can  be  found  in  Lamb  et  al58  and  a  full  description  of  CiDD  is  
provided  in  Appendix  B  section  6.3.          
  

3.2 FAP  colon  and  duodenum  transcription  profiles  
3.2.1

Gene  expression  signatures  of  at-‐‑risk  normal  mucosa  compared  to  polyps  
Before  identifying  gene  expression  signatures  representing  the  difference  between  normal  

mucosa  and  polyp  samples,  we  clustered  the  FAP  samples  based  on  their  quantified  gene  
expression  data  reported  by  Cufflinks  (see  Figure  20).    Generally,  the  colon  and  duodenum  
samples  cluster  separately  illustrating  that  the  tissue  specific  differences  in  gene  expression  
between  the  colon  and  duodenum  are  greater  than  the  gene  expression  differences  between  
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polyp  and  normal  mucosa  samples.    This  indicates  that  the  colon  and  duodenum  of  FAP  
patients  may  need  to  be  targeted  with  different  drugs.    However,  our  goal  is  to  identify  a  gene  
expression  signature  that  is  shared  between  the  colon  and  duodenum  so  that  we  can  identify  
candidate  drug  compounds  that  may  be  used  for  chemoprevention  in  both  tissues.    
  
Colon%
Duodenum%

  
Figure  20:  Unsupervised  clustering  of  colon  and  duodenum  samples  suggest  that  the  gene  expression  difference  
between  the  colon  and  duodenum  is  a  stronger  signature  than  the  one  that  differentiates  polyp  and  normal  samples.  

  
Our  strategy  for  finding  a  common  gene  expression  signature  for  chemoprevention  in  
both  the  colon  and  duodenum  of  FAP  patients  is  to  (1)  identify  a  colon  or  duodenum  gene  
expression  signature  and  then  (2)  check  if  that  signature  is  representative  of  the  differences  
between  the  at-‐‑risk  normal  mucosa  and  polyps  in  both  the  colon  and  duodenum  in  an  
unsupervised  clustering  analysis.    An  alternative  strategy  could  have  been  to  identify  a  gene  
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expression  signature  by  comparing  all  polyps  versus  all  normal  samples.    We  believe  however  
that  our  proposed  2-‐‑step  approach  is  more  robust  and  less  prone  to  overfitting  to  our  data  set.      
Given  that  we  have  more  colon  polyps  (5)  than  we  have  duodenum  polyps  (3),  we  likely  
would  have  more  power  to  detect  the  true  underlying  biological  gene  expression  signature  in  
the  colon  compared  to  the  duodenum  in  FAP  patients.    So  Cuffdiff  was  run  to  identify  
differentially  expressed  genes  between  the  at-‐‑risk  normal  mucosa  and  polyps  using  colon  
samples  only.    Using  the  criteria  described  in  section  3.1.3,  131  differentially  expressed  genes  
were  identified  (as  illustrated  by  the  rows  on  the  heat  map  of  Figure  21).    Contrary  to  Figure  20,  
the  sample  clustering  in  Figure  21  suggests  that  when  limited  to  the  genes  of  a  colon  gene  
expression  signature,  polyps  of  the  duodenum  cluster  with  those  in  the  colon.    This  suggests  
that  if  we  can  identify  a  chemopreventive  drug  or  compound  that  targets  this  colon  gene  
expression  signature,  that  compound  may  also  be  effective  for  chemoprevention  in  the  
duodenum.  
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FAP$polyp$signature$
UpregulatedDownregulatedSample$status$
NormalDuodenum-polypColon-polyp-

  
Figure  21:  Unsupervised  clustering  of  samples  using  an  FAP  colon  gene  expression  signature  that  characterizes  the  
difference  between  that  at-‐‑risk  normal  mucosa  and  polyps  in  the  colon  of  FAP  patients.  BH  adjusted  p-‐‑value  <  0.05  
and  log2  fold-‐‑change  >  1.    Using  this  signature,  the  duodenum  polyps  cluster  with  the  colon  polyps,  which  suggests  
that  if  we  can  identify  a  candidate  drug  to  target  colon  polyps,  that  drug  may  also  target  duodenum  polyps.  

  
  

We  then  characterized  pathways  enriched  with  these  signature  genes  that  are  deregulated  

in  the  colon  of  FAP  patients  using  Ingenuity  Pathway  Analysis  (IPA).    IPA  identified  37  pathways  
that  are  associated  with  the  FAP  colon  gene  expression  signature.    These  pathways,  an  
association  p-‐‑value  and  a  ratio  of  the  proportion  of  their  member  genes  that  are  part  of  the  
expression  signature  are  listed  in  Table  8.    As  expected,  the  WNT/beta-‐‑catenin  pathway  is  
associated  with  the  colon  gene  expression  signature  (p-‐‑value  =  0.021).    Furthermore,  several  
inflammatory  pathways  (labeled  with  *)  were  associated  with  the  gene  expression  signature,  
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which  might  be  expected  since  COX-‐‑2  inhibitors  are  known  to  repress  adenoma  development  
and  these  inhibitors  target  inflammatory  pathways20.    In  addition,  several  RXR  activation  
pathways  (labeled  with  **)  are  associated  with  the  FAP  colon  gene  expression  signature  
including:  (1)  FXR/RXR  activation,  (2)  LPS/IL-‐‑1  mediated  inhibition  of  RXR  function,  (3)  LXR/RXR  
activation,  (4)  PXR/RXR  activation,  and  (5)  VDR/RXR  activation.    The  development  of  new  
chemopreventive  strategies  may  benefit  by  targeting  these  pathways  in  addition  to  or  as  an  
alternative  to  inflammatory  pathways.      

  

63  

Pathways
FXR/RXR%Activation**
LPS/IL41%Mediated%Inhibition%of%RXR%Function**
Granulocyte%Adhesion%and%Diapedesis*
Agranulocyte%Adhesion%and%Diapedesis*
B%Cell%Development
Altered%T%Cell%and%B%Cell%Signaling%in%Rheumatoid%Arthritis
Allograft%Rejection%Signaling
Hepatic%Cholestasis
Cytotoxic%T%Lymphocyte4mediated%Apoptosis%of%Target%Cells*
Autoimmune%Thyroid%Disease%Signaling
MIF4mediated%Glucocorticoid%Regulation*
Graft4versus4Host%Disease%Signaling
T%Helper%Cell%Differentiation
LXR/RXR%Activation**
Hepatic%Fibrosis%/%Hepatic%Stellate%Cell%Activation
Antigen%Presentation%Pathway*
PXR/RXR%Activation**
Serotonin%Degradation
Atherosclerosis%Signaling
Superpathway%of%Melatonin%Degradation
OX40%Signaling%Pathway
Noradrenaline%and%Adrenaline%Degradation
VDR/RXR%Activation**
Antioxidant%Action%of%Vitamin%C
MIF%Regulation%of%Innate%Immunity
Sperm%Motility
Phospholipases
Melatonin%Degradation%I
Nur77%Signaling%in%T%Lymphocytes
Communication%between%Innate%and%Adaptive%Immune%Cells
Wnt/beta4catenin%Signaling
Dendritic%Cell%Maturation
Ephrin%B%Signaling
IL44%Signaling
Type%I%Diabetes%Mellitus%Signaling
Calcium4induced%T%Lymphocyte%Apoptosis
Eicosanoid%Signaling

P(value
2.75E407
1.95E406
1.41E405
1.07E404
1.10E404
1.15E404
1.32E404
1.41E404
1.55E404
2.75E404
3.31E404
3.80E404
3.98E404
4.68E404
5.37E404
6.92E404
1.07E403
1.23E403
1.35E403
1.38E403
1.58E403
1.74E403
4.37E403
5.37E403
6.31E403
7.08E403
7.24E403
1.35E402
1.82E402
1.95E402
2.14E402
2.40E402
3.09E402
3.09E402
3.09E402
3.16E402
3.98E402

Ratio
0.190
0.113
0.120
0.108
0.241
0.140
0.153
0.113
0.173
0.151
0.189
0.174
0.145
0.111
0.107
0.175
0.141
0.154
0.099
0.151
0.131
0.188
0.115
0.102
0.133
0.092
0.127
0.125
0.105
0.086
0.077
0.068
0.089
0.093
0.080
0.098
0.098

  

Table  8:  Pathways  associated  with  the  FAP  gene  expression  signature  using  Ingenuity  Pathway  Analysis  (IPA).    
Notable  pathways  include  the  WNT/beta-‐‑catenin  signaling  pathway  and  several  inflammatory  pathways*.    In  
addition,  several  RXR  activation  pathways**  were  identified.  

  
3.2.2

Gene  fusions  
After  identifying  and  characterizing  differentially  expressed  genes  between  the  at-‐‑risk  

normal  mucosa  and  polyps  in  FAP  patients,  Tophat-‐‑fusion63  was  run  on  RNA  sequencing  reads  
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that  failed  initial  alignment  to  RefSeq  gene  transcripts  through  Cufflinks,  and  269  gene  fusion  
candidates  were  identified.    To  reduce  the  false  positive  rate,  we  required  at  least  1  spanning  
read  (a  read  spanning  a  fusion  breakpoint),  1  spanning  pair  (a  read  pair  where  one  read  resides  
on  one  gene  and  another  resides  on  another  gene,  where  the  pair  of  reads  are  flanking  a  fusion  
breakpoint)  and  5  total  pieces  of  evidence  (e.g.,  the  sum  of  the  number  of  spanning  reads  and  
spanning  pairs)  to  call  putative  gene  fusions.    The  remaining  22  putative  gene  fusions  are  listed  
in  Table  9.  
  
Sample
FAP1_DA1_POLYP_COLON
FAP1_DA1_POLYP_COLON
FAP1_DA1_POLYP_COLON
FAP1_DA1_POLYP_COLON
FAP1_DB1_POLYP_DUODENUM
FAP1_DB1_POLYP_DUODENUM
FAP1_F1_POLYP_COLON
FAP1_F1_POLYP_COLON
FAP1_M1_POLYP_COLON
FAP6_B6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_D6_POLYP_COLON
FAP6_DC6_POLYP_DUODENUM
FAP6_DC6_POLYP_DUODENUM
FAP6_DD6_POLYP_DUODENUM
FAP6_DD6_POLYP_DUODENUM

Gene)1
PRSS3
PARL
GNPNAT1
ENSG00000159314
REG3G
ENSG00000266613
RRN3P2
ENSG00000248827
SLC25A11
PTEN
CEACAM6
RNF6
C11orf80
ZNRD1GAS1
RPLP0P2
ENSG00000225630
ENSG00000259000
LARP4
GRIN2B
ENSG00000232573
ENSG00000224879
ENSG00000232380

Gene)1)Position Gene)1)pos
Gene)2
Gene)2)Position Num)Spanning)Reads Num)Spanning)Pairs Strands
chr9:33798076
chr9
PRSS1
chr7:142460281
1
7
ff
chr3:183580484
chr3
ENSG00000217648 chr6:143663891
1
39
rf
chr14:53250202
chr14
PMS1
chr2:190687172
1
35
rf
chr17:43511559
chr17
LOC146880
chr17:62777797
1
29
rr
chr2:79255058
chr2
REG3A
chr2:79384427
1
6
fr
chr18:8413731
chr18
RFWD2
chr1:176012385
1
8
fr
chr16:29127646
chr16
ENSG00000259807 chr16:29228801
7
6
ff
chr5:107061587
chr5
USP7
chr16:9009202
1
26
fr
chr17:4843394
chr17
RNF167
chr17:4843823
1
14
rr
chr10:89705658
chr10
RPL11
chr1:24021154
1
26
ff
chr19:42266130
chr19
CEACAM5
chr19:42221373
6
196
ff
chr13:26796139
chr13
FOXO1
chr13:41192773
1
12
rf
chr11:66529497
chr11
C1QBP
chr17:5341442
1
48
ff
chr6:29975965
chr6
HLAGB
chr6:31323943
3
8
rf
chr11:61404487
chr11
RPLP0
chr12:120637006
2
56
fr
chr1:565454
chr1
CLCA1
chr1:86950604
1
5
rf
chr14:45334536
chr14
DOCK11
chrX:117707777
2
5
rf
chr12:50856408
chr12
C15orf41
chr15:36910662
9
5
ff
chr12:13768031
chr12
C12orf36
chr12:13529226
4
4
rr
chr14:99439637
chr14
RPL3
chr22:39714409
1
14
rf
chr2:79386904
chr2
REG3A
chr2:79386554
1
50
fr
chr13:69560049
chr13
ZDHHC20
chr13:21961731
2
87
fr

  

Table  9:  FAP  polyp  gene  fusions  identified  with  Tophat-‐‑fusion.  

  
Interesting  fusions  include  those  involving  the  genes  PTEN  and  REG3A.    In  CRC,  PTEN  is  
altered  through  mutations,  LOH  and  hypermethylation,  where  bi-‐‑allelic  inactivation  of  the  
protein  is  seen  in  20-‐‑30%  of  all  sporadic  cases64.    These  types  of  PTEN  events  were  not  observed  
in  our  data  set;  however  there  was  a  PTEN  fusion  event  identified  in  the  
FAP6_B6_POLYP_COLON  sample  suggesting  that  gene  fusions  may  be  another  mechanism  of  

  

65  

PTEN  inactivation.    The  only  gene  that  was  recurrently  altered  in  gene  fusion  events  was  
REG3A.    In  a  previous  study,  REG3A  was  shown  to  be  down-‐‑regulated  in  67%  (20  of  30  
samples)  of  primary  human  gastric  cancers  suggesting  that  REG3A  is  down-‐‑regulated  in  most  
primary  human  gastric  cancer  cells65  and  may  be  a  relevant  gene  in  the  development  of  
duodenum  adenomas.      
  

3.3 Candidate  chemopreventive  drugs  for  FAP  patients  
After  performing  transcriptional  profiling  and  identifying  gene  expression  signatures  of  
the  differences  between  at-‐‑risk  normal  mucosa  and  polyps  in  FAP  patients,  we  used  the  colon  
gene  expression  signature  to  identify  candidate  chemopreventive  drugs  using  CiDD.    Briefly,  as  
described  in  Appendix  B  section  6.3.2.2,  in  the  normal  workflow  of  CiDD,  a  user  specifies  a  
tumor  characteristic  of  interest,  such  as  a  BRAF  V600E  mutation.    CiDD  then  identifies  samples  
in  the  TCGA  harboring  that  tumor  characteristic  (e.g.,  CRC  BRAF  V600E  samples)  and  a  
reference  set  of  samples  (e.g.,  CRC  BRAF  wildtype  samples).    Next,  CiDD  performs  differential  
expression  analyses  on  automatically  downloaded  RNA  sequence  data  from  these  samples  and  
assesses  whether  a  gene  expression  signature  is  associated  with  the  tumor  characteristic  for  use  
in  subsequent  drug  discovery  screening  experiments.    In  the  case  of  our  FAP  project,  we  have  
already  identified  a  colon  gene  expression  signature  so  we  can  directly  use  it  for  drug  screening.    
Thus,  only  steps  3  and  4  of  the  CiDD  workflow  were  applied  to  the  FAP  colon  gene  expression  
signature  (see  Figure  22).    
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Figure  22:  The  FAP  gene  expression  signatures  were  directly  input  into  CiDD,  where  steps  3  and  4  of  the  generic  
workflow  were  run  for  the  identification  of  candidate  drugs.  

  
  

Table  10  lists  CiDD  identified  candidate  drugs  for  chemoprevention  in  the  at-‐‑risk  normal  

mucosa  of  FAP  patients.    Three  metrics  of  the  drug  screening  analyses  are  depicted  on  the  table:  
1. Enrichment  score:  a  score  in  the  range  of  -‐‑1  to  1  where  -‐‑1  is  reflective  of  a  drug  compound  
being  negatively  correlated  with  the  query  gene  expression  signature  and  1  representing  
positive  correlation.    The  score  is  calculated  using  an  algorithm  that  accounts  for  
correlation  of  the  query  signature  with  potentially  multiple  instances  of  a  drug-‐‑induced  
gene  expression  signature58.  
2. Permutation  P-‐‑value:  a  measure  of  significance  for  the  enrichment  score  based  on  
calculating  thousands  of  enrichment  scores  by  randomly  sampling  enrichment  scores  for  
candidate  compounds  and  assessing  the  significance  of  the  candidate  compound  
enrichment  score.  
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3. Specificity:  a  measure  of  the  selectivity  of  a  drug  compound  for  the  phenotype  of  interest.    
Random  query  signatures  are  extracted  from  MSigDB47  and  run  against  the  CMap  to  
generate  a  background  list  of  enrichment  scores  and  specificity  indicates  how  often  a  
score  equal  to  or  more  significant  than  the  enrichment  is  seen.  
  
Compound
Enrichment/score Permutation/P3value
TTNPB*
&0.926
0.020
SC&560
&0.896
0.000
PF&00539745&00
&0.884
0.010
Gly&His&Lys*
&0.851
0.020
cinchonine
&0.843
0.000
brinzolamide
&0.831
0.000
yohimbicGacid*
&0.821
0.020
biperiden
&0.793
0.000
viomycin
&0.785
0.010
canadine
&0.747
0.010
cyclicGadenosineGmonophosphate
&0.746
0.010
benzathineGbenzylpenicillin
&0.729
0.020
eticlopride
&0.725
0.020
vancomycin
&0.721
0.030
cloxacillin**
&0.689
0.040
colistin
&0.685
0.040
debrisoquine
&0.646
0.040
foliosidine
&0.602
0.000
diprophylline
&0.598
0.010
thiamazole
&0.550
0.020
piperacillin
&0.539
0.020

Specificity
0.006
0.010
0.013
0.019
0.003
0.000
0.010
0.019
0.045
0.029
0.016
0.026
0.010
0.022
0.016
0.029
0.010
0.026
0.013
0.048
0.029

  

Table  10:  Candidate  drugs  identified  from  the  FAP  colon  gene  expression  signature  that  describes  the  differences  
between  the  at-‐‑risk  normal  mucosa  and  polyps  in  the  colon  of  FAP  patients.    The  number  of  asterisks  following  a  
compound  indicates  if  the  compound  was  identified  as  a  candidate  drug  using  the  combined  colon  plus  duodenum  
gene  expression  signature  and/or  the  duodenum-‐‑only  gene  expression  signature.  

  
To  be  identified  as  a  candidate  drug  in  Table  10,  we  required  a  permutation  p-‐‑value  ≤  
0.05,  an  enrichment  score  <  0  and  a  specificity  ≤  0.05.    These  criteria  define  drug  compounds  
that,  at  a  level  of  statistical  significance,  induce  gene  expression  signatures  that  are  negatively  
correlated  with  the  colon  polyp  gene  expression  signature  in  addition  to  inducing  responses  
that  are  highly  specific  to  the  colon  polyp  signature.    In  the  results  tables,  the  drugs  are  ranked  
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by  their  enrichment  scores,  where  the  most  negatively  connected  drugs  are  ranked  towards  the  
top  of  the  list.    Of  initial  interest,  SC-‐‑560,  a  COX  inhibitor,  is  the  second  ranked  drug  in  the  list.    
This  drug  has  been  shown  to  be  effective  by  inhibiting  colon  cancer  cell  proliferation  with  
concomitant  G0/G1-‐‑phase  cell  cycle  arrest66.    Drugs  of  the  same  class,  Celecoxib  and  Rofecoxib  
have  also  shown  activity  for  the  prevention  of  adenomas  in  clinical  trials23,24,  providing  some  
validity  to  this  candidate  drug  list.  
To  reinforce  confidence  in  our  findings,  we  generated  additional  gene  expression  
signatures  using  different  comparison  classes  of  normal  mucosa  and  polyp  samples  with  the  
thought  that  drugs  that  appear  on  multiple  candidate  drug  lists  may  have  a  better  chance  of  
being  truly  effective  drugs  for  chemoprevention  in  both  the  colon  and  duodenum  of  FAP  
patients.    In    Table  11,  we  identified  candidate  drugs  using  a  query  signature  for  colon  and  
duodenum  samples  combined.    In  Table  12,  we  identify  candidate  drugs  to  repress  a  gene  
expression  signature  for  FAP  duodenum  samples  exclusively.    
  
Compound
Enrichment/score Permutation/P3value Specificity
spaglumic*acid
,0.983
0.000
0.000
lycorine
,0.833
0.000
0.010
cloxacillin**
,0.779
0.000
0.010
quinpirole*
,0.817
0.000
0.000
yohimbic*acid*
,0.905
0.010
0.000
arachidonyltrifluoromethane
,0.939
0.020
0.006
ketoconazole
,0.700
0.020
0.000
celecoxib
,0.652
0.020
0.000
cefotiam
,0.653
0.040
0.026
quipazine
,0.653
0.040
0.016

  

Table  11:  Candidate  drugs  identified  from  the  combined  colon  and  duodenum  gene  expression  signature.    The  
number  of  asterisks  following  a  compound  indicates  if  the  compound  was  identified  as  a  candidate  drug  using  the  
colon-‐‑only  gene  expression  signature  and/or  the  duodenum-‐‑only  gene  expression  signature.  
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From  these  lists,  we  identified  an  initial  pair  of  interesting  candidate  drugs  for  follow-‐‑up.    

To  treat  both  the  colon  and  duodenum  of  FAP  patients  in  Table  11,  Celecoxib  was  identified,  
which  is  a  COX-‐‑2  inhibitor  that  has  shown  substantial  activity  in  previous  studies  for  repressing  
the  development  of  colon  polyps23,24.    However,  as  explained  in  section  1.1.3,  this  drug  has  been  
associated  with  cardiovascular  side  effects  and  thus  is  not  FDA  approved.    Nevertheless,  
identifying  this  as  a  candidate  drug  again  provides  some  validity  in  the  candidate  drug  results.    
Another  interesting  drug  is  TTNPB,  which  is  the  top-‐‑ranked  compound  for  chemoprevention  in  
the  colon  in  Table  10  and  the  second-‐‑ranked  compound  for  chemoprevention  in  the  duodenum  
in  Table  12.    This  compound  was  also  near  the  top  of  the  ranked  candidate  compound  list  
(based  on  an  enrichment  score  of  -‐‑0.688)  for  the  combined  colon  and  duodenum  signature  in  
Table  11  although  the  permutation  p-‐‑value  did  not  reach  statistical  significance  so  TTNPB  is  not  
listed  in  this  table.    Additionally,  TTNPB  is  an  RXR  agonist,  and  the  pathways  identified  as  
deregulated  in  FAP  polyps  were  RXR  activation  pathways  (see  Table  8),  providing  additional  
biological  justification  for  testing  this  drug  compound  in  follow-‐‑up  experiments.  
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Compound
Enrichment/score Permutation/P3value
sulfaquinoxaline
,0.904
0.000
TTNPB*
,0.900
0.010
Gly,His,Lys*
,0.891
0.000
atractyloside
,0.853
0.000
Prestwick,1103
,0.817
0.000
clorsulon
,0.804
0.000
3,acetamidocoumarin
,0.797
0.000
gentamicin
,0.791
0.000
chenodeoxycholicJacid
,0.764
0.010
isometheptene
,0.755
0.010
ikarugamycin
,0.727
0.050
podophyllotoxin
,0.727
0.020
bumetanide
,0.720
0.020
naringenin
,0.715
0.020
quinpirole*
,0.706
0.020
etynodiol
,0.683
0.020
16,phenyltetranorprostaglandinJE2
,0.664
0.020
CP,863187
,0.648
0.020
iopromide
,0.646
0.020
cloxacillin**
,0.644
0.020
methyldopate
,0.644
0.020
harpagoside
,0.641
0.020
folicJacid
,0.636
0.020
josamycin
,0.635
0.010
diethylstilbestrol
,0.626
0.000
mefexamide
,0.621
0.020
suraminJsodium
,0.602
0.040
bambuterol
,0.601
0.040
ampyrone
,0.576
0.050
pindolol
,0.569
0.050

Specificity
0.003
0.006
0.006
0.000
0.000
0.006
0.032
0.022
0.026
0.016
0.035
0.048
0.032
0.029
0.016
0.006
0.026
0.045
0.042
0.029
0.048
0.038
0.045
0.019
0.010
0.032
0.035
0.026
0.029
0.026

  

Table  12:  Candidate  drugs  identified  from  the  duodenum  gene  expression  signature.    The  number  of  asterisks  
following  a  compound  indicates  if  the  compound  was  identified  as  a  candidate  drug  using  the  combined  colon  plus  
duodenum  gene  expression  signature  and/or  the  colon-‐‑only  gene  expression  signature.  

  

3.4 Discussion  
We  have  identified  an  FAP  colon  gene  expression  signature  representative  of  the  molecular  
differences  between  the  at-‐‑risk  normal  mucosa  and  polyps  of  FAP  patients  and  screened  it  
against  a  database  of  drug-‐‑induced  signatures  using  a  software  framework  that  we  developed  
called  CiDD.      We  have  validated,  in  silico,  the  candidate  celecoxib,  a  COX-‐‑2  inhibitor  that  has  
already  been  clinically  tested  as  a  chemopreventive  drug  in  FAP,  which  helps  support  the  
utility  of  our  approach.    CiDD  also  identified  the  novel  candidate  TTNPB,  which  is  an  RXR  
agonist  for  chemoprevention  in  both  the  colon  and  duodenum  of  FAP  patients.    
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Sulindac  and  bexarotene,  drugs  similar  to  celecoxib  and  TTNPB,  have  been  successfully  
tested  on  cell  lines  and  are  currently  being  tested  on  APCMin/+  mice  by  Dr.  Eduardo  Vilar  and  his  
lab  members  at  MD  Anderson  Cancer  Center.    The  APCMin/+  model  is  one  of  the  most  widely  
used  mouse  models  of  FAP.    These  mice  harbor  a  heterozygous  L850X  nonsense  mutation  in  
APC.  The  protocols,  breeding  of  mice  and  laboratory  work  for  the  testing  of  these  drugs  have  
been  created  and  managed  by  Dr.  Eduardo  Vilar  and  his  lab  members.  
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4 Conclusions  and  future  directions  
The  long-‐‑term  goal  of  the  project  described  in  this  dissertation  is  to  define  the  genomic  
landscape  of  FAP  polyps,  to  determine  their  biological  significance  and  to  use  this  information  
to  develop  novel  chemopreventive  strategies  for  FAP  patients.    Of  note,  although  hereditary  
forms  of  CRC  constitute  less  than  5%  of  all  cases,  their  study  has  tremendously  informed  the  
understanding  of  the  molecular  biology  of  CRC  in  general.    This  is  highlighted  by  the  current  
recommendation  to  use  aspirin  for  the  prevention  of  sporadic  CRC  and  the  approval  of  COX-‐‑2  
inhibitors  as  treatment  for  polyps  in  FAP22.    Thus,  our  long-‐‑term  goal  and  the  current  findings  
presented  in  this  dissertation,  and  the  conclusions  that  follow,  have  the  potential  to  impact  the  
care  of  not  only  FAP  patients  but  also  the  general  population.    In  this  chapter,  I  summarize  our  
conclusions  and  describe  possible  future  directions  of  our  FAP  project,  and  I  conclude  by  
speculating  on  the  additional  impact  on  cancer  research  that  may  be  made  through  the  new  
bioinformatics  tools  that  we  have  developed.  
  

4.1 Promising  candidate  genes  of  early  CRC  development  
The  basic  strategy  followed  in  this  dissertation  involved  the  genomic  and  transcriptomic  
profiling  of  FAP  polyps,  which  are  benign  lesions,  and  the  comparison  of  these  profiles  to  those  
of  CRC  tumors.    This  strategy  allowed  us  to  identify  and  differentiate  the  events  that  may  be  
crucial  for  the  initial  development  of  these  pre-‐‑cancerous  lesions  versus  those  that  might  be  
responsible  for  developing  these  lesions  into  carcinomas.    This  strategy,  which  leverages  TCGA  
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data,  can  generally  be  applied  to  other  NGS-‐‑based  chemoprevention  projects  for  any  tissue  type  
that  is  represented  within  the  TCGA  initiative.  
In  summary,  somatic  APC  truncating  mutations  and  loss  of  chromosome  5q  were  
recurrent  across  polyps.    Driver  events  such  as  activating  KRAS  mutations  were  identified  in  
multiple  polyps.    Further,  analysis  of  mutation  allele  fractions  suggests  that  several  of  the  
polyps  studied  are  multi-‐‑clonal  and  accumulating  additional  driver  events.    Excluding  the  
known  genes  APC  and  KRAS,  50  candidate  genes  have  been  identified  that  could  potentially  
play  a  role  in  future  chemopreventive  drug  development  projects.    Of  these  genes,  notable  
inhibitors  of  beta-‐‑catenin  in  the  WNT  signaling  pathway  were  identified,  namely  AXIN2,  
TCF7L2,  FBXW7  and  SOX9  (in  addition  to  APC).    ARID1A,  which  is  a  MYC  inhibitor  that  helps  
to  control  cellular  proliferation  was  also  recurrently  mutated  in  our  data  set  (see  Figure  17).    The  
majority  of  the  candidate  genes  have  been  previously  associated  with  CRC,  providing  
additional  evidence  that  they  are  important  in  the  early  development  of  CRC.    In  addition,  a  
PTEN  gene  fusion  was  detected  and  a  novel,  recurrent  REG3A  fusion  was  identified  in  
duodenum  polyps  from  2  patients.    These  genes  are  currently  being  biologically  validated  with  
functional  studies  in  the  lab  of  Eduardo  Vilar  at  MD  Anderson  Cancer  Center.  
  

4.2 Next  steps  in  the  characterization  of  FAP  adenomas  and  the  development  
of  FAP  chemopreventive  strategies    
We  identified  a  gene  expression  signature  representative  of  the  molecular  differences  
between  at-‐‑risk  normal  mucosa  and  polyps  in  the  colon  of  FAP  patients  that  was  associated  
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with  deregulation  of  inflammatory  pathways  and  RXR  activation  pathways  (Table  8).    We  
screened  this  signature  against  drug-‐‑induced  signatures  using  our  CiDD  software.      Using  a  
combined  gene  expression  signature  representative  of  the  differences  between  the  at-‐‑risk  
normal  mucosa  and  polyps  in  both  the  colon  and  duodenum  of  FAP  patients,  CiDD  identified  
Celecoxib,  a  COX-‐‑2  inhibitor  that  targets  inflammatory  pathways,  which  has  previously  been  
clinically  developed  as  a  chemopreventive  drug,  thus  illustrating  the  validity  of  our  approach.    
CiDD  also  identified  the  novel  chemopreventive  candidate  drug  TTNPB,  an  RXR  agonist,    in  
separate  analyses  using  FAP  colon  and  then  duodenum  samples.    Sulindac  and  bexarotene,  
drugs  of  similar  function  to  celecoxib  and  TTNPB,  are  currently  being  tested  on  APCmin/+  mice  in  
the  lab  of  Eduardo  Vilar  at  MD  Anderson  Cancer  Center.  
An  additional  40  FAP  samples  have  been  RNA  sequenced  recently  at  the  MD  Anderson  
Cancer  Center  sequencing  core  facility  and  these  data  were  not  included  in  the  analyses  in  this  
dissertation.    These  samples  will  be  analyzed  to  perform  a  more  in-‐‑depth  characterization  of  the  
colon  and  duodenum  transcriptomes  in  the  near  future.    These  data  will  help  us  to  refine  the  
FAP  gene  expression  signatures  and  allow  us  to  more  confidently  define  the  transcriptome  
differences  between  the  colon  and  duodenum  of  FAP  patients,  which  may  provide  insights  into  
how  best  to  treat  the  at-‐‑risk  normal  mucosa  in  both  the  colon  and  duodenum  of  FAP  patients.      
Additional  data  types  may  also  prove  useful  in  continuing  to  refine  our  genomic  analyses  
of  colon  polyps  and  potentially  duodenum  polyps  such  as  SNP  arrays  for  higher-‐‑resolution  
copy  number  variant  calling  or  whole  genome  sequencing  for  mining  DNA  in  non-‐‑coding  
regions  of  the  genome.    Additionally,  power  to  detect  mutations  in  the  polyps  could  be  
improved  by  deepening  sequence  coverage,  which  would  be  an  especially  useful  strategy  for  
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mutation  calling  in  low  purity  settings.    Deeper  coverage  would  also  help  in  characterizing  
polyp  clonality.    Tools  for  characterizing  clonality  are  dependent  on  accurate  somatic  mutation  
calling  and  the  precise  characterization  of  allele  fractions  for  those  mutations,  both  of  which  are  
more  accurate  with  deeper  sequencing.      
To  overcome  problems  of  limited  DNA  in  polyps,  we  could  perform  mutation  calling  and  
transcriptome  characterization  from  the  same  RNA  sequence  reads  of  polyps.    It  is  possible  to  
detect  somatic  mutations  in  the  RNA  sequence  data,  which  would  allow  us  to  characterize  
mutations  in  genes  that  are  transcribed.    Methods  such  as  SNPiR  exist  for  calling  variants  in  
RNA  sequence  data.    SNPiR  has  shown  98%  specificity  and  70%  sensitivity  of  calling  coding  
variants  in  RNA  sequence  data  that  were  verified  using  exome  and  whole  genome  sequencing67.    
Other  chemoprevention  clues  may  be  hidden  in  the  genomes  of  normal  mucosa  samples.    
So  another  focus  of  future  work  is  to  characterize  aberrations  found  in  the  colon  normal  mucosa  
of  FAP  patients.    This  characterization  may  provide  insights  into  pre-‐‑  or  early-‐‑adenoma  
development  that  may  be  very  useful  in  the  development  of  chemopreventive  strategies.  
  

4.3 Bioinformatics  software  developed  for  NGS-‐‑based  chemopreventive  
research  
This  project  required  the  development  of  several  pipelines  and  tools.    In  order  to  annotate  
our  data  set  easily  and  flexibly  in  combination  with  other  large-‐‑scale  data  sets  such  as  the  1000  
Genomes  Project,  the  Exome  Sequencing  Project,  the  COSMIC  database  and  several  others,  we  
developed  variant  tools,  which  simplified  the  management  and  characterization  of  samples  and  
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their  mutations  tremendously.    We  also  characterized  chromosomal  allelic  imbalance  (AI)  in  the  
pre-‐‑cancerous  setting,  where  low  “tumor”  purities  can  make  this  data  more  difficult  to  analyze  
compared  to  that  of  tumors,  using  software  that  we  developed  for  NGS  data  called  hapLOHseq.    
CiDD  was  developed  to  computationally  identify  candidate  drugs  to  target  tumor  gene  
expression  signatures  inferred  from  RNA  sequence  data.  
   These  tools  could  be  applied  to  many  settings.    Variant  tools  is  a  generic  toolset  for  the  
analysis  of  genetic  variants  and  can  be  applied  to  all  NGS  disease-‐‑research  studies  including  
cancer  and  non-‐‑cancer  related  diseases.    hapLOHseq  can  be  applied  to  a  variety  of  settings  where  
the  detection  of  subtle  chromosomal  AI  events  is  helpful.    This  includes,  the  early  detection  of  
cancer  or  metastatic  disease,  the  sensitive  detection  of  recurrence,  the  characterization  of  cancer  
evolution  temporally  and  spatially,  etc.    As  a  complementary  tool,  CiDD  can  be  used  to  identify  
an  initial  set  of  candidate  drugs  to  target  specific  subtypes  of  cancer  that  might  be  detected.    
Further,  CiDD  may  be  helpful  for  candidate  drug  identification  for  any  tumor  exome  or  whole  
genome  study  being  performed  today,  even  in  the  absence  of  RNA  sequence  data  in  these  
studies.    CiDD  makes  this  possible  because  CiDD  can  obtain  RNA  sequence  data  from  TCGA  as  
a  surrogate  for  RNA  sequence  of  samples  being  genomically  characterized  (by  identifying  
TCGA  samples  that  are  genomically  similar  to  those  being  studied).  
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5 Appendix  A:  Sequencing  analysis  pipelines  
In  the  following  sections,  I  document  the  tools,  versions  of  tools  and  commands  executed  
for  sequencing  analysis  pipelines  implemented  for  this  project.    The  pipelines  are  described  
using  tables  where  the  rows  in  the  table  specify  an  ordered  list  of  minimal  commands  needed  to  
replicate  analyses  described  in  this  dissertation.    In  practice,  these  commands  were  
implemented  to  run  on  a  cluster  and  high-‐‑performance  servers.    Various  steps  were  parallelized  
on  a  chromosome  level  such  that  for  a  single  sample,  22  jobs  (one  for  each  chromosome  
excluding  chromosomes  X  and  Y)  would  run  in  parallel  in  a  cluster  environment.    To  simplify  
the  description  of  the  major  steps  of  these  pipelines,  split/merge  commands  and  intermediate  
reporting  steps  that  are  common  to  such  pipelines,  have  been  omitted.  
  

5.1 Exome  sequence  alignment  
Here  we  include  the  minimal  commands  that  could  be  used  to  repeat  the  alignment  
procedure  of  our  FAP  exome  sequence  data.    The  Burrows-‐‑Wheeler  Aligner  (BWA)29  is  used  for  
initial  alignment.  Picard  is  used  for  manipulating  and  cleaning  up  Sequence  Alignment/Map  
(SAM)  format  files68.    The  Genome  Analysis  Toolkit  (GATK)30  was  used  to  perform  local  
realignment  of  sequencing  reads.    SamTools68  was  used  for  indexing  bam  files  and  generating  
mapping  statistics.    For  high-‐‑level  quality  assessment,  SamTools  was  used  to  assess  the  
proportion  of  aligned  reads  that  were  aligned  on-‐‑target  (e.g.,  the  number  of  reads  aligned  to  the  
exome  target  region),  which  is  a  reflection  of  the  quality  of  the  exome  capture  process,  and  
BEDtools35  was  run  to  estimate  aligned  sequencing  depth.  
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Software Version
bwa
0.5.9(r16
bwa
0.5.9(r16
picard

1.95

samtools
picard
samtools

0.1.16
1.95
0.1.16

gatk

2.6.4

gatk
picard
samtools

2.6.4
1.95
0.1.16

gatk

2.6.4

gatk

2.6.4

bedtools
samtools

2.16.1
0.1.16

Command
aln
sampe

Parameters1of1interest

Comment
Align1reads1to1the1human1reference1build1hg19.
Generate1sam1format1alignment1for1read1pairs.
Soft(clip1alignments1that1hang1off1the1end1of1
CleanSam
reference1sequenceand1set1MAPQ1to101if1a1read1is1
unmapped.
view
Convert1from1sam1to1bam1format.
SortSam
SORT_ORDER=coordinate
Sort1reads1by1genomic1position.
index
Create1bam1file1index1for1fast1read1access.
((known:dbsnp1dbsnp_137.hg19.vcf
Identify1potentially1problematic1aligned1regions1
RealignerTargetCreator
((known:indels11000G_biallelic.indels.hg19.vcf around1known1common1polymorphisms1and1indels.
IndelRealigner
Realign1reads1around1identified1regions.
MarkDuplicates
REMOVE_DUPLICATES=true
Mark1and1remove1redundant1sequencing1read1pairs.
index
Re(index1the1realigned1and1cleand1bam1file.
(cov1ReadGroupCovariate
This1is1the1first1pass1of1the1base1quality1score1
(cov1QualityScoreCovariate
recalibration,1which1collects1metrics1in1recalibration1
BaseRecalibrator
(cov1CycleCovariate
tables1for1the1specified1covariates1used1for1
(cov1ContextCovariate
recalibration.
Generate1bam1with1recalibrated1quality1scores1using1
PrintReads
the1output1BQSR1file1from1the1previous1command.
coverage
Generate1coverage1statistics.
idxstats
Get1summary1of1mapped1and1unmapped1reads.

  

Table  13:  A  minimal  list  of  ordered  commands  required  for  the  alignment  of  exome  sequencing  reads  to  the  human  
reference  hg19  build.  

  

5.2 Calling  point  mutations  
Given  the  aligned  sequence  files  produced  by  our  exome  sequence  alignment  pipeline,  
MuTect32  is  run  on  polyp-‐‑blood  sample  pairs  for  the  sensitive  detection  of  point  mutations.    
Potential  false  positive  mutations  that  might  be  common  polymorphisms  are  identified  by  
cross-‐‑checking  candidate  mutations  against  population  variant  databases  (including  the  1000  
Genomes36  project  and  the  Exome  Sequencing  Project)  and  removing  those  seen  in  1%  or  more  
of  the  general  population.    A  custom  verification  pipeline  (described  in  section  2.1.4)  is  also  run  
that  looks  for  evidence  of  variant  reads  in  the  paired  blood  and  normal  mucosa  for  each  
candidate  polyp  mutation,  where  mutations  are  filtered  out  if  variant  reads  are  found  in  2%  or  
5%  of  reads  in  the  blood  or  normal  mucosa,  respectively.    Subsequently,  a  subset  of  
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nonsynonymous  mutations  were  visually  verified  using  the  Integrative  Genomics  Viewer  (IGV)31.    
For  each  patient,  we  performed  visual  verification  by  inspecting  the  sequencing  reads  at  each  
candidate  mutation  site  across  all  of  that  patient’s  samples.      We  looked  for  signs  of  false  
positives,  which  include:  
1. Mutations  appearing  to  be  located  only  on  the  ends  of  reads,  which  are  lower  
quality  base  calls.  
2. Observing  several  variant  alleles  around  the  candidate  mutation,  which  suggests  
that  there  may  be  an  indel  in  the  surrounding  area,  resulting  in  poorly  mapped  
reads  and  the  generation  of  false  positives.  
We  found  that,  after  running  our  verification  pipeline  (described  in  section  2.1.4),  there  were  
very  few  mutations  that  failed  visual  verification.  
  
Software

Version Parameters/of/interest

alignment)pipeline

mutect

1.4

Comment
All)Illumina)Hi/seq)2000)reads)were)aligned)using)the)
alignment)pipeline)described)in)Appendix)A,)section)5.1.
Call)somatic)point)mutations)by)comparing)each)polyp)to)a)
//reference_sequence)ucsc.hg19.fasta
matched)blood)sample.))Information)in)COSMIC)and)dbSNP)
//cosmic)hg19_cosmic_v54_120711.vcf
is)used)to)distinguish)true)somatic)events)from)false)
//dbsnp)dbsnp_137.hg19.vcf
positives.
  

Table  14:  MuTect  calls  point  mutations  for  polyp  (or  tumor)  samples  using  paired  sequence  alignment  files.  

  
Subsequently,  mutation  reports  were  generated  using  variant  tools33,  where  we  annotated  our  
mutations  with  information  from  COSMIC43,  dbNSFP41,  the  1000  Genomes  Project36  and  the  
Exome  Sequencing  Project.  
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5.3 Calling  insertions  and  deletions  
Similarly  to  point  mutation  calling,  somatic  insertions  and  deletions  (indels)  were  detected  
using  paired  polyp  and  blood  samples.    IndelLocator  (i.e.,  IndelGenotyperV2)  was  run  to  call  the  
indels.    The  same  verification  pipeline  (described  in  section  2.1.4)  was  run  to  identify  false  
positives  by  searching  for  evidence  of  variant  reads  in  each  polyp’s  paired  blood  and  normal  
mucosa  sample.    Unlike  with  point  mutations,  where  we  visually  verified  only  a  subset  of  the  
data  (because  there  were  very  few  false  positives  identified  through  their  visual  verification),  all  
indels  were  visually  verified  using  IGV  because  of  their  higher  false-‐‑positive  rate.  
  
Software

Version Parameters/of/interest

alignment)pipeline
IndelGenotyperV2 36.3336 //somatic

Comment
All)Illumina)Hi/seq)2000)reads)were)aligned)using)the)
alignment)pipeline)described)in)Appendix)A,)section)5.1.
Call)somatic)insertions)and)deletions)by)comparing)each)
polyp)to)a)matched)blood)sample.

  

Table  15:  IndelLocator  calls  insertions  and  deletions  for  polyp  (or  tumor)  samples  using  paired  sequence  alignment  
files.  

  

5.4 Chromosomal  allelic  imbalances  
Chromosomal  allelic  imbalances  (AI)  are  called  using  hapLOHseq  (see  Appendix  B,  section  
6.2).    hapLOHseq  identifies  regions  of  the  genome  where  there  is  an  excess  of  one  haplotype  (i.e.,  
allelic  imbalance).    To  do  this,  first  germline  haplotypes  need  to  be  statistically  estimated  (i.e.,  
genotypes  need  to  be  phased).    Then  hapLOHseq  is  run  to  look  for  segments  of  the  genome  where  
allele  frequencies  that  are  higher  than  expected  (e.g.,  greater  than  0.5)  are  enriched  for  the  alleles  
in  an  estimated  germline  haplotype.    These  are  the  candidate  AI  regions.      
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First,  the  GATK  is  used  to  call  genotypes  for  blood  samples  at  sites  that  are  polymorphic  
in  the  1000  Genomes  project.    Then,  MaCH69,  a  Markov  Chain  based  haplotyper,  is  used  to  
statistically  estimate  haplotypes  (using  a  reference  panel  of  200  European  haplotypes).    Of  note,  
hapLOHseq  also  includes  a  phasing  algorithm  that  we  developed  called  pairwise-‐‑phasing  (see  
Appendix  B,  section  6.2.2.1.2),  where  the  main  benefit  of  pairwise-‐‑phasing  is  that  one  can  phase  
a  variant  call  format  (VCF)  file  directly  without  the  need  of  processing  sequencing  read  files.    
Finally,  hapLOHseq  is  run  using  each  polyp’s  VCF  file  and  the  corresponding  estimated  
germline  haplotypes.    To  classify  each  putative  hapLOHseq  event  as  somatic,  we  verified  that  the  
events  did  not  exist  in  the  blood  samples  by  running  hapLOHseq  on  the  blood  and  normal  
mucosa  samples  as  well.  
  
Software

Version

Command

Parameters1of1interest

UnifiedGenotyper

/gt_mode)GENOTYPE_GIVEN_ALLELES
/out_mode)EMIT_ALL_SITES
/stand_call_conf)0.0
//annotation)AlleleBalance
//annotation)DepthPerAlleleBySample
//annotation)Coverage
//annotation)AlleleBalanceBySample

alignment)pipeline

gatk

mach

haplohseq

2.6.4

1.0.18

0.1

//rounds)30
//states)50
//phase
/h)EUR.200.haplotypes
//est_aberrant_emissions
//num_states)2
//initial_param_normal)0.5
//initial_param_event)0.51
//event_prevalence)0.001
//event_length)50
//vcf_min_depth)10

Comment
All)Illumina)Hi/seq)2000)reads)were)aligned)using)the)
alignment)pipeline)described)in)Appendix)A,)section)5.1.
Call)genotypes)(within)the)exome)target)region))at)the)sites)
that)are)polymorphic)in)the)1000)genomes)project.))The)
positions)for)the)1000)genomes)SNP)sites)were)obtained)by)
downloading)the)EUR)reference)panel)data)from)
http://www.sph.umich.edu/csg/abecasis/MACH/download/)
and)then)intersecting)these)coordinates)with)the)target)
region)of)the)Nimblegen)SeqCap)EZ3)capture)chip.
Custom)scripts)were)run)to)transform)the)VCF)generated)by)
the)GATK)into)PED)format)for)MaCH.))A)reference)panel)of)
200)European)haplotypes)(/h)))were)downloaded)from)and)
http://www.sph.umich.edu/csg/abecasis/MACH/download/)
were)used)as)input)into)the)phasing.

Identify)allelic)imbalance)events)using)the)estimated)
haplotypes)and)the)polyp)VCF)files.))hapLOHseq)is)described)
in)Appendix)B,)section)6.2.

  

Table  16:  Minimal  commands  executed  for  the  calling  genotypes,  estimating  haplotypes  and  then  detecting  allelic  
imbalance  events  from  exome  sequence  data.  
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5.5 Quantifying  transcripts  and  identifying  differentially  expressed  genes  
The  Tuxedo  protocol59  was  implemented  to  perform  RNA  sequence  transcript  
quantification  and  for  the  analysis  of  differential  gene  expression.    TopHat60  is  used  for  
alignment  of  initial  reads  to  the  human  genome  reference  hg19.    Cufflinks61  then  assembles  and  
quantifies  isoform  and  gene-‐‑level  transcripts.    Subsequently,  the  software  package  Cuffdiff62  is  
used  to  identify  differentially  expressed  genes,  where  genes  with  an  adjusted  Benjamini-‐‑
Hochberg  p-‐‑values  less  than  0.05  and  a  log2  fold-‐‑change  >=  1  or  log2  fold-‐‑change  <=  -‐‑1  are  
labeled  as  differentially  expressed.    CummerBund  (not  shown  below)  is  an  R  package  that  is  part  
of  the  Tuxedo  protocol,  designed  for  the  interrogation  of  CuffDiff  results,  which  we  used  to  
explore  the  expression  data.  
Software

Version

Parameters/of/interest
**fusion*search3
**keep*fasta*order3
**bowtie13
**no*coverage*search3
*r303
**mate*std*dev3803
**fusion*min*dist31000003
**fusion*anchor*length313
3**fusion*ignore*chromosomes3chrM
hg19/Homo_sapiens/UCSC/hg19/Sequence/BowtieIndex/genome

tophat

2.0.9

cufflinks

2.1.1

cuffmerge

1.0.0

*g3hg19/Homo_sapiens/UCSC/hg19/Annotation/Genes/genes.gtf
*s3hg19/Homo_sapiens/UCSC/hg19/Sequence/Chromosomes

cuffdiff

2.1.1

*b3hg19/Homo_sapiens/UCSC/hg19/Sequence/Chromosomes

Comment

This3performs3mapping3of3RNA*seq3reads3to3the3human3genome3
reference3hg19.

This3assembles3transcripts3and3quatifies3isoform*level3and3gene*level3
expression3using3FPKM.
The3hg193gene3definition3file3(*g)3and3the3reference3sequence3(*s)3are3
resources3that3were3downloaded3from3the3cufflinks3website3
(http://cufflinks.cbcb.umd.edu/igenomes.html).
The3reference3fasta3for3bias3correction3(*b)3is3the3same3parameter3value3
used3in3the3previous3cuffmerge3step3(*s).

  

Table  17:  Minimal  ordering  of  commands  to  quantify  transcripts  and  identify  differentially  expressed  genes  for  a  
single  2-‐‑class  comparison.  

  

5.6 Detecting  gene  fusions  
RNA  sequence  reads  were  aligned  using  TopHat  to  the  human  genome  reference  hg19.    
The  remaining  unmapped  read  pairs  were  used  as  input  to  Tophat  Fusion63.    Tophat  Fusion  
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identifies  putative  gene  fusions.    We  filtered  these  gene  fusions  and  required  putative  fusion  
events  to  have  at  least  1  read  mapped  to  a  fusion  breakpoint,  1  read  pair  with  reads  flanking  the  
fusion  breakpoint  and  a  total  of  5  (reads  plus  read  pairs)  providing  such  pieces  of  evidence  for  
candidate  fusion  events.  
  
Software

tophat

tophat*fusion*post

Version

2.0.9

2.0.9

Parameters/of/interest
**fusion*search3
**keep*fasta*order3
**bowtie13
**no*coverage*search3
*r303
**mate*std*dev3803
**fusion*min*dist31000003
**fusion*anchor*length313
3**fusion*ignore*chromosomes3chrM
hg19/Homo_sapiens/UCSC/hg19/Sequence/BowtieIndex/genome
**num*fusion*reads31
**num*fusion*pairs31
**num*fusion*both35
hg19/Homo_sapiens/UCSC/hg19/Sequence/BowtieIndex/genome

Comment

This3performs3mapping3of3RNA*seq3reads3to3the3human3
genome3reference3hg19.33The3read3pairs3that3do3now3align3
the3hg193are3used3in3the3fusion3detection3step.

Align3initially3unmapped3read3pairs3to3the3human3genome3
reference3hg19.33Identify3candidate3fusion3events3and3
separately3report3those3events3where3there3exists3at3least313
read3that3spans3the3fusion3breakpoint,313read3pair3that3
straddles3the3fusion3breakpoint,3and3there3exists3at3least353
pieces3of3evidence3total3between3the3reads3and3read3pairs.

  

Table  18:  Minimal  commands  to  generate  a  list  of  candidate  gene  fusions  from  RNA  sequence  data.  
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6 Appendix  B:  Bioinformatics  software  developed  and  applied  
in  this  project  
6.1 NGS  variant  management,  annotation  and  analysis:  vtools  
The  contents  of  this  chapter  are  based  on  the  following  article,  reprinted  with  permission,  
from  the  journal  Bioinformatics:  
  
San  Lucas,  F.  A.,  Wang,  G.,  Scheet,  P.  &  Peng,  B.  Integrated  annotation  and  analysis  of  genetic  
variants  from  next-‐‑generation  sequencing  studies  with  variant  tools.  Bioinformatics  28,  421–422  
(2011).  
  
6.1.1

Introduction  
Tracking  samples  and  predicted  variants  from  next-‐‑generation  sequencing  (NGS)  projects  

often  requires  building  custom  analysis  pipelines.    Data  standards  such  as  the  BED70  and  VCF71  
file  specifications  can  be  used  to  represent  these  variants  in  a  common  format,  simplifying  
integration  of  tools  and  the  construction  of  these  analysis  pipelines.    Difficulties  include  the  
integration  of  diverse  annotation  sources  and  the  management  of  many  large  intermediate  files  
containing  millions  of  predicted  variants  and  millions  more  associated  annotations  for  each  
sample.  These  annotation  sources  and  intermediate  files  often  have  fundamental  inconsistencies  
using  either  0-‐‑  or  1-‐‑based  coordinates  and  potentially  different  genomic  builds,  which  can  
complicate  their  management  and  integration.  
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For  biologists  or  analysts  who  have  familiarity  with  programming  and  running  tools  from  
the  command  line,  there  are  many  useful  tools  that  can  be  integrated  into  custom  pipelines  to  
annotate  and  filter  variants.    These  tools  include  ANNOVAR34  and  BEDTools35.    However,  
building  effective  pipelines  that  relate  variants  to  their  samples  and  sample  attributes  (such  as  
cases  and  controls),  while  applying  multiple  annotation  sources  requires  a  large  customization  
effort.    A  framework  for  building  pipelines  that  facilitate  simple,  reproducible  and  recurrent  
analyses  is  currently  lacking.    Therefore,  we  have  developed  variant  tools,  a  flexible,  open-‐‑source  
toolset  upon  which  custom  pipelines  can  be  easily  constructed.    This  toolset  facilitates  the  
storage  of  variants  (alongside  their  sample  details)  as  well  as  the  annotation,  filtering  and  
reporting  of  these  variants  at  multiple  levels  –  starting  with  variant  reports  based  on  individual  
samples  to  project-‐‑wide  variant  reports.  
  
6.1.2

Methods  
Python  scripting  language  and  it  can  incorporate  either  SQLite  or  MySQL  as  the  backend  

database  engine.    The  toolset  is  designed  around  a  master  variant  table  that  often  consists  of  
millions  of  variants  for  all  of  the  samples  in  a  sequencing  project  along  with  variant  attributes  
(called  fields  in  variant  tools).    Variant  fields  can  include  sample  statistics,  which  variant  tools  can  
generate,  or  information  provided  by  annotation  data  sources.  Regardless  of  the  source  of  these  
fields,  they  can  be  used  to  select,  output  and  analyze  genetic  variation  from  the  project.        As  
illustrated  in  Figure  5,  analyzing  genetic  variants  from  NGS  projects  typically  involves  four  
steps,  namely  importing,  annotating,  filtering,  and  reporting:  
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Sample  and  variant  import:  variant  tools  accommodates  a  variety  of  variant  file  formats.  It  
supports  import  of  VCF  files  or  other  tab-‐‑delimited  formats  such  as  intermediate  output  
from  ANNOVAR  or  BEDTools.  It  is  capable  of  annotating  and  reporting  on  all  types  of  
variants,  including  indels,  as  long  as  annotation  sources  are  available.  The  toolset  also  
supports  annotation  and  reporting  of  project  variants  using  multiple  genomic  builds,  by  
automatically  downloading  and  integrating  the  UCSC  liftOver  tool70.  As  an  example,  if  
variants  are  imported  to  a  project  using  build  hg18,  they  can  be  annotated  using  
annotation  sources  designed  for  build  hg19,  and  exported  based  on  either  hg18  or  hg19  
coordinates.  
  
Annotation:  variant  tools  can  incorporate  databases  that  annotate  individual  variants,  
genomic  locations  and  regions,  such  as  genes,  and  other  annotation  fields.    A  growing  
number  of  annotation  sources  such  as  dbNSFP41  or  KEGG  pathways72  can  be  downloaded  
automatically  by  variant  tools  whereas  customized  annotation  databases  could  be  created  
following  a  well-‐‑documented  procedure.    Any  genomic  data  source  can  be  imported  into  
the  database  as  long  as  project  variants  can  be  linked  to  the  annotation  source  through  an  
annotation  attribute  (such  as  genomic  coordinates  or  a  gene  name).      
  
Select  variants  of  interest:  Variants  can  be  selected  by  read  depth  (if  provided  by  the  
imported  VCFs),  by  any  of  the  available  annotation  fields  (such  as  variant  type,  gene,  
pathway  or  predicted  damaging  effects)  or  by  sample  frequency  across  subsets  of  
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samples,  which  is  useful  for  comparing  variants  across  populations  such  as  cases  and  
controls.  Complex  criteria  involving  multiple  fields  from  different  annotation  sources  can  
be  used  to  select  or  filter  variants.  Selected  variants  can  be  counted,  exported,  or  saved  to  
separate  underlying  tables,  where  they  can  be  annotated  and  filtered  separately  from  
other  variants.  
  
Export  reports:  Variants  from  a  table  can  be  exported  with  an  arbitrary  number  of  fields,  
regardless  of  their  sources.  This  allows  users  to  output  sample  statistics  such  as  numbers  
of  homozygous  and  heterozygous  genotypes  in  samples  for  selected  variants  alongside  
annotation  information.  More  interestingly,  arithmetic  operations  and  aggregate  functions  
can  be  used  to  output  summary  statistics  of  variants  such  as  the  average  depth  of  
coverage  for  a  particular  set  of  variants.    
  
variant  tools  installs  easily  and  sets  up  a  working  environment  with  human  genome  
annotation  sources  that  can  be  downloaded  automatically.    Because  variant  tools  manages  
project  variants  and  annotation  sources  for  the  user,  it  is  easier  to  reanalyze  variants  as  genomic  
builds  change  and  as  annotation  sources  are  updated  or  become  available.    The  burden  of  
tracking  VCF  files,  annotation  files  and  numerous  scripts  is  reduced.    variant  tools  is  freely  
available  at  http://varianttools.sourceforge.net.    This  website  includes  source  code,  
documentation,  tutorials  and  a  description  of  available  public  annotation  data  sets.  
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6.1.3

Discussion  
Despite  an  intuitive  command-‐‑line  interface,  some  high-‐‑level  reports,  such  as  calculating  

sample  transition/transversion  ratios  or  reporting  the  number  of  variants  per  gene,  involve  
several  vtools  commands.    To  simplify  the  use  of  variant  tools,  we  provide  a  reporting  command  
vtools_report  that  generates  example  summary  reports.  These  reports  make  the  use  of  variant  
tools  more  practical,  and  the  vtools_report  source  code  provides  examples  of  how  to  combine  
and  further  customize  vtools  commands.  
Within  variant  tools,  variants  are  linked  to  but  stored  separately  from  their  annotations  
within  a  relational  database  removing  the  need  to  store  large,  repetitive,  intermediate  
annotation  files,  which  helps  to  conserve  disk  space.    To  improve  query  performance  in  
annotation  and  filtering,  database  indexes  are  automatically  created  for  the  users.    These  
indexes  do  add  to  the  storage  needs  of  variant  tools.      
For  an  example,  we  created  a  vtools  project  with  44  whole  genome  VCF  files  with  161  
million  predicted  sample  variants.    This  required  3.3G  of  disk  space  to  store  the  variants  within  
an  SQLite  database  compared  to  2G  of  disk  space  for  the  VCF  files  compressed  or  9G  
uncompressed.    As  an  added  benefit  of  the  vtools  approach,  these  variants  were  stored  using  
both  hg18  and  hg19  genomic  coordinates  within  SQLite.    When  using  a  MacPro  workstation  
with  2  Quad-‐‑Core  Intel  Xeon  Processors  at  2.26GHz  and  8G  of  RAM,  the  project  creation  
required  3.5  hours.    This  time  can  be  reduced  to  an  hour  if  variants  are  processed  in  parallel  by  
vtools  on  a  cluster  system  before  they  are  merged  to  a  larger  project.    The  time  required  for  
subsequent  annotation  and  filtering  of  these  variants  ranged  from  1  to  10  minutes.    Additional  
details  and  other  examples  can  be  found  in  the  tutorials  section  of  the  software  website.    
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We  have  provided  a  pre-‐‑configured  but  customizable  framework  for  the  analysis  of  
predicted  variants  from  NGS  data.  Although  our  efforts  were  motivated  by  a  desire  to  produce  
initial,  non-‐‑statistical  analyses,  we  are  currently  expanding  our  software  to  include  a  suite  of  
powerful  tests  for  association  studies.    Our  general  framework  will  allow  the  direct  comparison  
and  implementation  of  a  wide  array  of  analytical  methods.  
  

6.2 Detection  of  allelic  imbalance  events:  hapLOHseq  
6.2.1

Introduction  
A  well-‐‑studied  mechanism  by  which  cancer  cells  alter  the  activity  of  tumor  suppressor  

genes  and  oncogenes  is  through  copy  number  alteration  (CNA)  events.    One  such  aberration  class  
that  we  focus  on  in  this  project  is  chromosomal  allelic  imbalance  (AI).    We  define  chromosomal  
AI  as  genomic  aberrations  of  greater  than  10  megabases  due  to  amplification,  deletion  or  copy  
neutral  loss-‐‑of-‐‑heterozygosity  (cn-‐‑LOH)  events.    The  detection  and  characterization  of  these  
chromosomal  events  has  many  potential  applications  in  cancer  studies.    For  example,  
characterizing  tumor  samples  with  specific  chromosomal  amplifications  and  deletions  can  be  
used  to  inform  therapeutic  decision-‐‑making  as  these  events  provide  insights  into  the  
progression  of  aberrant  cells  to  cancer  and  even  to  metastasis73.    Further,  the  sensitive  detection  
of  specific  AI  biomarkers  can  be  used  for  the  early  detection  of  cancer  and  for  the  management  
of  cancer  resistance74.  
The  traditional  strategies  for  identifying  CNA  or  AI  events  employ  cytogenetic  
technologies,  such  as  karyotyping  and  fluorescence  in  situ  hybridization  (FISH).    In  the  last  decade,  
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array-‐‑based  comparative  hybridization  (aCGH)  and  single-‐‑nucleotide  polymorphism  (SNP)  array  
based  approaches  have  become  popular  technologies  for  CNA  detection75.    One  drawback  of  
these  methods,  however,  is  that  their  probes  are  sparsely  located  along  the  genome  and  they  are  
pre-‐‑defined,  making  it  challenging  to  pinpoint  event  boundaries  and  detect  novel  and  rare  AI  
events.    More  recently,  methods  based  on  whole  genome  sequencing  data  have  gained  in  
popularity,  due  to  their  higher-‐‑resolution,  more  precise  detection  of  CNA  boundaries,  and  
ability  to  identify  novel  CNAs76.    In  addition,  some  tools  exist  for  the  detection  of  CNA  from  
exome  sequencing  and  are  designed  to  address  some  of  the  issues  inherent  in  this  data.    
Examples  of  these  tools  include  ExomeDepth77  and  ExomeCNV78.    ExomeDepth  models  the  
relative  coverage  between  a  sample  of  interest  and  its  expected  coverage  based  on  a  statistical  
model  generated  from  a  reference  panel  of  exome  sequenced  samples.    The  ExomeDepth  
statistical  model  is  designed  to  account  for  the  capture  bias  in  coverage  that  is  common  to  
exome  sequence  data.    ExomeCNV  takes  a  similar  approach,  but  also  incorporates  allele  
frequencies  at  heterozygous  sites  for  detection  of  cn-‐‑LOH  events.    These  methods  are  designed  
to  identify  exon  and  gene-‐‑level  copy  number  events  from  either  paired  samples  or  from  a  
sample  and  a  reference  panel  of  exomes.      
No  method  exists  however  for  detecting  subtle  chromosomal  AI  events  in  exome  sequence  
data  which  could  be  extremely  valuable  in  cancer  studies,  especially  where  limited  tissue  
availability  exists  and  renders  surveys  with  other  technologies  (e.g.,  SNP  arrays)  impossible.    
Subtle  AI  events  are  those  amplification,  deletion  or  cn-‐‑LOH  events  that  exist  in  a  small  
proportion  of  the  cells  sequenced,  potentially  in  20%  or  less  of  the  cells.    hapLOHseq  is  a  software  
tool  that  we  developed  especially  for  the  sensitive  detection  of  chromosomal  AI  events  from  
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next-‐‑generation  sequencing  (NGS)  data,  and  more  specifically  from  exome  sequencing  data  for  the  
project  described  in  this  dissertation.    hapLOHseq  is  a  NGS-‐‑based  adaptation  of  a  method  called  
hapLOH51,  which  was  designed  for  the  subtle  detection  of  AI  events  inferred  from  SNP  array  
data.    Inputs  to  hapLOHseq  include  variant  call  format  (VCF)  files  generated  from  either  whole-‐‑
genome  or  exome  sequencing  and  optionally,  statistically  phased  germline  haplotypes  for  these  
samples.    The  output  for  each  hapLOHseq  run  is  a  report  of  putative  AI  regions  of  the  genome  
along  with  a  detailed  report  that  includes  the  probability  of  each  polymorphic  heterozygous  site  
being  in  a  region  of  AI.      
hapLOHseq  relies  on  AI,  or  the  deviation  from  the  expected  one-‐‑to-‐‑one  allele  ratio  at  
heterozygous  sites  in  germline  DNA.    For  example,  consider  a  heterozygous  site  with  arbitrarily  
labeled  alleles  of  A  and  B.    A  duplication  event  over  the  site  results  in  either  an  AAB  or  ABB  
genotype  with  a  corresponding  imbalanced  allele  ratio  of  2:1  or  1:2.    A  deletion  event  results  in  
an  A-‐‑  or  B-‐‑  genotype  with  severely  imbalanced  allele  ratios  of  1:0  or  0:1.    Similarly,  cn-‐‑LOH  
events  result  in  AA  or  BB  genotypes  with  allele  ratios  of  2:0  or  0:2.    With  high-‐‑purity  tumor  
samples  and  characterization  of  germline  genotypes  from  paired  normal  samples,  one  can  
directly  compare  genotypes  of  the  tumor  and  normal  samples  and  clearly  characterize  the  
tumor  genome  and  infer  copy  number  changes  using  existing  methods  such  as  ExomeCNV78.    
However,  when  the  sample  has  low  tumor  purity  and  contains  a  high-‐‑proportion  of  normal  
cells  and  a  small  proportion  of  tumor  cells,  the  called  genotypes  will  reflect  those  of  the  
germline,  not  the  tumor.    Thus,  to  characterize  the  tumor  we  must  make  inferences  of  
aberrations  using  subtle  signals  of  AI  inferred  from  the  lower-‐‑level  allele  read  counts.  
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6.2.2

Methods  
The  hapLOHseq  method  works  by  capturing  subtle  AI  signals  whenever  there  exists  

imbalances  in  haplotypes  rather  than  simply  relying  on  imbalances  observed  at  independent,  
heterozygous  sites.    The  method  consists  of  3  general  steps,  which  include  the  following:  
1. Estimate  germline  haplotypes  using  statistical,  population  genetics,  from  the  
called  genotypes.    These  haplotypes  can  be  estimated  from  a  germline  sample  or  
alternatively,  directly  from  a  tumor  sample  in  situations  where  the  tumor  purity  is  
very  low  (e.g.,  the  proportion  of  normal  cells  is  very  high).  
2. Assess  similarity  between  the  observed  reference  allele  frequencies  from  the  
sequencing  reads  and  the  estimated  haplotypes.  
3. Identify  AI  regions  where  this  similarity  is  higher  than  expected  indicating  
haplotype  imbalance.  
These  steps  are  described  in  further  detail  in  the  following  sections.  
  
6.2.2.1
6.2.2.1.1

Estimation  of  germline  haplotypes  
Existing  statistical  software  

Several  statistical  software  packages  can  be  used  to  estimate  haplotypes  for  use  in  
hapLOHseq  such  as  MaCH69,  Beagle79  or  fastPHASE80.    In  this  project,  we  used  MaCH  as  described  
in  Appendix  A,  section  5.4.    In  order  to  properly  estimate  haplotypes  using  this  strategy,  it  is  
necessary  to  have  and  process  binary  alignment  map  (BAM)  files.    The  reason  for  this  is  that  from  
variant  call  format  (VCF)  files,  which  is  usually  the  end  product  for  a  sequenced  sample,  one  
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cannot  distinguish  between  missing  genotypes  and  homozygous  reference  sites  (because  VCFs  
typically  do  not  report  homozygous  reference  genotypes).    Going  back  to  reads  in  a  BAM  file  to  
make  homozygous  reference  calls  can  be  resource  intensive,  requiring  large  amounts  of  disk  
space  for  storage  and  a  high-‐‑number  of  processors  often  in  a  distributed  computing  
environment  for  analysis.    In  addition,  users  typically  have  VCF  files  of  sequence  variant  calls  
but  they  may  not  have  access  to  the  low-‐‑level  read  data  (i.e.,  BAM  files).      
To  address  this,  we  have  developed  a  computationally  efficient  method  of  phasing,  called  
pairwise  phasing,  that  is  embedded  in  hapLOHseq  and  runs  on  VCF  files  (without  the  need  for  
BAM  files).    We  describe  the  pairwise  phasing  method  and  compare  its  phasing  accuracy  to  
MaCH’s  phasing  accuracy  in  the  subsequent  sections.  
  
6.2.2.1.2

Pairwise  phasing  

The  basic  idea  behind  pairwise  phasing  is  to  estimate  haplotypes  using  genotypes  provided  
in  a  VCF  file  in  an  iterative,  pairwise  fashion.    Given  all  of  the  heterozygous  sites  in  a  VCF  file  
that  are  polymorphic  in  the  1000  Genomes  (1KG)  Project  (we  call  these  sites  informative  
heterozygous  sites),  the  pairwise  phasing  algorithm  walks  across  these  sites  and  iteratively  
appends  an  allele  from  each  heterozygous  site  that  is  more  likely  to  be  phased,  or  paired,  with  an  
allele  of  the  current  informative  heterozygous  site  based  on  pre-‐‑computed  pairwise  linkage  
disequilibrium  (LD)  calculations.    These  paired  alleles  are  provided  with  hapLOHseq  in  a  pairwise  
phase  map.      
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Figure  23:  A  snippet  of  a  pairwise  phase  map.      Each  row  corresponds  to  a  1KG  polymorphic  site  and  is  defined  with  a  
genomic  coordinate  and  reference  and  alternate  alleles.    The  ref-‐‑paired  alleles  specify  the  alleles  at  subsequent  
polymorphic  sites  that  are  more  likely  to  be  paired  with  the  reference  allele  in  the  current  row  based  on  pre-‐‑
computed  LD  values.  

  
The  pairwise  phase  map  contains  a  row  for  each  polymorphic  site  in  the  1KG  data  set  (see  
Figure  23).    Each  polymorphic  site  is  defined  by  a  coordinate  and  a  reference  and  alternate  
allele.    The  ref-‐‑paired  alleles  are  strings  of  alleles  at  subsequent  polymorphic  sites  that  are  more  
likely  to  be  paired  with  the  reference  allele  for  the  genotype  in  the  current  row  in  the  map  based  
on  pre-‐‑computed  LD  values.    The  length  of  the  ref-‐‑paired  alleles  character  string  is  referred  to  
as  the  depth  of  the  pairwise  phase  map.    An  exhaustive  pairwise  phase  map  would  contain  ref-‐‑
paired  alleles  for  all  subsequent  polymorphic  sites  on  the  current  chromosome.    This  would  
result  in  a  very  large  pairwise  phase  map  and  an  inefficient  phasing  algorithm  because  at  some  
genetic  distance  LD  becomes  negligible  and  accounting  for  these  data  becomes  detrimental  to  
the  performance  of  the  phasing  algorithm.    Optimally,  the  pairwise  phase  map  would  be  deep  
enough  to  pair  up  the  vast  majority  of  adjacent  informative  heterozygous  sites  but  the  map  
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would  not  be  unnecessarily  deep  resulting  in  an  inefficient  algorithm.    Thus,  depth  can  be  
thought  of  as  a  tuning  parameter  of  our  pairwise  phasing  algorithm.  
To  estimate  an  optimal  depth  for  the  pairwise  phase  map,  we  generated  a  histogram  of  
the  numbers  of  polymorphic  markers  in  between  each  pair  of  adjacent  informative  het  sites  in  a  
1KG  sample,  inferred  from  a  whole  genome  VCF  file  and  an  exome-‐‑only-‐‑version  of  the  VCF  file  
(see  Figure  24).    The  distributions  in  the  2  plots  are  similar,  where  the  vast  majority  of  adjacent  
informative  het  pairs  have  less  than  50  polymorphic  sites  between  them.    This  suggests  that  a  
pairwise  phase  map  depth  of  50  may  be  optimal  for  capturing  most  of  the  pairwise  information  
within  these  data  types  without  adding  inefficiency  to  the  pairwise  phasing  process.  
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Figure  24:  Distribution  of  the  number  of  1KG  polymorphic  sites  that  are  in  between  adjacent  informative  
heterozygous  sites  in  a  TCGA  germline  sample  (TCGA-‐‑19-‐‑2620).  

  
  

Here  I  describe  the  algorithm  for  determining  the  ref-‐‑paired  alleles.    Given  m  

polymorphic  sites  in  a  reference  panel  (e.g.,  a  set  of  1KG  haplotypes),  and  a  depth  of  d,  for  each  
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polymorphic  site,  we  assess  its  LD  with  d  subsequent  sites.    Let  i  and  j  (i  =  1,…,m;  j  =  i+1,…,i+d)  
refer  to  2  polymorphic  sites  in  the  reference  panel,  where  i  is  the  current  heterozygous  site  and  j  
is  a  paired  heterozygous  site.    We  determine  which  allele  at  each  site  j  is  phased  with  the  
reference  allele  at  the  current  site  i,  by  computing  DRR  and  DRA.    DRR  is  a  measure  of  LD  between  
the  reference  allele  at  site  i  and  the  reference  allele  at  site  j  and  represents  how  often  reference  
alleles  at  sites  i  and  j  co-‐‑occur  on  the  same  haplotypes  in  the  reference  panel  relative  to  the  
expectation  based  on  allele  frequencies.    Similarly,  DRA  is  a  measure  of  the  LD  between  the  
reference  allele  at  site  i  and  the  alternate  allele  at  site  j.    Here  are  the  simple  6  lines  of  pseudo  
code.  
[1] DRR = PRiRj – PRiPRj
[2] DRA = PRiAj – PRiPAj
[3] if DRR > DRA then
[4]

Ri paired with Rj

[5] else
[6]

Ri paired with Aj

  
This  algorithm  calculates  LD  values  and  determines  allele  pairings  for  each  polymorphic  
site  with  a  predetermined  number  of  subsequent  polymorphic  sites.    This  number  is  the  depth  of  
the  pairwise  phase  map  discussed  previously.    By  default,  our  hapLOHseq  pairwise  phase  maps  
are  constructed  to  a  depth  of  50.    Of  note,  in  cases  where  this  depth  is  not  large  enough  to  
accommodate  pairs  of  informative  het  sites  that  are  genomically  spaced  with  more  than  50  
polymorphic  sites  between  them,  phasing  is  assigned  randomly.    A  whole  genome  and  an  
exome  version  of  the  pairwise  phase  maps  will  be  made  available  with  hapLOHseq.    
  

97  

Given  a  pairwise  phase  map,  phasing  simply  consists  of  incrementing  along  each  
informative  het  site  in  a  sample  of  interest,  identifying  the  next  informative  het  site,  and  
determining  which  allele  at  the  next  het  site  is  phased  with  the  reference  allele  at  the  current  site  
through  a  simple  lookup  in  the  pairwise  phase  map.    As  the  algorithm  iterates  over  all  
informative  het  pairs,  it  builds  up  haplotype  estimates  one  pair  at  a  time.    The  performance  of  
the  phasing  algorithm  scales  linearly  with  the  number  of  informative  het  sites  that  are  available  
in  the  input  VCF  file.    Of  importance,  although  this  was  not  our  original  motivation,  it  takes  a  
few  minutes  to  run  pairwise  phasing  and  hapLOHseq  on  hundreds  of  exome  sequenced  samples  
as  opposed  to  days  or  weeks  to  run  the  MaCH  pipeline  and  hapLOHseq.  
  

To  assess  the  performance  of  the  pairwise  phasing  algorithm  at  varying  depths,  we  

generated  pairwise  phase  maps  at  varying  depths  and  then  performed  pairwise  phasing  on  a  
1000  Genome  sample’s  whole  genome  VCF  file  and  an  exome-‐‑only-‐‑version  of  the  VCF  file.    
Figure  25  illustrates  the  phasing  performance  of  our  algorithm  by  comparing  our  estimated  
haplotypes  to  the  haplotype  published  by  the  1000  Genomes  project.    The  figure  indicates  that,  
as  expected,  phasing  whole  genome  VCFs  provides  more  accurate  estimates  of  haplotypes  as  
compared  to  exome  VCFs  due  to  the  much  higher  number  of  data  points  available  in  whole  
genome  sequencing  data.    In  addition,  the  accuracies  of  the  haplotype  estimates  peak  at  around  
a  depth  of  40  or  50  in  the  pairwise  phase  map  which  further  supports  our  decision  to  use  a  
pairwise  depth  of  50  by  default  in  the  construction  of  pairwise  phase  maps.  
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Figure  25:  Phase  concordance  (an  estimate  haplotype  similarity)  for  whole  genome  and  exome-‐‑estimated  haplotypes  
compared  to  the  haplotype  published  by  the  1000  Genomes  project  for  a  sample  using  pairwise  phase  maps  at  
varying  depths.    This  suggests  that  there  is  negligible  gain  in  phasing  accuracy  at  a  pairwise  depth  of  30  or  more.  

    
6.2.2.1.3

Performance  of  MaCH  and  pairwise  phasing  

To  assess  the  phasing  accuracy  of  MaCH  and  pairwise  phasing,  we  took  a  tumor/normal  
pair  of  samples  from  a  TCGA  patient  (TCGA-‐‑19-‐‑2620)  and  phased  its  germline  haplotypes  
using  both  strategies  on  three  chromosomes  (8,  9  and  10)  where  there  are  obvious  chromosomal  
AI  events  in  its  paired  tumor  sample.    In  these  regions,  we  can  easily  identify  the  true  
overrepresented  and  underrepresented  haplotypes  because  the  allele  frequency  bands  are  
separate  and  distinct  (see  Figure  26).    To  identify  these  true  haplotypes,  at  each  heterozygous  
site  in  these  tumor  sample  chromosomes,  we  identify  the  overrepresented  allele  (i.e.,  the  allele  
at  greater  than  0.5  allele  frequency)  and  assign  it  to  the  overrepresented  haplotype  and  assign  
the  underrepresented  allele  (i.e.,  the  allele  at  a  less  than  0.5  allele  frequency)  to  the  
underrepresented  haplotype.      
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Figure  26:  Variant  allele  frequencies  across  the  exome  at  heterozygous  sites  in  a  tumor  sample  for  a  TCGA  patient  
(TCGA-‐‑19-‐‑2620).    A  clear  separation  of  allele  frequencies,  producing  2  bands,  can  be  visually  identified  across  
chromosomes  8,  9  and  10.  

  
The  two  resulting  haplotypes  define  the  true  germline  haplotypes  on  these  chromosomes  
for  this  patient.    This  process  was  repeated  for  both  a  whole  genome  and  an  exome  VCF  for  
tumor  samples  of  the  same  patient.    We  then  ran  our  MaCH  phasing  pipeline  and  our  pairwise  
phasing  algorithms  on  the  germline  samples  for  this  patient  on  chromosomes  8,  9  and  10.    To  
assess  the  accuracy  of  the  phasing  strategies,  we  calculated  the  switch  accuracy81,  a  measure  of  
the  similarity  between  the  true  haplotypes  and  those  estimated,  for  each  phasing  analysis  and  
report  them  in  Table  19.      If  two  haplotypes  have  no  resemblance,  we  would  expect  a  switch  
accuracy  of  around  0.5.    If  two  haplotypes  were  identical,  the  switch  accuracy  would  be  1.  
  
Phasing(strategy Sequencing(tech Num(markers Switch(accuracy
Pairwise(phasing
Exome
669
0.777
MaCH(phasing
Exome
770
0.784
Pairwise(phasing Whole(genome
103388
0.943
MaCH(phasing
Whole(genome
104606
0.942
  
Table  19:  Performance  of  pairwise  and  MaCH  phasing  in  the  exome  and  whole  genome  contexts.    The  switch  
accuracies  are  nearly  equal  comparing  pairwise  and  MaCH  phasing.      
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Table  19  also  indicates  the  number  of  informative  het  sits  (i.e.,  Num  markers)  available  to  
each  phasing  strategy.    The  MaCH  phasing  pipeline  requires  access  to  the  raw  sequence  files  
and  calling  genotypes  at  sites  in  the  1000  Genomes  reference  panel.    By  processing  the  BAM  
files  directly  as  opposed  to  using  only  variant  sites  (which  are  available  in  VCF  files),  this  
strategy  allows  for  homozygous  genotypes  being  available  for  phasing  and  additional  
heterozygous  sites  being  available  for  hapLOHseq  event  calling.    The  MaCH  phasing  strategy  is  
much  more  computationally  demanding  with  the  potential  benefit  of  better  phasing  and  
subsequently  more  accurate  AI  event  calling.    There  were  101  additional  heterozygous  markers  
in  the  exome  analysis  and  1,218  additional  heterozygous  markers  in  the  whole  genome  analysis  
using  the  MaCH  strategy  versus  pairwise  phasing.    Switch  accuracies  however  between  MaCH  
and  pairwise  phasing  are  almost  identical,  suggesting  that  the  substantial  computational  gains  
and  the  ease  of  use  of  pairwise  phasing  come  at  a  minimal  cost  when  switch  errors  are  the  
relevant  loss  function.    For  hapLOHseq  and  hapLOH  this  is  indeed  the  case.    We  assess  the  
improvement  of  hapLOHseq  event  calling  using  MaCH  versus  pairwise  phasing  (due  to  the  
increased  number  of  informative  markers  associated  with  MaCH  phasing)  in  section  6.2.3.  
  
6.2.2.2

Phase  concordance  with  frequency-‐‑based  phasing  

After  statistical  estimation  of  germline  haplotypes,  we  assessed  whether  or  not  these  
haplotypes  were  in  allelic  imbalance  in  regions  of  the  genome  where  there  appear  to  exist  an  
excess  haplotype  and  an  underrepresented  haplotype  based  on  allele  frequencies.    First,  we  
determine  what  VCF  allele  frequencies  indicate  to  be  the  excess  haplotype  by  applying  a  
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threshold  at  each  marker  independently  in  a  frequency-‐‑based  phasing  algorithm.    The  threshold  
is  defined  as  the  median  variant  allele  frequency  in  the  data  set.    The  alleles  above  the  threshold  
constitute  one  haplotype  and  the  alleles  below  the  threshold  constitute  the  other.    If  no  
imbalance  exists,  these  allele-‐‑frequency  based  haplotypes  reflect  only  stochastic  deviation.    
Otherwise,  if  there  exists  some  true  level  of  AI,  the  frequency-‐‑based  haplotypes  should  bear  
some  resemblance  to  the  estimated  germline  haplotypes.    This  resemblance  is  quantified  with  
phase  concordance,  a  measure  of  similarity  between  2  haplotypes.    Switch  accuracy81,  or  more  
appropriately,  switch  consistency  accommodates  errors  in  statistical  haplotype  reconstructions  
and  is  used  as  the  metric  for  phase  concordance  in  hapLOHseq.    This  is  the  same  phase  
concordance  metric  that  is  used  by  hapLOH  and  is  described  in  detail  in  the  corresponding  
manuscript51.      
Briefly,  I  describe  how  phase  concordance  is  calculated.    At  each  pair  of  adjacent  
informative  het  sites,  if  the  overrepresented  alleles  (e.g.,  the  alleles  with  allele  frequencies  larger  
than  the  frequency  threshold)  reside  on  the  same  statistically  estimated  haplotype,  a  “1”  is  
recorded.    If  the  alleles  reside  on  different  statistically  estimated  haplotypes,  a  “0”  is  recorded.    
In  normal  regions  of  the  genome,  we  do  not  expect  that  an  excess  haplotype  exists.    In  this  case,  
we  expect  to  record  “1”s  and  “0”s  at  random,  and  the  running  average  of  these  numbers,  the  
phase  concordance,  would  be  0.5.    In  regions  where  there  is  allelic  imbalance  and  where  an  excess  
haplotype  exists,  we  expect  that  the  frequency-‐‑based  haplotypes  have  some  resemblance  to  the  
statistically  estimated  haplotypes,  and  we  expect  to  observe  a  higher  number  of  “1”s  (e.g.,  we  
expect  a  phase  concordance  >  0.5).    This  string  of  “1”s  and  “0”s  is  referred  to  as  switch  
enumerations.  
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6.2.2.3

Identification  of  allelic  imbalance  regions  with  a  hidden  Markov  model  

To  identify  regions  of  the  genome  with  higher  than  expected  phase  concordance,  we  
implemented  a  simple  HMM  that  was  proposed  and  implemented  in  hapLOH51.    The  observed  
data  in  the  HMM  are  the  aforementioned  switch  enumerations.    Let  i  =  1,…,m  represent  
informative  heterozygous  sites  in  the  genome.    Let  Li  be  an  indicator  for  whether  or  not  the  
interval  between  i  and  i+1  is  contained  within  a  region  of  AI  in  the  tumor  genome.    Li,…,LM-‐‑1  
form  a  Markov  chain  on  two  or  more  states.    By  default,  hapLOHseq  implements  a  2-‐‑state  HMM  
where  state  0  represents  no  AI  and  state  1  represents  AI.    If  there  are  multiple  AI  event  states  
(e.g.,  HMMs  with  3  or  more  states),  each  event  state  corresponds  to  a  different  degree  of  AI.    
The  transition  probabilities  are  constructed  as  shown  in  Figure  27.  
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Figure  27:  hapLOHseq  HMM  state  transition  diagram.    There  is  one  normal  state  and  one  or  more  AI  event  states  
where  if  there  exists  more  than  one  AI  state,  each  AI  state  represents  events  with  different  degrees  of  AI.    By  default,  
hapLOHseq  uses  one  event  state  (i.e.,  n  =  1).  

  

  

103  

We  let  αl  (l  =  0,1,…,n)  denote  the  emission  probability  Pr(xi=1|Li=l).    The  emission  
probability  α0  for  the  normal  state  is  set  to  0.5  by  default,  which  is  the  expected  phase  
concordance  in  normal  regions  of  the  genome.    In  these  regions,  the  frequency-‐‑based  
haplotypes  have  no  resemblance  to  the  statistically  estimated  haplotypes  because  there  is  no  
haplotype  imbalance.    For  other  states,  the  parameter  will  be  larger  than  0.5  and  will  be  
estimated  using  the  Baum-‐‑Welch  algorithm82  which  is  an  algorithm  that  attempts  to  find  the  
HMM  parameters  that  maximize  the  likelihood  of  the  observed  switch  enumerations.    These  
parameters  are  estimated  separately  for  each  chromosome.    The  probability  that  the  process  is  
in  state  l  at  marker  interval  i  is  calculated  using  the  standard  forward  and  backward  algorithm82  
and  these  are  reported  in  hapLOHseq  output  files.  
  

Initial  values  for  𝜆!   and  𝜆!   are  set  from  2  user  parameters  that  represent  the  expected  

event  prevalence  (p)  and  the  expected  event  length  (y)  in  megabases.    By  default,  hapLOHseq  
takes  the  default  size  of  a  genome  analyzed  (3  billion  for  humans)  and  divides  that  by  the  
number  of  informative  het  sites  in  the  sample  being  analyzed.    This  value  represents  the  
average  distance  between  informative  het  sites  in  megabases.    The  expected  event  length  y  is  
then  divided  by  this  distance  and  represented  in  terms  of  numbers  of  het  sites  with  an  x  in  the  
parameterizations  below.      Prevalence  is  represented  with  a  p.  
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For  further  details  of  this  HMM  including  its  performance  in  simulated  settings  please  see  the  
hapLOH  manuscript51.    In  the  next  section,  we  apply  and  assess  the  performance  of  hapLOHseq  
using  the  MaCH  and  pairwise  phasing  strategies  on  a  TCGA  sample  at  various  tumor  purities.  
  
6.2.3

Results  
We  obtained  the  whole  genome  and  exome  sequencing  reads  for  the  tumor  (brain  tissue)  

and  normal  (blood)  sample  of  a  patient  with  glioblastoma  (TCGA-‐‑19-‐‑2620)  from  TCGA.    
Additionally,  the  published  LOH  and  CNA  calls  for  this  tumor  sample  inferred  from  SNP  
arrays  were  obtained  for  comparison  to  hapLOHseq  AI  calls.    To  assess  the  performance  of  
hapLOHseq  at  different  levels  of  tumor  purity,  we  created  computational  mixtures  of  the  reads,  
which  represent  tumor  sequencing  at  various  purity  levels.    Sequencing  read  pairs  from  the  
tumor  and  normal  BAM  files  were  randomly  sampled  and  merged  into  mixed  BAM  files  at  the  
tumor  proportions  listed  in  the  first  column  of  Table  20.    TCGA  estimates  that  the  proportion  of  
tumor  DNA  that  is  in  the  tumor  sample  is  80%.    Thus,  an  estimate  of  the  actual  proportion  of  
tumor  DNA  in  each  of  these  mixtures  is  listed  in  the  second  column  of  Table  20.  
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Tumor&sample&proportion&(%) Tumor&DNA&proportion&(%)
0
0
5
4
10
8
15
12
20
16
25
20
35
28
50
40
70
56
100
80

  

Table  20:  Tumor  mixtures  generated  by  mixing  random  sequence  read  pairs  from  a  tumor  and  normal  sample  from  a  
TCGA  patient  (TCGA-‐‑19-‐‑2620).    Reads  were  mixed  using  the  sample  proportions  specified.    TCGA  estimates  that  the  
tumor  sample  has  80%  tumor  DNA  and  20%  normal  DNA.    The  estimated  tumor  DNA  proportion  of  each  mixture  is  
specified.  

  
hapLOHseq  was  then  run  on  the  tumor  mixture  BAM  files  for  both  whole  genome  and  
exome  sequencing  using  two  phasing  strategies  –  MaCH  and  pairwise  phasing  as  described  in  
section  6.2.2.1.    hapLOHseq  was  run  on  all  of  these  samples  using  an  estimated  event  length  of  20  
megabases.    The  event  prevalence  parameter  was  set  to  0.001  for  the  exome  sequencing  runs  
and  set  to  0.00001  for  the  whole  genome  sequencing  runs.    The  prevalence  for  the  whole  
genome  analyses  was  set  lower  to  reduce  noise  in  the  whole  genome  sequencing  results.        
hapLOHseq  plots  were  then  generated  for  4  sets  of  runs.  Figure  28  and  Figure  29  show  the  
results  of  running  hapLOHseq  on  the  exome  sequencing  tumor  mixture  samples  using  MaCH  
and  pairwise  phasing,  respectively.    Figure  30  and  Figure  31  show  the  results  of  running  
hapLOHseq  on  the  whole  genome  sequencing  tumor  mixture  samples  using  MaCH  and  pairwise  
phasing,  respectively.    These  figures  include  at  the  top,  2  panels  that  show  the  LOH  and  CNA  
calls  across  the  genome  published  by  the  TCGA.    The  intensity  of  the  red  color  in  the  LOH  plot  
reflects  the  degree  of  LOH  observed  at  these  sites.    In  the  CNA  plot,  red  represents  
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amplification  events  and  blue  represents  deletion  events.    The  intensity  of  those  colors  reflects  
the  copy  number  change  observed  in  these  regions.    The  subsequent  hapLOHseq  plots  show  
(with  gray  dots)  the  variant  allele  fractions  (VAFs)  observed  in  the  various  tumor  mixture  
samples  at  polymorphic  sites  across  the  genome  that  are  heterozygous  in  the  germline  sample.    
In  addition,  there  is  a  red  line  that  shows  the  probability  of  regions  of  the  genome  being  in  
allelic  imbalance  based  on  probabilities  (from  0  to  1)  reported  by  hapLOHseq.  
As  can  be  seen  in  these  plots,  at  higher  tumor  purities,  it  is  easier  to  identify  AI  events.    In  
the  exome  sequencing  analyses,  the  more  prominent  events,  which  were  identified  by  TCGA  on  
chromosomes  8,  9  and  10  can  be  found  in  the  hapLOHseq  results  at  20%  tumor  purity  with  some  
signal  of  the  events  showing  in  purities  as  low  as  8%.    The  MaCH  phasing  strategy  appears  to  
be  performing  better  than  the  pairwise  phasing  at  these  lower  tumor  purities.    Given  that  the  
phasing  accuracy  of  MaCH  and  pairwise  phasing  are  almost  identical,  the  improvement  in  
hapLOHseq  sensitivity  is  likely  due  to  the  increased  number  of  informative  het  sites  (770  using  
the  MaCH  strategy  versus  669  using  the  pairwise  phasing  strategy)  that  are  available  to  
hapLOHseq  using  the  MaCH  phasing  strategy.  
  

  

107  

4%#tumor#purity#
8%#tumor#purity#
12%#tumor#purity#
16%#tumor#purity#
20%#tumor#purity#
28%#tumor#purity#
40%#tumor#purity#
56%#tumor#purity#
80%#tumor#purity#

  

Figure  28:  hapLOHseq  calls  at  different  computational  dilutions  for  a  single  TCGA  sample  derived  from  exome  
sequencing  data  using  MaCH  to  statistically  estimate  germline  haplotypes.    Calls  made  and  published  from  SNP  
microarray  analysis  by  the  TCGA  are  represented  in  the  top  two  bars  (LOH  and  CNA  events,  respectively).  
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Figure  29:  hapLOHseq  calls  at  different  computational  dilutions  for  a  single  TCGA  sample  derived  from  exome  
sequencing  data  using  pairwise  phasing  to  estimate  germline  haplotypes.    Calls  made  and  published  from  SNP  
microarray  analysis  by  the  TCGA  are  represented  in  the  top  two  bars  (LOH  and  CNA  events,  respectively).  

  

108  

4%#tumor#purity#
8%#tumor#purity#
12%#tumor#purity#
16%#tumor#purity#
20%#tumor#purity#
28%#tumor#purity#
40%#tumor#purity#
56%#tumor#purity#
80%#tumor#purity#

  

Figure  30:  hapLOHseq  calls  at  different  computational  dilutions  for  a  single  TCGA  sample  derived  from  whole  
genome  sequencing  data  using  MaCH  to  statistically  estimate  germline  haplotypes.    Calls  made  and  published  from  
SNP  microarray  analysis  by  the  TCGA  are  represented  in  the  top  two  bars  (LOH  and  CNA  events,  respectively).  
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Figure  31:  hapLOHseq  calls  at  different  computational  dilutions  for  a  single  TCGA  sample  derived  from  whole  
genome  sequencing  data  using  pairwise  phasing  to  estimate  germline  haplotypes.    Calls  made  and  published  from  
SNP  microarray  analysis  by  the  TCGA  are  represented  in  the  top  two  bars  (LOH  and  CNA  events,  respectively).  
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The  sensitivity  of  hapLOHseq  on  whole  genome  sequencing  data  is  much  better  at  tumor  
purities  in  the  range  of  8%  to  29%.    The  boundaries  of  events  are  more  well-‐‑defined  and  the  less  
prominent  events  identified  by  TCGA  on  chromosomes  16,  19  and  22  are  identified  at  12%  
tumor  purity  with  some  signal  also  seen  at  8%  tumor  purity.    The  choice  of  phasing  strategy  
with  whole  genome  sequencing  appears  to  have  little  to  no  effect  on  the  sensitivity  of  
hapLOHseq.    This  is  likely  because  the  phasing  accuracy  of  MaCH  and  pairwise  phasing  are  
virtually  identical  and  the  number  of  informative  het  sites  is  so  large  (greater  than  100,000)  that  
the  difference  in  these  numbers  (see  Table  19)  between  the  2  strategies  is  negligible.  
To  summarize  hapLOHseq  performance,  receiver  operating  characteristic  (ROC)  curves  in  
Figure  32  and  Figure  33  show  the  sensitivity  and  specificity  of  hapLOHseq  on  calling  events  
larger  than  10  megabases  on  the  computational  dilutions  of  the  TCGA  sample.    Table  21  lists  the  
area  under  the  curve  (AUC)  corresponding  to  these  ROC  curves.    At  purities  between  12%  and  
16%  hapLOHseq  is  able  to  detect  some  events  in  the  exome  data.    At  these  purities,  as  observed  
in  the  hapLOHseq  plots,  MaCH  phasing  is  identifying  events  more  precisely,  likely  due  to  the  
increased  number  of  informative  het  sites  available.      Applied  to  whole  genome  sequencing,  
hapLOHseq  is  able  to  pick  up  events  at  tumor  purities  in  between  4%  and  8%  where  the  choice  of  
phasing  strategy  has  little  effect  on  the  accuracy  of  identifying  AI  regions.      
Of  note,  the  AUC  at  80%  tumor  purity  is  lower  than  that  compared  to  many  of  the  AUC  
values  at  lower  tumor  purities.    We  believe  that  at  80%  tumor  purities,  hapLOHseq  is  detecting  
low-‐‑proportion  chromosomal  events  on  chromosome  14.    We  believe  these  are  true  events  that  
were  not  detected  in  TCGA  analyses.    We  believe  this  to  be  the  case  because  we  see  the  same  
event  across  different  technologies  and  phasing  strategies  but  only  at  high  tumor  purities.  
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Figure  32:  ROC  comparison  for  MaCH  and  pairwise  phasing  for  exome  sequencing  data.  
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Figure  33:  ROC  curves  for  MaCH  versus  pairwise  phasing  for  whole  genome  sequence  data.  
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Pairwise/phasing MaCH/phasing
Tumor Pairwise/phasing MaCH/phasing
Whole/genome/ Whole/genome/
purity Exome/(AUC)
Exome/(AUC)
(AUC)
(AUC)
80
0.984
0.963
0.956
0.958
56
0.992
0.991
0.980
0.974
40
0.999
0.994
0.986
0.985
28
0.794
0.784
0.985
0.985
20
0.696
0.809
0.988
0.984
16
0.665
0.799
0.982
0.981
12
0.606
0.749
0.982
0.981
8
0.551
0.590
0.902
0.819
4
0.420
0.531
0.635
0.625
  

Table  21:  AUC  for  hapLOHseq  calling  strategies  using  pairwise  and  MaCH  phasing  for  exome  and  whole  genome  
samples  at  varying  levels  of  tumor  purity.  

  
6.2.4
  

Discussion  
We  have  presented  a  new  method  for  the  detection  of  subtle  AI  events  in  NGS  data  called  

hapLOHseq.    We  have  also  implemented  a  very  efficient  pairwise-‐‑phasing  algorithm  that  allows  
for  the  estimation  of  haplotypes  directly  from  VCF  files,  allowing  users  to  run  hapLOHseq  
without  the  need  for  low-‐‑level  sequencing  read  files,  which  may  either  not  be  available,  or  
which  may  be  too  resource  intensive  to  run  efficiently  on  a  large  number  of  samples.    In  
summary,  hapLOHseq  is  able  to  detect  AI  events  from  exome  sequencing  data,  where  these  
events  exist  in  12%  to  16%  of  the  cells  sequenced.    Applied  to  whole  genome  sequencing  data,  
hapLOHseq  has  more  sensitivity,  being  able  to  detect  events  occurring  in  4%  to  8%  of  the  cells  
sequenced.    hapLOHseq  may  be  useful  for  the  detection  and  profiling  of  AI  in  tumor  samples  
that  are  either  heavily  diluted  with  normal  tissue  cells  or  in  heterogeneous  tumor  samples.  
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6.3 Identification  of  candidate  drugs:  cidd  
Cancer  in  silico  Drug  Discovery  (CiDD)  is  a  software  framework  for  the  identification  of  
candidate  drugs  to  target  tumors  with  specific  molecular  characteristics.    The  description  of  
CiDD  in  this  section  is  part  of  a  manuscript  entitled  Cancer  in  silico  Drug  Discovery:  a  systems  
biology  tool  for  identifying  candidate  drugs  to  target  specific  molecular  tumor  subtypes  (authored  by  F.  
Anthony  San  Lucas,  Jerry  Fowler,  Kyle  Chang,  Scott  Kopetz,  Eduardo  Vilar  and  Paul  Scheet)  
that  is  currently  under  review  at  the  journal  Molecular  Cancer  Therapeutics.  
6.3.1

Introduction  
Selection  of  targeted  therapies  for  cancer  drug  development  has  traditionally  been  based  

on  the  presence  or  absence  of  specific  somatic  mutations  and  this  has  been  shown  to  be  an  
effective  strategy  to  improve  patient  outcomes83–86.  However,  a  large  number  of  targeted  drugs  
and  other  compounds  that  have  anti-‐‑tumor  properties  have  not  been  linked  to  specific  
mutations,  or  biomarkers,  that  could  be  used  to  predict  their  selective  efficacy87.  Although  next-‐‑
generation  sequencing  (NGS)  allows  researchers  to  rapidly  and  comprehensively  profile  tumor  
mutations,  the  vast  majority  of  these  data  have  not  been  useful  in  the  clinical  setting  since  only  a  
small  number  of  mutations  have  been  used  to  inform  prognosis  or  guide  therapeutic  
decisions88–90.    
Several  computational  approaches  exist  and  have  been  implemented  to  predict  the  
functional  impact  of  mutations,  and  even  to  predict  whether  a  specific  mutation  is  a  driver  of  
the  carcinogenesis  process,  based  on  several  factors  such  as  evolutionary  conservation,  
predicted  effects  on  protein  structure  and  observed  recurrence  in  existing  cancer  data  sets39,42,91.  
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However,  these  computational  predictions  provide  little  insight  into  how  cellular  processes  are  
altered  as  a  consequence  of  the  mutations.  One  strategy  to  assess  whether  or  not  specific  
mutations  are  influential  on  cellular  processes  is  to  determine  whether  or  not  a  mutation  
induces  a  signature  of  gene  expression  changes92.  Gene  expression  signatures  associated  with  an  
individual  mutation  could  then  be  examined  to  characterize  its  cellular  impact47  and  the  
signature  could  be  used  as  a  target  for  candidate  drug  therapies58.  We  have  developed  the  
Cancer  in  silico  Drug  Discovery  (CiDD)  platform  for  the  purposes  of  characterizing  tumors  with  
specific  mutations,  or  more  generally  tumors  with  specific  clinicopathological  or  molecular  
characteristics,  based  on  their  putative  effects  on  gene  expression,  and  to  identify  candidate  
drugs  to  treat  these  tumors.    
Here,  we  describe  the  general  framework  and  integrated  data  sets  of  this  novel  platform.  
CiDD  has  been  designed  to  generate  hypotheses  for  the  following  three  general  problems:  1)  to  
determine  if  particular  clinical  or  molecular  characteristics  are  functional  and  therefore  induce  
unique  gene  expression  signatures;  2)  to  find  candidate  drugs  to  treat  specific  tumor  subgroups  
based  on  these  expression  changes;  and  3)  to  identify  cell  lines  that  resemble  the  tumors  being  
studied  for  subsequent  in  vitro  experimentation.    
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Figure  34:  Overview  of  CiDD.    The  primary  objective  of  CiDD  is  to  specify  initial  candidate  drug  compounds  and  cell  
lines  for  laboratory  drug  experiments  for  a  tumor  characteristic  being  researched.  

    

In  addition,  to  illustrate  the  use  of  CiDD,  we  have  applied  it  to  a  clinically  relevant  context  
in  cancer  drug  development.  We  report  the  in  silico  identification  of  candidate  drug  therapies  
for  colorectal  cancers  (CRCs)  harboring  the  BRAF  V600E  mutation.  Approximately  10%  of  CRCs  
harbor  the  BRAF  V600E  mutation,  which  confers  a  poor  prognosis  and  presents  a  therapeutic  
challenge86,93.  We  describe  the  analyses  performed  with  CiDD  that  have  identified  novel  targets  
for  BRAF  mutant  CRCs  and  have  validated  drugs  that  have  already  been  identified  as  agents  
that  target  this  tumor  subtype  such  as  EGFR  inhibitors.  
  
6.3.2

Methods  
CiDD  is  a  systematic  drug  discovery  platform  that  integrates  and  analyzes  large-‐‑scale  

cancer  data  sets  with  the  primary  goal  of  identifying  candidate  drugs  and  cell  lines  to  be  
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validated  experimentally  in  vitro  (see  Figure  34).  The  core  data  sets  used  by  CiDD  include  The  
Cancer  Genome  Atlas  (TCGA),  the  Connectivity  Map  (CMap)  and  the  Cancer  Cell  Line  Encyclopedia  
(CCLE).  CiDD  is  purely  computational  and  depends  on  publicly  available  clinical  and  
experimental  datasets,  as  well  as  annotation  databases.  CiDD  is  written  in  Python,  has  R  
package  dependencies  and  is  command-‐‑line  driven  allowing  it  to  be  integrated  into  
bioinformatics  pipelines.  The  software  and  code  are  freely  available  at  
http://scheet.org/software.  
  
6.3.2.1

Data  assembly  

Required  experimental  data  sets  for  performing  CiDD  analyses  are  TCGA28  and  the  
CMap58.    The  CCLE94  is  required  to  identify  cell-‐‑lines  most  appropriate  for  subsequent  
experimentation.  TCGA  includes  clinical,  mutation  and  gene  expression  data  for  thousands  of  
samples  across  multiple  cancer  types.  CiDD  provides  commands  to  download,  query  and  
analyze  these  data.  The  CMap  is  a  collection  of  gene  expression  data  for  cell  lines  treated  with  
small  molecules  paired  with  pattern-‐‑matching  algorithms  that  attempt  to  identify  biologically  
functional  connections  between  drugs  and  gene  expression  profiles58.  CiDD  utilizes  CMap  build  
02,  which  contains  more  than  7,000  expression  profiles  representing  the  effects  of  1,309  
compounds.  The  CCLE  provides  molecular  profiles  for  947  cancer  cell  lines  which  include  DNA  
copy  number,  gene  expression  and  DNA  mutation  data94.    
The  experimental  data  from  CMap  consists  of  rank-‐‑based  gene  expression  values  from  the  
Affymetrix  HG-‐‑U133A  microarray.  Thus  CMap  is  designed  for  the  analysis  of  Affymetrix  gene  
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expression  data  only,  which  hinders  using  CMap  with  gene  expression  data  collected  from  non-‐‑
Affymetrix  platforms.  To  overcome  this  limitation,  CiDD  transforms  bulk-‐‑downloaded  CMap  
data  from  Affymetrix  probe-‐‑based  rank  values  to  Entrez  gene-‐‑based  ranks.  Gene-‐‑based  ranks  
are  determined  by  taking  the  mean  probe  rank  for  each  gene,  sorting  the  mean  rank  values  and  
then  assigning  a  rank  for  each  gene  based  on  the  sorted  values.  This  allows  results  from  RNA  
sequencing  and  Agilent  microarray  technologies,  such  as  those  provided  by  TCGA,  to  be  
analyzed  with  the  drug-‐‑perturbed  data  of  the  CMap  in  a  standardized  way  at  the  gene  level.  A  
similar  strategy  has  been  applied  in  the  R  package  gCMAP95  that  allows  users  to  query  the  
CMap  using  Affymetrix  probe  identifiers  or  gene  symbols.  Gene-‐‑expression  signatures  derived  
from  both  Agilent  gene  expression  microarrays  and  RNA  sequencing  have  identified  validated  
candidate  drugs  when  analyzed  with  the  Affymetrix-‐‑based  drug  signatures  of  CMap96–98  
demonstrating  the  feasibility  of  a  cross-‐‑platform  approach.    
CiDD  also  uses  optional  annotation  data  sets,  which  include  the  Molecular  Signatures  
Database  (MSigDB)47  for  characterizing  gene  sets  and  drug  databases  including  DrugBank99,  
Matador100  and  KEGG  Drug72  for  annotating  candidate  drugs.  These  drug  databases  provide  
information  such  as  drug  pharmacology,  gene  and  pathway  targets  to  make  the  drug  reports  
produced  by  CiDD  more  informative  for  researchers.  Public  data  from  TCGA  are  automatically  
downloaded  by  CiDD,  while  data  from  CMap,  CCLE  and  MSigDB  require  registration  at  their  
respective  websites  prior  to  downloading.  Upon  download,  CiDD  automatically  prepares  and  
manages  all  of  the  data  sets  for  drug  discovery  analyses.  Further  descriptions  of  the  contents  of  
these  data  sets  along  with  installation  and  pre-‐‑processing  details  are  provided  in  section  6.3.3.1.  
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6.3.2.2

CiDD  workflow  

A  common  workflow  using  the  CiDD  framework  is  illustrated  in  Figure  35.  Initially,  a  
CiDD  project  based  on  a  TCGA  cancer  type  is  created  and  clinical,  mutation  and  gene  
expression  data  for  TCGA  samples  are  automatically  downloaded.  For  an  analysis,  CiDD  first  
identifies  samples  for  use  in  computational  experiments  from  TCGA  based  on  user-‐‑defined  
clinicopathological  or  molecular  phenotypes,  such  as  specific  gene  mutations,  microsatellite  
instability  status,  tumor  stage,  or  a  variety  of  other  patient  or  tumor  characteristics  reported  
through  TCGA  projects.  Based  on  the  defined  phenotype,  CiDD  identifies  2  classes  of  samples  
to  compare.  For  a  mutation-‐‑based  phenotype,  CiDD  establishes  one  class  containing  samples  
with  a  defined  mutation  or  set  of  mutations  and  a  second  class  containing  samples  that  are  
wild-‐‑type  for  the  genes  of  interest.  For  a  clinical  phenotype,  the  user  specifies  both  classes  
explicitly,  such  as  the  two  classes  corresponding  to  microsatellite  instable  and  microsatellite  
stable  tumors.  CiDD  then  attempts  to  identify  a  gene-‐‑expression  signature  that  is  associated  
with  the  defined  patient  or  tumor  characteristic.  If  a  gene  expression  signature  exists  for  the  
phenotype  of  interest,  that  signature  is  characterized  with  gene  sets  defined  in  MSigDB  and  the  
signature  is  used  to  identify  candidate  drug  therapies  through  pattern-‐‑matching  algorithms  
proposed  by  the  CMap.  Subsequently,  CiDD  characterizes  candidate  drugs  using  databases  
such  as  DrugBank,  Matador  and  KEGG  Drug.  Finally,  CiDD  identifies  candidate  cell  lines  on  
which  to  test  the  drugs  in  vitro  by  analyzing  experimental  data  from  the  CCLE.  The  primary  
results  of  a  CiDD  execution  are  a  biologically  annotated  candidate  drug  list  and  candidate  cell  
lines  for  subsequent  drug  experimentation.    
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Figure  35:  Steps  and  data  sets  of  a  basic  CiDD  workflow  that  identifies  candidate  drugs  for  a  given  molecular  or  
clinicopathological  phenotype  of  interest.  

  
6.3.2.3

Gene  signature  identification  

TCGA  provides  gene  expression  data  from  Agilent  microarrays,  Illumina  GA  RNA  
sequencing  and  Illumina  HiSeq  RNA  sequencing.  The  gene  expression  data  type  to  analyze  can  
be  specified  as  a  parameter  to  CiDD.  By  default,  CiDD  will  choose  the  technology  that  provides  
data  for  the  largest  number  of  samples  with  the  phenotype  of  interest.  Using  the  R  package  
Limma101  which  is  designed  for  both  microarray  and  RNA  sequencing  differential  expression  
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analyses,  CiDD  identifies  up-‐‑  and  down-‐‑regulated  genes.  CiDD  characterizes  differential  
expression  results  with  known  biological  pathways  by  performing  gene  set  tests  from  the  piano  
Bioconductor  package102,  while  using  gene  sets  defined  by  MSigDB.    
  
6.3.2.4

Generation  of  a  k-‐‑top  scoring  pairs  (k-‐‑TSP)  classifier  

For  generating  a  classifier  that  is  robust  across  gene  expression  technologies,  CiDD  takes  a  
non-‐‑parametric  approach  to  classification  and  adopts  an  extension  of  the  top  scoring  pairs  (TSP)  
method103.  Using  the  R  package  ktspair104,  CiDD  generates  a  k-‐‑TSP  classifier  for  predicting  the  
status  of  the  phenotype  of  interest  on  independent  samples.  The  algorithm  works  by  first  
ranking  gene  expressions  for  each  sample  and  then  identifying  pairs  of  genes  whose  relative  
orderings  within  each  sample  class  are  opposite  of  one  another.  By  default,  to  improve  
computational  performance,  CiDD  limits  the  number  of  genes  considered  for  inclusion  in  the  
classifier  to  only  those  genes  in  the  gene  expression  signature.  For  each  gene  in  a  pair,  g1  and  g2,  
and  for  each  sample  s,  the  algorithm  keeps  track  of  whether  the  expression  of  g1  in  sample  s  is  
less  than  the  expression  of  g2  in  sample  s.  The  pairs  that  most  consistently  maintain  their  relative  
expression  ordering  in  class  1  while  having  a  reverse  ordering  in  class  2  become  gene  pairs  in  
the  classifier.  A  score  is  assigned  to  each  pair  by  the  ktspair  algorithm  that  represents  the  
percentage  of  samples  in  the  two  classes  that  exhibit  the  expected  ordering  of  g1  and  g2.  CiDD  
chooses  the  k  pairs  that  meet  a  default  threshold  score  of  at  least  0.8.  The  prediction  is  class  1  if  
the  average  expression  value  for  the  g1  genes  is  lower  than  the  average  expression  value  for  the  
g2  genes;  it  is  class  2,  otherwise.  
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6.3.2.5

Candidate  drug  identification  

CiDD  connects  the  gene  expression  changes  associated  with  the  phenotype  of  interest  
with  candidate  drug  compounds  that  induce  a  negatively  correlated  gene  expression  profile.  
CiDD  compares  the  phenotype  gene  expression  changes,  termed  a  query  signature,  to  rank-‐‑
based  gene  expression  profiles  induced  by  CMap  compounds.  To  compare  rank-‐‑based  gene  
expression  profiles,  CiDD  implements  a  nonparametric  pattern-‐‑matching  algorithm  based  on  
the  Kolmogorov-‐‑Smirnov  statistic  as  described  by  Lamb  et  al58.  Briefly,  where  up-‐‑regulated  
query  genes  tend  to  appear  near  the  bottom  of  a  compound’s  ranked  gene  expression  profile  
and  down-‐‑regulated  query  genes  appear  near  the  top  of  the  ranked  gene  expressions,  this  
suggests  negative  connectivity.  Positive  connectivity  refers  to  the  reverse  scenario,  where  up-‐‑
regulated  query  genes  appear  near  the  top  of  a  compound’s  ranked  gene  expression  profile  and  
down-‐‑regulated  query  genes  appear  near  the  bottom  of  the  ranked  profile.  There  are  multiple  
connectivity  scores  for  each  drug,  one  for  each  experiment  where  that  drug  was  tested  against  
an  individual  cell  line.  Connectivity  scores  range  from  -‐‑1  to  +1  corresponding  to  negative  and  
positive  connectivity.  Enrichment  is  a  measure  that  aggregates  the  connectivity  scores  for  all  
instances  of  a  drug  experiment  to  determine  if  they  collectively  have  a  negative  or  positive  
connectivity  (ranging  from  -‐‑1  to  1)  with  the  phenotype  of  interest.  To  assess  the  significance  of  
the  enrichment  score,  we  have  implemented  the  permutation  procedure  used  by  CMap,  where  
the  Kolmogorov-‐‑Smirnov  statistic  is  computed  for  a  set  of  CMap  expression  profiles  generated  
from  a  single  compound  of  interest  within  an  ordered  list  of  all  the  CMap  expression  profiles.  
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This  provides  an  empirical  p-‐‑value  (CMap  refers  to  it  as  a  permutation  p-‐‑value),  a  measure  of  the  
proportion  of  times  the  observed  enrichment  of  a  set  of  instances,  or  one  more  striking,  would  
happen  by  chance.  The  metric  specificity  is  a  measure  of  the  selectivity  of  a  drug  compound  for  
the  phenotype  of  interest.  To  determine  specificity,  random  query  signatures  are  extracted  from  
MSigDB  and  run  against  the  CMap  to  generate  a  background  list  of  enrichment  scores.  
Candidate  drug  compounds  are  deemed  to  have  high  specificity  if  results  from  these  random  
query  signatures  do  not  identify  the  same  candidate  drug  compounds  as  those  from  the  query  
signature.  CiDD  then  queries  data  downloaded  from  drug  databases  to  annotate  the  candidate  
drug  compounds  with  meaningful  clinical  and  biological  information  to  facilitate  the  biological  
interpretation  of  the  list  of  candidate  drugs.    
  
6.3.2.6

Cell  line  identification  

CiDD  first  selects  CCLE  cell  lines  based  on  user-‐‑specified  tissue  types.  Then,  CiDD  
optionally  identifies  cell  lines  that  contain  a  user-‐‑specified  mutation  by  interrogating  CCLE  
mutation  annotation  files  derived  from  either  targeted  sequencing  of  common  cancer  genes  or  
from  Oncomap  3.0,  which  is  a  SNP  array  that  genotypes  samples  at  the  most  common  cancer  
mutation  sites.  Finally,  CiDD  runs  its  k-‐‑TSP  classifier  on  CCLE  gene  expression  data,  as  
described  in  the  previous  section,  to  predict  if  a  cell  line’s  gene  expression  profile  is  
representative  of  the  phenotype  being  studied.  Cell  lines  that  meet  these  criteria  are  reported  as  
candidates  for  use  in  subsequent  drug  experiments.  
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6.3.3

CiDD  software  description  

6.3.3.1

Installation  

Cancer  in  silico  Drug  Discovery  (CiDD)  is  designed  to  run  on  Linux  or  Mac  OS  X  
environments  with  a  recommended  minimum  of  100  GB  of  free  disk  space  and  4  GB  of  
memory,  making  it  runnable  on  most  bioinformatics  desktop  computers.    CiDD  is  written  in  
Python  and  has  software  and  data  dependencies.    To  use  CiDD,  users  should  follow  the  
software  and  data  set  installation  procedures  described  here.  
6.3.3.1.1

Software  installation  

Software  pre-‐‑requisites  
The  following  should  be  installed  before  installing  CiDD.  
•

Python  2.7  or  greater  

•

Python  libraries:  numpy  and  lxml  

•

R  3.0  or  greater  

•

R  packages:  edgeR,  Limma,  piano  

•

firehose_get  (https://confluence.broadinstitute.org/display/GDAC/Download)  

•

tcga_util:  a  companion  Python  module  for  use  with  CiDD  (http://scheet.org/software)  

  
CiDD  software  installation  
To  install  CiDD,  download  the  source  code  from  http://scheet.org/software  and  install  the  cidd  
command-‐‑line  tool  by  running  the  following:    
sudo  python  setup.py  install  
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6.3.3.1.2

Data  set  installation  

CiDD  stores  and  manages  data  within  a  local  data  store.    A  data  store  is  a  directory  on  the  
user  file  system  where  data  sets  used  by  the  CiDD  framework  are  stored.    A  user  can  create  a  
single  data  store  that  is  shared  between  multiple  CiDD  projects  and  analyses.  To  do  this,  a  user  
can  set  an  environment  variable  called  $DATA_STORE  to  the  full  path  of  the  data  store  
directory.    This  will  tell  CiDD  where  to  find  the  default  data  store.    As  an  alternative,  a  user  can  
specify  the  location  of  their  data  store  with  each  CiDD  command  through  a  -‐‑-‐‑data_store  
parameter.    This  alternative  approach  works  best  if  a  user  wants  to  keep  TCGA  cancer  type  data  
separate  and  manage  multiple  data  stores.    The  following  steps  are  required  to  initialize  a  CiDD  
data  store:  
1. Create  the  directory  structure:    
mkdir  ccle  cmap  drug_annotations  msigdb  tcga  custom  
Alternatively,  if  no  data  store  exists  when  the  cidd  setup  command  is  run  to  initialize  a  
CiDD  project  (see  section  6.3.3.2.1)  CiDD  will  create  an  empty  data  store  directory  
structure  and  automatically  populate  the  data  store  with  an  initial  TCGA  data  set.  
2. Download  and  store  CiDD  required  data  sets  within  the  data  store  subdirectories.    
Project-‐‑specific  TCGA  data  are  automatically  downloaded  and  managed  by  CiDD  in  the  
local  data  store.    The  user  must  download  other  required  data  sets  into  the  data  store  
(details  follow).        
3. Download  and  install  optional  drug  annotation  data  sets  within  the  data  store  
subdirectories.    These  files  are  only  needed  for  annotating  candidate  drug  reports  
(details  follow).  
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Here  we  describe  the  external  data  sets  and  files  that  the  CiDD  framework  uses.    There  are  3  
datasets  listed  here  that  are  required  to  run  CiDD  and  need  to  be  downloaded  manually  and  
stored  in  the  local  data  store.    Other  data  sets  are  optional.    
  
Data  set  descriptions  
TCGA  data105  are  automatically  downloaded  and  managed  by  tcga_util,  which  is  a  
companion  Python  module  for  use  with  CiDD.    For  a  specified  cancer  project  in  TCGA,  CiDD  
automatically  downloads  the  clinical  data,  somatic  mutations  and  gene  expression  data  from  
RNA-‐‑sequencing  and  Agilent  microarrays.    The  amount  of  data  downloaded  from  TCGA  is  
dependent  on  the  cancer  and  data  type  being  studied.    In  addition  to  the  default  data  
downloaded,  data  such  as  protein  expression  or  miRNA  expression  could  also  be  downloaded  
by  tcga_util  explicitly.    The  estimated  download  size  of  TCGA  data  ranges  from  100  –  200  MB  
for  most  cancer  projects.  
The  Connectivity  Map  (CMap)58,  MSigDB47  and  the  Cancer  Cell  Line  Encyclopedia  (CCLE)94  
data  downloads  require  user  registration  at  their  respective  websites  as  detailed  below.    Data  
from  DrugBank99,  MATADOR100  and  KEGG72  Drug  are  not  required  by  CiDD,  but  if  available,  
they  provide  annotation  sources  for  candidate  drugs.    Details  of  non-‐‑TCGA  data  dependencies  
are  listed  here.  
  
CONNECTIVITY  MAP  (required)  
requires  registration:  
  

  

yes  
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website:  

  

  

  

http://www.broadinstitute.org/cmap  

install  location:  

  

  

$DATA_STORE/cmap    

data  files:  

  

  

  

  

  

•

instance  inventory:  

cmap_instances_02.xls  (1.6  MB)  

•

data  matrix:    

  

rankMatrix.txt.zip  (309  MB)  

•

gene  sets:      

  

msigdb_gene_sets.zip  (270  KB)  

requires  registration:  

  

yes  

website:  

  

  

http://www.broadinstitute.org/gsea/msigdb/collections.jsp  

install  directory:     

  

$DATA_STORE/msigdb    

data  files:  

  

C2  curated  gene  sets:  c2.all.v4.0.symbols.gmt  (3.1  MB)  

  
MSIGDB  (required)  

  

  

  

  
CANCER  CELL  LINE  ENCYCLOPEDIA  (required)  
requires  registration:  

  

yes  

website:  

  

  

http://www.broadinstitute.org/ccle/data/browseData  

install  directory:     

  

$DATA_STORE/ccle    

data  files:  

  

  

  

  

  

  

  

•

mRNA  expression:       

CCLE_Expression_Entrez_2012-‐‑09-‐‑29.gct  (167.2  MB)  

•

Cell  Line  Annotations:    

CCLE_sample_info_file_2012-‐‑10-‐‑18.txt  (196  KB)  

•

Oncomap  mutations:      

CCLE_Oncomap3_2012-‐‑04-‐‑09.maf  (318  KB)  
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•

Hybrid  capture  sequencing  mutations:  
CCLE_hybrid_capture1650_hg19_NoCommonSNPs_NoNeutralVariants_CDS_2012.05.0
7.maf  (56.5  MB)  

  
DRUGBANK  (optional)  
requires  registration:  

  

no  

website:  

  

  

http://www.drugbank.ca/downloads  

install  directory:     

  

$DATA_STORE/drug_annotations/drugbank  

data  files:  

  

full  database  in  XML  format:  drugbank.xml.zip  (16  MB)  

requires  registration:  

  

no  

website:  

  

  

http://matador.embl.de  

install  directory:     

  

$DATA_STORE/drug_annotations/matador  

data  files:  

  

drug-‐‑protein  interactions:  matador.tsv.gz  (419  KB)  

  

  

  

  
MATADOR  (optional)  

  

  

  

  
KEGG  DRUG  (optional)  
requires  registration:  

  

no  

FTP  site:  

  

  

ftp://ftp.genome.jp/pub/kegg/medicus  

install  directory:     

  

$DATA_STORE/drug_annotations/keggdrug  

data  files:  

  

drug-‐‑molecule  interactions:  drug.kegg  (21.7  MB)  
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6.3.3.2

CiDD  commands  

The  CiDD  framework  is  flexible  for  incorporation  into  custom  workflows.    The  workflow  
can  be  modified  and  steps  can  be  replaced  with  user-‐‑defined  scripts.    All  workflow  steps  are  
executed  with  simple  CiDD  commands  that  are  described  here,  where  the  intermediate  input  
and  output  files  of  each  command  are  stored  and  used  in  subsequent  steps.    Separating  steps  in  
this  way  allows  users  to  more  easily  replace  steps  in  the  workflow  with  their  own  preferred  
methods  or  scripts.    As  an  example,  in  a  common  workflow,  a  user  specifies  a  molecular  or  
clinicopathological  phenotype  of  interest  for  a  cancer  type.    CiDD  would  then  identify  sample  
IDs  for  2  classes  of  samples  for  subsequent  gene  expression  analyses.    Alternatively,  instead  of  
specifying  a  clinical  characteristic  or  mutation  as  the  phenotype  of  interest,  a  user  can  perform  
their  own  analyses  to  identify  samples  with  phenotypes  that  might  not  be  directly  supported  by  
CiDD  that  she  is  interested  in.    This  might  include  a  class  of  samples  with  a  particular  
methylation  profile  for  a  phenotype.    The  user  could  run  an  externally  generated  classifier  
based  on  methylation  data  and  then  identify  their  own  subsets  of  samples  based  on  the  
classifier’s  predictions.    She  can  then  supply  her  sample  identifiers  with  class  labels  to  CiDD  at  
step  2,  bypassing  step  1.    Similarly,  other  steps  in  the  workflow  can  be  replaced  with  user-‐‑
created  scripts.    Here  we  describe  the  CiDD  commands.    For  a  description  of  parameters  for  
each  CiDD  command,  users  can  specify  the  -‐‑h  flag  with  each  command  (e.g.,  cidd  setup  -‐‑h).    
6.3.3.2.1

cidd  setup  

A  CiDD  project  is  initialized  with  the  command  cidd  setup.    Upon  execution,  clinical  data,  
somatic  mutations  and  gene  expression  data  are  automatically  downloaded  into  the  user  data  
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store  for  a  specified  TCGA  cancer  type  specified  with  a  -‐‑-‐‑cohort  parameter.    Other  TCGA  data  
such  as  methylation  or  protein  expression  data  can  be  downloaded  explicitly  into  the  user  data  
store  with  the  tcga_util  command.    Multiple  cidd  setup  commands  can  be  run  for  the  same  
CiDD  project  to  install  data  for  multiple  TCGA  cancer  types  or  multiple  data  release  versions  at  
anytime.    By  default,  subsequent  CiDD  analyses  will  use  the  latest  data  sets  downloaded  unless  
otherwise  specified  through  command  parameters.  
6.3.3.2.2

cidd  clinical_signature,  cidd_mutation_signature  and  cidd  custom_signature  

For  a  specified  clinical  or  mutation-‐‑based  phenotype,  these  commands  can  be  used  to  
identify  gene  expression  signatures  and  then  to  characterize  gene  expression  signatures  using  
gene  set  tests.    CiDD  uses  the  R  package  Limma101  to  identify  differentially  expressed  genes  
between  the  two  classes  as  defined  by  command  parameters.    Limma  supports  both  continuous  
expression  measurements  of  microarray  data  and  count  measurements  from  RNA  sequencing106  
which  is  appropriate  for  analysis  of  the  TCGA  data,  which  consists  of  gene  expression  data  
from  Agilent  microarrays,  Illumina  GA  RNA  sequencing  and  Illumina  HiSeq  RNA  sequencing.    
The  choice  of  expression  data  type  can  be  specified  through  an  -‐‑-‐‑expression_type  parameter.    By  
default,  CiDD  will  choose  the  expression  technology  that  has  data  available  for  the  largest  
number  of  samples  with  the  phenotype  of  interest.    CiDD  requires  a  Benjamini-‐‑Hochberg  
adjusted  p-‐‑value  to  be  less  than  or  equal  to  0.05  and  a  log2  fold  change  greater  than  1  to  label  a  
gene  as  being  differentially  expressed  for  inclusion  in  the  gene  signature,  although  these  default  
parameters  can  be  modified.    The  resulting  sets  of  up-‐‑  and  down-‐‑regulated  genes  comprise  the  
gene  expression  signature,  which  putatively  represents  the  functional  consequence  of  the  
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mutation  or  phenotype  being  studied.    A  third,  more  generic,  signature-‐‑based  command  cidd  
signature  can  be  executed  if  a  user  wants  to  generate  a  signature  based  on  two  classes  of  
samples  where  they  have  determined  sample  class  membership  external  to  CiDD.    This  
command  can  also  be  used  if  users  want  to  generate  a  signature  using  their  own  gene  
expression  data  set  external  to  the  TCGA.  
This  signature  is  then  characterized  with  MSigDB47  using  the  Bioconductor  package  
piano102.    By  default,  the  reports  generated  by  CiDD  identify  KEGG  pathways  that  are  associated  
with  the  phenotype  of  interest.    Other  MSigDB  options  for  gene  set  groupings  are  also  
supported  by  CiDD,  such  as  those  defined  by  BIOCARTA,  REACTOME,  and  GO.  
6.3.3.2.3

cidd  classifier  

This  command  supports  the  generation  of  a  mutation  or  phenotype  classifier  through  
cidd  classifier  generate  and  the  application  of  the  classifier  for  prediction  with  the  cidd  classifier  
predict  command.    CiDD  constructs  the  gene  expression  classifier  with  an  extension  of  the  
widely  used  non-‐‑parametric,  rank-‐‑based  algorithm,  top  scoring  pairs  (TSP)103,107  called  k-‐‑TSP104  
that  is  later  applied  downstream  on  CCLE  samples  to  help  identify  candidate  cell  lines  on  
which  to  test  drug  compounds.    If  an  independent  data  set  is  available,  one  can  also  apply  the  
classifier  on  this  data  set  to  assess  the  performance  of  the  classifier.  
6.3.3.2.4

cidd  drugs  

The  cidd  drugs  command  takes  the  signature  generated  from  the  cidd  signature  
commands  and  finds  candidate  drugs  from  the  CMap  that  induce  a  gene  expression  signature  
in  the  opposite  direction  to  the  one  associated  with  the  phenotype  of  interest.    The  CMap  is  a  
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collection  of  gene  expression  data  for  cell  lines  treated  with  bioactive  small  molecules  paired  
with  pattern-‐‑matching  algorithms  that  attempt  to  identify  biologically  functional  connections  
between  drugs  and  gene  expression  profiles58.    CiDD  utilizes  CMap  build  02,  which  contains  
more  than  7,000  expression  profiles  representing  the  effects  of  1,309  compounds.    After  
identifying  candidate  drugs,  the  cidd  drugs  command  annotates  the  candidate  drugs  using  
drug  databases.  
Before  running  cidd  drugs,  CiDD  performs  pre-‐‑processing  of  the  CMap  data.    CMap  
(http://www.broadinstitute.org/cmap)  is  designed  to  allow  users  to  upload  a  list  of  up-‐‑  and  
down-‐‑regulated  Affymetrix  probe  IDs  that  comprise  a  gene  expression  signature  under  study.    
The  underlying  gene  expression  data  for  CMap  were  collected  from  Affymetrix  HG-‐‑U133A  
gene  expression  microarrays  and  are  designed  for  use  on  Affymetrix  gene  expression  data,  
which  hinders  using  CMap  with  gene  expression  data  collected  from  non-‐‑Affymetrix  platforms.    
Thus,  CiDD  transforms  bulk-‐‑downloaded  CMap  data  from  Affymetrix  probe-‐‑based  rank  values  
to  Entrez  gene-‐‑based  ranks.    Gene-‐‑based  ranks  are  determined  by  taking  the  mean  probe  rank  
for  each  gene,  sorting  the  mean  rank  values  and  then  assigning  a  rank  for  each  gene  based  on  
the  sorted  values.    This  allows  results  from  RNA  sequencing  and  Agilent  microarray  
technologies,  such  as  those  provided  by  TCGA,  to  be  analyzed  with  the  drug-‐‑perturbed  data  of  
the  CMap  in  a  standardized  way  at  the  gene  level.    A  similar  strategy  has  been  applied  in  the  R  
package  gCMAP95  that  allows  users  to  query  the  CMap  using  microarray  probe  identifiers  or  
gene  symbols.    Gene-‐‑expression  signatures  derived  from  both  Agilent  gene  expression  
microarrays  and  RNA  sequencing  have  identified  validated  candidate  drugs  when  analyzed  
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with  the  Affymetrix-‐‑based  drug  signatures  of  CMap96–98  demonstrating  the  feasibility  of  a  cross-‐‑
platform  approach.      
Further  supporting  a  cross-‐‑platform  approach,  the  pattern  matching  algorithms  of  the  
CMap  are  rank-‐‑based  and  robust  to  distributional  assumptions  of  the  data  and  to  differences  in  
normalization  procedures  across  multiple  data  sets58.  The  command  cidd  drugs  compares  the  
phenotype  gene  expression  changes,  termed  a  query  signature,  to  rank-‐‑based  gene  expression  
profiles  induced  by  CMap  compounds.    The  algorithm  connects  the  gene  expression  changes  
induced  by  the  phenotype  of  interest  with  candidate  drug  compounds  that  induce  a  negatively  
correlated  gene  expression  profile.    To  compare  rank-‐‑based  gene  expression  profiles,  CiDD  
implements  the  nonparametric  pattern-‐‑matching  algorithms  based  on  the  Kolmogorov-‐‑Smirnov  
statistic  as  described  by  Lamb  et  al58.      
  

Briefly,  the  “enrichment  score”  describes  the  connectivity  between  a  drug  and  a  query  

signature.    This  score  ranges  from  -‐‑1  to  +1  where  a  score  near  -‐‑1  reflects  negative  connectivity  
and  a  score  near  +1  reflects  positive  connectivity.    A  “permutation  p-‐‑value”  ranging  from  0  to  1  
provides  a  measure  of  significance  for  this  score.    A  “specificity”  value  ranging  from  0  to  1  
describes  how  specific  the  drug  is  for  the  query  signature,  where  a  value  close  to  0  reflects  high  
specificity.    After  calculating  these  metrics,  CiDD  then  queries  data  downloaded  from  drug  
databases  to  annotate  the  candidate  drug  compounds  with  meaningful  clinical  and  biological  
information  to  facilitate  the  biological  interpretation  of  the  list  of  candidate  drugs.    CiDD  
annotates  candidate  CMap  drug  compounds  with  DrugBank99,  KEGG  Drug72  and  Matador100.  
CiDD  attempts  to  link  CMap  provided  compound  names  to  drug  database  names,  identifiers  
and  drug  aliases.    Where  links  exist,  the  CMap  identifiers  are  annotated  with  drug  
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pharmacology,  drug  gene  targets  and  drug  pathway  targets  to  help  put  the  drugs  into  a  
biological  context  for  clinical  researchers.    Additionally,  Matador  provides  known  drug-‐‑mRNA  
and  drug-‐‑protein  interactions.  
6.3.3.2.5

cidd  cell_lines  

The  CCLE  provides  molecular  profiles  for  947  cancer  cell  lines  which  include  DNA  copy  
number,  gene  expression  and  DNA  mutation  data94.    From  this  data,  cidd  cell_lines  searches  the  
CCLE  to  identify  cell  lines  that  most  closely  resemble  the  cancer  subtype  being  studied  based  on  
a  specified  tissue,  a  possible  mutation  of  interest  and  the  gene  expression  classifier  generated  by  
CiDD.    Cell  lines  that  fulfill  criteria  based  on  these  characteristics  are  recommended  for  use  in  
subsequent  drug  experiments.  If  a  specific  mutation  is  being  studied  (e.g.,  BRAF  V600E),  that  
mutation  is  searched  for  in  the  CCLE  data  set  by  querying  mutations  detected  from  Oncomap  
arrays  and  capture  sequencing.    These  mutations  are  limited  to  381  specific  mutations  across  33  
genes  using  Oncomap  3.0  and  to  the  coding  regions  of  the  1651  genes  defined  in  the  CCLE  
target  capture  region.    Search  criteria  can  be  relaxed  through  parameters  of  the  command.  
6.3.3.2.6

tcga_util  

TCGA  datasets  are  sufficiently  useful  and  complex  to  warrant  their  own  tool  for  
downloading,  querying,  pre-‐‑processing  and  managing  them.    For  this  purpose,  we  developed  
tcga_util,  a  Python  package,  for  use  within  the  CiDD  framework;  however,  tcga_util  can  also  be  
useful  as  a  stand-‐‑alone  tool  for  generalized  TCGA  analyses.    tcga_util  manages  TCGA  data  
locally  and  has  been  designed  for  simple  use  at  the  command-‐‑line,  which  allows  
bioinformaticians  to  integrate  TCGA  data  into  their  own  repeatable  analyses  or  custom  
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applications  and  pipelines.    CiDD  uses  this  package  directly  for  the  automated  download  and  
management  of  TCGA  data.    These  data  sets  are  the  source  of  the  clinical  and  molecular  data  for  
CiDD  to  perform  molecular  characterization  of  the  phenotypes  of  interest.    Examples  of  clinical  
information  includes  age  at  diagnosis,  gender  and  tumor  stage  as  well  as  molecular  diagnostics  
such  as  the  presence  of  specific  KRAS  or  BRAF  mutations  and  microsatellite  instability  status.    
Available  clinical  data  varies  across  TCGA  tumor  types.    Molecular  data  available  include  
whole  genome  and  exome  sequencing,  methylation  profiling,  and  gene  and  protein  expression  
profiling,  among  other  data  types.    Alternatively,  direct  TCGA  data  download  through  URLs  
and  web  forms  is  available  through  the  NCI'ʹs  TCGA  Data  Portal105.    Another  more  user-‐‑friendly  
alternative  for  downloading  and  exploring  subsets  of  TCGA  data  is  the  cBioPortal108,  which  
includes  visual  tools  for  browsing  and  analyzing  TCGA  data.    An  option  for  bulk  TCGA  data  
download  is  the  utility  firehose_get.    Firehose  is  a  large-‐‑scale  data  analysis  pipeline  that  
automatically  performs  standard  pre-‐‑processing  of  TCGA  data,  easing  the  integration  of  data  
across  cancer  types  and  making  the  data  more  amenable  to  downstream  analyses  
(https://confluence.broadinstitute.org/display/GDAC).    The  main  goal  of  tcga_util  is  to  help  
users  query,  download  and  filter  through  analysis-‐‑ready  TCGA  data  for  use  in  downstream  
analyses.    To  avoid  duplication  of  effort,  tcga_util  leverages  firehose_get  for  the  majority  of  its  
TCGA  data  download,  while  adding  functionality  for  the  filtering  and  querying  of  downloaded  
data.    tcga_util  provides  the  following  functionality:    
1. download  of  TCGA  clinical  and  experimental  data  into  a  local  data  store  organized  by  
cancer  and  data  type  simplifying  repeat  or  new  analyses,  
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2. sample  query  tools  to  easily  find  samples  of  interest  based  on  clinical  and  mutational  
criteria,  
3. creation  of  filtered  data  matrices  that  are  composed  of  data  for  samples  of  interest  that  
are  easier  to  work  with  in  downstream  analysis  tools  such  as  R,  
4. ability  to  update  the  local  data  store  with  the  latest  TCGA  data  releases,  and    
support  of  version  tracking  downloaded  TCGA  data  for  analysis  reproducibility.  
6.3.3.3

CiDD  file  descriptions  

The  files  described  here  are  generated  by  the  previously  described  CiDD  commands.    
Several  of  these  files  are  intermediate  results,  being  output  by  one  CiDD  command  and  then  
used  as  input  in  subsequent  CiDD  commands.    
6.3.3.3.1

Sample  files:  {analysis_name}_{cases|controls}.samples  

For  a  specified  mutation  or  clinical  characteristic,  CiDD  defines  two  classes  of  samples  –  a  case  
class  and  a  control  class.    The  sample  files  list  the  TCGA  identifiers  that  are  a  part  of  each  class.    
These  are  generated  by  the  cidd  signature  commands  and  used  by  tcga_util  to  construct  case  
and  control  gene  expression  matrices.  
6.3.3.3.2

RNA  sequencing  read  count  matrices:  {analysis_name}_{cases|controls}.readcounts  

CiDD  downloads  TCGA  level  3  RNA  sequencing  data  by  default.    The  downloaded  read  count  
data  has  been  RSEM  normalized.    These  files  are  tab-‐‑delimited  where  genes  correspond  to  rows  
and  samples  correspond  to  columns.    Values  in  the  files  correspond  to  read  counts.    One  file  is  
generated  for  each  class  of  samples  by  the  cidd  signature  commands.  
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6.3.3.3.3

Agilent  expression  matrices:  {analysis_name}_{cases|controls}.expr  

CiDD  downloads  TCGA  level  3  Agilent  gene  expression  data  by  default.    These  data  have  been  
Lowess  normalized.    These  files  are  tab-‐‑delimited  where  genes  correspond  to  rows  and  samples  
correspond  to  columns.    Values  in  the  matrix  correspond  to  a  gene  expression  level.    One  file  is  
generated  for  each  class  of  samples  by  the  cidd  signature  commands.  
6.3.3.3.4

Differential  expression  results:  {analysis_name}.diff_exp  

Differential  expression  results  from  Limma  are  output  in  the  diff_exp  tab-‐‑delimited  file.    These  
results  are  produced  by  the  cidd  signature  commands.    Each  row  corresponds  to  a  gene  and  
differential  expression  metrics  are  represented  in  the  columns.    These  columns  include:  
•

logFC:  log2  fold-‐‑change  corresponding  to  the  phenotype  of  interest  

•

AveExpr:  average  log2-‐‑expression  value  

•

t:  t-‐‑statistic  

•

P.Value:  differential  expression  raw  p-‐‑value  

•

adj.P.Val:  Benjamini-‐‑Hochberg  adjusted  p-‐‑value  or  q-‐‑value  

•

B:  log-‐‑odds  that  the  gene  is  differentially  expressed  

Documentation  describing  Limma  can  be  found  at  
http://www.bioconductor.org/packages/release/bioc/html/limma.html.  
6.3.3.3.5

Gene  expression  signature  files:  {analysis_name}_{up|down}.sig  

The  signature  files  contains  a  list  of  up  and  down-‐‑regulated  gene  identifiers  based  on  fold-‐‑
change  and  significance  thresholds  that  define  differentially  expressed  genes.    These  parameters  
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can  be  specified  in  the  cidd  signature  commands.    The  signature  files  produced  by  the  cidd  
signature  commands  are  input  to  the  cidd  drugs  command.  
6.3.3.3.6

Signature  heatmap:  {analysis_name}_heatmap.png  

A  sample  and  gene  clustered  heatmap  using  the  case  and  control  samples  and  signature  genes  
is  generated  by  the  cidd  signature  commands.    See  Figure  36  for  an  example  heatmap.    The  
clustering  of  case  samples  based  on  signature  genes  is  illustrated  with  a  dendrogram  at  that  top  
of  the  heatmap  where  black  bars  label  the  case  samples.  
6.3.3.3.7

Gene  set  analysis  results:  {analysis_name}.gsa  

Gene  set  analysis  results  from  the  Bioconductor  package  piano102  are  output  to  the  gsa  file.    Each  
row  corresponds  to  a  gene  set.    By  default,  CiDD  uses  KEGG  gene  sets  defined  in  MSigDB47  for  
the  gene  set  tests.    Columns  in  the  file  specify  the  numbers  of  genes  in  each  gene  set  along  with  
test  statistic  values  and  p-‐‑values  that  indicate  whether  or  not  each  gene  set  is  associated  with  
the  phenotype  of  interest.    The  software  and  documentation  are  available  at  
http://bioconductor.org/packages/devel/bioc/html/piano.html.  
6.3.3.3.8

Candidate  drug  report:  {analysis_name}.drugs  

The  candidate  drug  report  is  a  tab-‐‑delimited  file  produced  by  the  cidd  drugs  command.    Each  
row  corresponds  to  a  drug,  and  the  column  data  are  described  below.    See  Lamb  et  al58  for  
algorithm  details  for  calculating  values  for  mean_connectivity_score,  enrichment  and  
permutation_p.  
•

  

num_instances:  the  number  of  times  that  this  drug  was  tested  on  a  cell  line  
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•

mean_connectivity_score:  the  average  connectivity  score  ranging  from  -‐‑1  to  1  across  all  
instances  of  a  drug.    The  closer  the  connectivity  score  is  to  -‐‑1  (i.e.,  the  stronger  the  
negative  connectivity),  the  more  we  might  expect  that  the  drug  will  negate  the  gene  
expression  signature  of  the  phenotype  of  interest.      

•

enrichment:  a  measure  of  enrichment  of  all  of  the  instances  of  a  drug  having  a  negative  
or  positive  connectivity  (ranging  from  -‐‑1  to  1)  with  the  gene  expression  signature  of  the  
phenotype  of  interest  

•

permutation_p:  an  estimate  of  the  likelihood  that  the  enrichment  of  a  set  of  instances  in  
the  list  of  all  instances  in  a  given  result  would  be  observed  by  chance  

•

non_null_percentage:  the  number  of  instances  with  non-‐‑zero  connectivity  scores  

•

specificity:    a  measure  of  the  selectivity  of  a  drug  compound  for  the  phenotype  of  
interest.    Random  query  signatures  are  extracted  from  MSigDB  and  run  against  the  
CMap  to  generate  a  background  list  of  enrichment  scores  and  specificity  indicates  how  
often  a  score  equal  to  or  smaller  than  the  enrichment  is  seen.  

•

pharmacology_drugbank:  general  description  of  the  drug  potentially  including  the  drug  
origin,  composition,  pharmacokinetics,  pharmacodynamics,  therapeutic  use  and  
toxicology  

•

pathways_keggdrug:  pathway  targets  of  the  drug  

•

targets_keggdrug:  gene  targets  of  the  drug  

interactions_matador:  protein  and  gene  interactions  of  which  the  drug  is  known  to  be  a  part  of  
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6.3.3.3.9

Cell  line  report:  {analysis_name}.cell_lines  

The  cell  line  report  lists  cell  lines  that  are  similar  to  the  case  samples  identified  by  CiDD.    Each  
row  in  the  report  corresponds  to  a  candidate  cell  line.  
6.3.4

Results:  application  of  CiDD  to  BRAF  V600E  colorectal  cancer  
We  applied  CiDD  to  identify  candidate  drugs  to  treat  CRCs  harboring  BRAF  V600E  

mutations  using  mutation  and  RNA-‐‑sequencing  data  from  the  TCGA  colon  and  rectum  
projects.  We  also  identified  cell  lines  from  the  CCLE  that  are  representative  of  colorectal  tumors  
with  BRAF  mutations,  thus  making  them  candidates  for  in  vitro  drug  testing.  We  refer  to  these  
analyses  as  the  TCGA-‐‑derived  analyses.    We  then  compared  our  systematic  TCGA-‐‑derived  
analyses  generated  with  CiDD  with  analyses  performed  using  a  previously  published  gene  
expression  signature  for  BRAF  V600E  generated  from  CRC  samples  of  the  PETACC3  (Pan-‐‑
European  Trials  in  Alimentary  Tract  Cancers)  clinical  trial93.  We  refer  to  these  previously  
published  gene  expression  analyses  as  the  PETACC3-‐‑derived  analyses.  
The  following  commands  were  run  to  perform  the  TCGA-‐‑derived  expression  analyses  and  
can  be  run  to  replicate  the  analysis  using  the  same  version  of  TCGA  data  as  described  in  the  
main  manuscript:  
[1] cidd setup -dr 2014_01_15 -ar 2013_09_23 \
-c coadread crc_brafv600e_proj
[2] cidd mutation_signature -dr 2014_01_15 -ar 2013_09_23 \
-c coadread -g BRAF -aac V600E \
-gnc 20 -lfc 2 -lperm 1000 -gperm 1000 \
-gsm samplePermutation -n crc_brafv600e
[3] cidd classifier generate -n crc_brafv600e
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[4] cidd drugs -np 1000 -nt 20 -n crc_brafv600e
[5] cidd cell_lines –g BRAF –aac V600E \
–t LARGE_INTESTINE \
–n crc_brafv600e  
  
The  following  describes  the  commands  for  the  analysis:  
1. Setup  a  CiDD  project  called  crc_brafv600e_proj  and  initialize  it  with  data  from  the  
TCGA  colon  and  rectum  (i.e.,  coadread)  project  using  data  released  on  2014_01_15  and  
analyses  released  on  2013_09_23.      
2. Generate  a  mutation  gene  expression  signature  and  characterize  that  signature  with  
KEGG  pathways.    The  mutation  is  specified  to  be  in  the  BRAF  gene  with  an  amino  acid  
change  of  V600E.    By  specifying  the  analysis  name  crc_brafv600e,  output  files  of  this  
command  are  prefixed  with  crc_brafv600e  and  can  be  automatically  identified  by  CiDD  
in  subsequent  steps  by  specifying  the  analysis  name.    A  minimum  log  fold  change  of  2  is  
specified  for  identifying  differentially  expressed  genes.    By  default,  a  Benjamini  
Hochberg  p-‐‑value  of  0.05  is  required  for  identifying  differentially  expressed  genes.    To  
assess  significance  for  KEGG  gene  set  tests,  this  command  specifies  the  use  of  permuting  
sample  labels  (as  opposed  to  permuting  gene  labels)  1000  times.  
3. Generate  a  k-‐‑TSP  classifier  to  predict  BRAF  V600E  CRC  status  based  on  the  sample  class  
files  generated  in  [2]  by  using  the  same  analysis  name  crc_brafv600e.  
4. Identify  candidate  drugs  from  the  CMap  using  the  mutation  signature  generated  in  [2]  
by  specifying  the  same  analysis  name  crc_brafv600e.    The  command  specifies  the  use  of  
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20  threads  and  1000  permutations  for  assessing  the  significance  (a  permutation_p  value)  
for  the  reported  connectivity  scores.  
5. Identify  candidate  cell  lines  that  are  derived  from  a  LARGE_INTESTINE  tissue  type,  
that  harbor  a  BRAF  V600E  mutation  and  that  exhibit  a  gene  expression  profile  similar  to  
BRAF  V600E  CRCs  based  on  the  classifier  generated  for  the  crc_brafv600e  analysis.  
  
6.3.4.1

Identification  of  a  BRAF  V600E  gene  expression  signature  

Among  all  TCGA  CRC  samples,  we  used  CiDD  to  identify  20  samples  with  a  BRAF  V600E  
mutation  and  149  BRAF  wild-‐‑type  samples  with  available  Illumina  GA  RNA  sequencing  data.  
Then,  CiDD  identified  63  up-‐‑regulated  and  170  down-‐‑regulated  genes  (log  fold-‐‑change  >=  2  and  
Benjamini  Hochberg  adjusted  p-‐‑value  <=  0.05)  that  generated  a  clustering  of  samples  representative  
of  BRAF  mutation  status  as  shown  in  Figure  36.    
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Figure  36:  CiDD-‐‑generated  heat  map  and  clustering  of  BRAF  V600E  mutated  CRCs  based  on  TCGA  Illumina  GA  
RNA  sequencing  data.  Differentially  expressed  genes  comparing  BRAF  V600E  and  BRAF  wildtype  samples  were  
identified  using  the  Limma  package  in  R  and  required  to  have  a  Benjamini  Hochberg  adjusted  p-‐‑value  <=  0.05  and  a  
minimum  log  fold  change  >=  2.    Hierarchical  clustering  of  the  samples  and  genes  were  performed  using  hclust  with  a  
“pearson”  distance  measure  in  R.    The  BRAF  V600E  gene  expression  signature  is  represented  with  the  vertical  
colored  bar  on  the  right  side  of  the  figure,  where  red  represents  down-‐‑regulated  genes  and  blue  up-‐‑regulated  genes.    
BRAF  V600E  mutant  samples  all  reside  within  2  sample  clusters  of  the  heatmap,  which  suggests  that  the  BRAF  V600E  
signature  captures  the  gene  expression  response  of  BRAF  V600E  mutations.  

  
Then,  we  identified  pathways  associated  with  the  BRAF  signature  through  CiDD  using  
Wilcoxon-‐‑based  gene  set  tests102.  For  assessing  significance  of  the  gene  set  tests,  CiDD  
performed  1000  runs  of  the  differential  expression  analyses,  permuting  the  BRAF  mutant  status  
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of  samples  within  each  run.  Fifteen  KEGG  gene  sets  were  associated  with  the  BRAF  V600E  
status  (FDR  adjusted  p-‐‑value  <=  0.05).  To  incorporate  PETACC3-‐‑derived  pathways  as  part  of  the  
pathway  analysis,  a  list  of  the  top  20  pathways  based  on  an  average  ranking  within  the  TCGA  
and  PETACC3-‐‑derived  pathway  lists  is  provided  in  Table  22.  Because  raw  gene  expression  data  
was  not  available  for  the  PETACC3-‐‑derived  signature,  gene  set  tests  were  not  performed.  
Instead,  for  the  PETACC3-‐‑derived  analysis,  hypergeometric  tests  were  applied  to  identify  KEGG  
pathways  enriched  with  genes  from  this  signature.  Twenty-‐‑seven  KEGG  pathways  are  enriched  
with  genes  from  the  PETACC3-‐‑derived  signature  (p-‐‑value  <=  0.05).  The  pathway  ordering  in  
Table  1  reflects  the  average  of  the  p-‐‑value  ranks  within  each  set.  Full  reports  are  provided  in  
Supplementary  Results  (see  the  tcga_gsa  and  petacc3_hyper  sheets  for  the  TCGA-‐‑derived  and  
PETACC3-‐‑derived  reports  respectively).  These  pathways  are  consistently  related  to  CRC  biology  
such  as  the  top  ranked  pathway  (“Colorectal  Cancer”)  and  other  pathways  related  to  TGFβ  
signaling  (“TGF  Beta  Signaling  Pathway”),  which  are  well  known  for  their  role  in  CRC.  
Additionally,  it  is  known  that  the  BRAF  gene  plays  a  role  in  controlling  cellular  proliferation  
and  differentiation  through  regulation  of  the  MAP  kinase  signaling  pathway109,  and  the  “MAPK  
Signaling  Pathway”  is  also  represented  in  the  top  ranked  pathways.  
  

  

143  

  
Table  22:  The  top  20  ranked  pathways  associated  with  BRAF  V600E  status  based  on  systematic  TCGA  gene  
expression  analyses  presented  with  those  derived  from  the  independent  PETACC3-‐‑based  analyses.  The  table  is  
ordered  by  the  overall  rank  of  each  pathway  where  the  overall  rank  represents  an  average  rank  across  both  the  
TCGA-‐‑  and  PETACC-‐‑derived  analyses.  P-‐‑values  and  ranks  for  pathways  associated  for  both  the  TCGA-‐‑  and  
PETACC-‐‑derived  analyses  are  shown.  These  pathways  are  consistently  related  to  CRC  biology  such  as  the  top-‐‑
ranked  pathway  “Colorectal  Cancer”  and  the  “TGF  Beta  Signaling  Pathway”  in  addition  to  the  “MAPK  Signaling  
Pathway”  which  is  known  to  play  a  role  in  BRAF-‐‑mutant  CRC.  

  
Finally,  we  used  CiDD  to  identify  an  11-‐‑pair  k-‐‑TSP  classifier  for  predicting  the  BRAF  
V600E  status  of  independent  samples  using  the  TCGA  data  set.  The  classifier  gene  pairs  are  
listed  in  Table  23.    For  prediction,  a  default  predictive  score  of  0.8  on  the  TCGA  data  set  is  
required  for  inclusion  into  the  classifier.    If  the  average  value  or  rank  for  the  g1  genes  is  less  than  
that  of  the  g2  genes,  the  sample  is  predicted  to  harbor  a  BRAF  V600E  mutation  and  otherwise  the  
sample  is  predicted  to  be  BRAF  wild  type.  
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Table  23:  TCGA-‐‑derived  k-‐‑TSP  classifier  for  predicting  BRAF  V600E  status  

  
6.3.4.2
  

Validation  of  the  TCGA-‐‑derived  gene-‐‑pair  classifier  for  predicting  BRAF  V600E  status  

In  order  to  validate  the  TCGA-‐‑derived  gene  expression  analyses,  we  compared  the  

performance  of  a  previously  reported  BRAF  V600E  gene  expression  classifier  derived  from  the  
PETACC3  clinical  trial  93  against  the  gene  expression  classifier  that  we  identified  from  the  TCGA  
data  set.  
The  PETACC3-‐‑derived  gene  expression  signature  for  our  drug  analyses  consisted  of  193  
up-‐‑regulated  and  92  down-‐‑regulated  probes.  These  probes  correspond  to  224  unique  genes.  The  
research  group  also  developed  a  32-‐‑pair  TSP  classifier  based  on  Affymetrix  probe  IDs  for  
predicting  the  BRAF  V600E  status  of  CRCs.    We  translated  these  probe  IDs  to  Entrez  gene  IDs  
so  the  classifier  could  be  applied  to  RNA  sequencing  and  Agilent  test  data  sets.    To  assess  the  
robustness  of  their  gene  expression  results,  we  applied  the  gene-‐‑based  PETACC3-‐‑derived  
classifier  to  TCGA  samples  that  were  retrieved  and  annotated  with  BRAF  mutation  statuses  by  
CiDD.  When  applied  to  TCGA  RNA  sequencing  data,  the  PETACC3-‐‑derived  classifier  resulted  in  
93.3%  sensitivity  and  83.5%  specificity  for  detecting  BRAF  V600E  samples.  
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To  assess  the  quality  of  the  systematic  TCGA-‐‑derived  classifier  generated  by  CiDD,  we  
compared  the  performance  of  the  TCGA-‐‑  and  PETACC3-‐‑derived  classifiers  on  3  independent  
data  sets  (see  Table  24)  –  two  have  been  previously  published  and  are  available  in  the  Gene  
Expression  Omnibus110,111  and  the  third  is  the  CCLE  data  set.  The  sensitivity  and  specificity  of  
both  classifiers  are  comparable  on  the  GSE35896  and  GSE42284  data  sets  with  the  PETACC3-‐‑
derived  classifier  exhibiting  small  improvements  in  specificity.  The  PETACC3-‐‑derived  classifier  
achieved  100%  sensitivity  but  only  30%  specificity  for  BRAF  status  prediction  on  the  CCLE  large  
intestine  data  set.  The  TCGA-‐‑derived  classifier  had  lower  sensitivity  (71%)  but  achieved  better  
specificity  (62%).  These  results  suggest  that  the  systematically  obtained  BRAF  V600E  classifier  
from  CiDD  is  comparable  to  the  published  PETACC3-‐‑derived  signature  and  that  the  TCGA-‐‑
derived  classifier  may  even  have  improved  specificity  for  distinguishing  BRAF  wild-‐‑type  cell  
lines  from  the  BRAF  mutant  cell  lines.  
  

  
Table  24:  Performance  of  the  TCGA-‐‑  and  PETACC3-‐‑derived  BRAF  V600E  CRC  classifiers  when  applied  to  
independent  gene  expression  data  sets.  The  sensitivity  and  specificity  of  both  classifiers  are  comparable  with  the  
PETACC3-‐‑derived  classifier  exhibiting  small  improvements  in  specificity  on  the  GSE35896  and  GSE42284  data  sets.  
The  TCGA-‐‑derived  classifier  had  lower  sensitivity  (71%)  but  achieved  better  specificity  (62%)  on  the  CCLE  data  set.  
These  results  suggest  that  the  systematically  obtained  BRAF  V600E  classifier  from  CiDD  is  comparable  to  the  
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published  PETACC3-‐‑derived  signature  and  that  the  TCGA-‐‑derived  classifier  may  even  have  improved  specificity  for  
distinguishing  BRAF  wild-‐‑type  cell  lines  from  the  BRAF  mutant  cell  lines.  

  
6.3.4.3

Candidate  drug  therapies  for  BRAF  V600E  CRC  

Using  both  the  TCGA  and  PETACC3-‐‑derived  gene  expression  signatures,  CiDD  identified  
potentially  novel  candidate  drugs  to  treat  BRAF  V600E  CRCs.  Drugs  with  a  negative  
enrichment  score  and  a  permutation  p-‐‑value  less  than  0.1  using  the  TCGA  gene  expression  
signature  are  listed  in  Table  3.  Three  compounds,  Gefitinib,  MG-‐‑262  and  Trapidil,  were  
identified  using  both  the  TCGA  and  PETACC3-‐‑derived  gene  expression  signatures.  Independent  
research  groups  have  recently  shown  that  EGFR  inhibitors  such  as  Gefitinib  and  proteosome  
inhibitors  such  as  MG-‐‑262  are  effective  drugs  for  treatment  of  colorectal  tumors  with  BRAF  
mutations86,112.  Trapidil  is  a  novel  candidate  drug  that  inhibits  phosphodiesterase  and  TXA2.    
  

  
Table  25:  Candidate  drug  compounds  identified  systematically  by  CiDD  for  BRAF  V600E  CRC  based  on  the  TCGA-‐‑
derived  gene  expression  signature.  Nine  drugs  were  identified  having  both  a  negative  enrichment  score  and  a  
maximum  permutation  P-‐‑value  of  0.1.  Three  of  these  drugs  (*)  were  also  identified  using  the  PETACC3-‐‑derived  gene  
expression  signature.  
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6.3.4.4

Cancer  cell  lines  that  most  resemble  BRAF  V600E  CRC  

Finally,  in  order  to  identify  candidate  cell  lines  for  in  vitro  testing,  CiDD  analyzed  data  
from  the  CCLE.  From  947  cell  lines  in  the  CCLE,  CiDD  identified  48  large  intestine  samples  that  
we  consider  to  be  representative  of  colorectal  tumors.  Then  CiDD  reduced  this  number  to  7,  
representing  those  large  intestine  cell  lines  that  have  BRAF  V600E  mutations.  Finally,  using  the  
11  gene-‐‑pair  k-‐‑TSP  classifier  generated  by  CiDD,  5  of  these  cell  lines  were  predicted  to  be  BRAF  
V600E  on  the  basis  of  having  similar  gene  expression  profiles  to  the  TCGA  BRAF  V600E  
mutated  CRCs.  The  five  identified  cell  lines  include  RKO,  SNUC5,  CL34,  COLO205  and  HT29.  
OUMS23  and  SW1417  are  the  two  BRAF  V600E  large  intestine  cell  lines  that  are  predicted  to  be  
BRAF  wild-‐‑type  by  the  TCGA-‐‑derived  gene  expression  classifier.  
  
6.3.5

Discussion  
As  genomic  technologies  have  ushered  in  the  potential  for  targeted  drug  development,  

large-‐‑scale  public  genomic  databases  have  matured  in  size,  scope  and  information  content  to  
complement  this  effort.    It  is  thus  advantageous,  and  indeed  possibly  necessary,  to  apply  
computational  genomics  to  inform  the  drug  discovery  process.  While  subgroup  classification  
for  prognostic  assessment  and  therapeutic  planning  has  been  applied  clinically  for  decades,  
especially  among  hematologic  malignancies  and  in  some  solid  tumors  such  as  breast  cancers,  
other  tumor  types  such  as  CRCs  appear  phenotypically  homogenous  and  are  thus  clinically  
indistinguishable.  In  order  to  reveal  subclasses  for  these  tumors  and  to  generalize  their  genome-‐‑
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based  classification,  the  use  of  genetic  and  transcriptomic  analyses  may  prove  essential.  Systems  
biology  tools  such  as  CMap,  and  we  believe  CiDD  as  well  now,  help  fill  this  need  of  identifying  
candidate  interventions  that  target  specific  pathways  deregulated  in  these  tumor  subclasses.  In  
this  regard,  CMap  provided  the  original  approach  to  guide  drug  development  based  on  
transcriptomic  data.  CiDD  is  taking  this  systems  biology  approach  further  by  extending  the  
CMap  with  the  clinical  and  molecular  data  of  TCGA  along  with  the  high-‐‑throughput  
experiments  of  the  CCLE  for  the  purposes  of  systematic  cancer  drug  discovery.    While  current  
public  resources  such  as  that  of  TCGA  are  impressive,  they  are  likely  just  a  beginning.    The  
basic  logic  of  CiDD  naturally  extends  to  utilization  of  forthcoming,  larger-‐‑scale  databases  from  
drug  perturbation  experiments  and  genetic  and  transcriptomic  sequencing  of  tumors  of  a  wider  
array  of  sizes  and  associated  clinical  outcomes.      
We  believe  CiDD  is  the  first  framework  that  supports  systematic  drug  discovery  based  on  
user-‐‑specified  TCGA  clinical  and  molecular  phenotypes.  CiDD  allows  researchers  to  perform  
the  following:  (1)  assess  whether  or  not  a  mutation  or  clinical  phenotype  is  associated  with  a  
gene  expression  signature,  (2)  identify  candidate  drugs  to  target  this  gene  expression  signature,  
and  (3)  identify  cell  lines  for  subsequent  in  vitro  drug  experimentation.  We  have  illustrated  the  
power  of  such  an  approach  in  a  meaningful  application  to  CRCs  with  somatic  mutations  in  
BRAF.    CiDD  also  offers  utility  to  researchers  simply  wishing  to  interrogate  and  organize  TCGA  
data,  as  it  can  be  applied  to  create  an  inventory  of  available  TCGA  data  with  particular  clinical  
or  genomic  features,  such  as  available  data  sets  or  patients  with  particular  mutations,  
independently  of  its  drug  identification  capabilities.      
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One  of  the  most  crucial  steps  in  the  BRAF  V600E  analysis  was  identifying  a  gene  
expression  signature  associated  with  the  BRAF  V600E  mutation  and  generating  a  classifier  for  
predicting  mutation  status.    In  both  of  these  cases,  we  showed  that  the  signature  and  classifier  
of  the  CiDD  framework  are  comparable  to  those  identified  from  the  published  PETACC3-‐‑derived  
analyses93.  Similarly  to  the  PETACC3-‐‑derived  signature  and  classifier,  the  CiDD-‐‑generated  
signature  was  composed  of  genes  representative  of  known  pathways  associated  with  the  BRAF  
V600E  mutation,  most  notably  the  “MAPK  Signaling  Pathway”,  and  the  performance  of  the  
classifier  on  independent  data  sets  generated  from  orthogonal  gene  expression  technologies  
showed  robustness.    The  advantage  of  CiDD  analyses  is  that  they  are  systematic  studies  of  
generally  available  datasets.  We  did  not  have  to  generate  any  of  our  own  experimental  data,  
and  the  gene  expression  analyses  can  be  relatively  easily  replicated  and  repeated  for  other  
mutation  or  clinical  phenotypes.  
Once  we  validated  the  gene  expression  signature,  we  used  CiDD  to  identify  candidate  
compounds  for  tumors  harboring  the  well-‐‑known  BRAF  V600E  mutation.    Since  the  initial  
communication  of  the  presence  of  mutations  in  the  kinase  BRAF  in  cancer113,  activating  
mutations  have  been  described  in  several  malignancies  with  different  frequencies  such  as  hairy  
cell  leukemia  (100%),  melanoma  (50-‐‑60%),  thyroid  carcinoma  (30-‐‑50%)  and  CRC  (10%)114.  The  
most  frequently  identified  mutation  is  a  valine-‐‑to-‐‑glutamic  acid  substitution  at  codon  600  
(V600E)  that  activates  the  signaling  cascade  downstream  of  MEK  and  ERK113.  Other  mutations  
have  been  found  at  the  same  codon  and  are  considered  equivalents  in  terms  of  oncogenic  
activation114.  Therefore,  substantial  efforts  were  invested  on  developing  ATP-‐‑competitive  RAF  
inhibitors  such  as  Vemurafenib  and  Dabrafenib  to  specifically  target  the  MAPK  pathway.  Yet,  
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the  clinical  success  of  BRAF  inhibition  has  been  variable  and  highly  dependent  on  the  tumor  
context.  In  this  regard,  Vemurafenib  has  demonstrated  improvement  in  survival  in  patients  
diagnosed  with  stage  IV  melanomas  harboring  the  BRAF  V600E  mutation115.  However,  this  
degree  of  clinical  benefit  has  not  been  observed  in  the  same  molecular  context  in  CRCs116.  This  is  
probably  secondary  to  the  intrinsic  mechanisms  of  resistance  to  BRAF  inhibition  that  are  
specific  to  the  tumor  context114.  BRAF  mutations  in  CRCs  have  been  associated  with  poor  
prognosis  and  an  aggressive  disease  course,  and  a  characteristic  clinical  phenotype  consistent  
with  older  age  at  diagnosis,  female  gender,  right-‐‑sided  location  and  the  presence  of  high  levels  
of  microsatellite  instability117,118.  
Two  strategies  have  been  suggested  to  overcome  the  primary  resistance  to  BRAF  
inhibition  in  CRC  biology.  One  strategy  that  has  been  supported  independently  by  two  
different  groups  is  the  inhibition  of  the  EGFR  pathway  by  using  monoclonal  antibodies  against  
EGFR  (such  as  Cetuximab)  or  kinase  inhibitors  (such  as  Gefinitib  and  Erlotinib)  in  combination  
with  BRAF  inhibitors.  EGFR  is  activated  by  feedback  mechanisms  upon  BRAF  inhibition,  thus  
reactivating  ERK  via  RAS  and  CRAF,  therefore  combinations  of  EGFR  and  BRAF  inhibition  will  
synergize  in  terms  of  activity86,119–121.  The  second  strategy  is  based  on  targeting  the  proteasome  
pathway.  This  has  demonstrated  specific  activity  against  BRAF  V600E  mutant  CRC  cell  lines  
and  tumor  xenografts.  This  set  of  experiments  was  performed  using  classical  (Bortezomib)  and  
novel  (Carfilzomib)  proteasome  inhibitors  and  demonstrated  similar  activity.  However,  as  
opposed  to  EGFR  feedback,  proteasome  inhibition  seems  to  function  independently  of  BRAF  
inhibition  112.  CiDD  has  been  able  to  identify  both  types  of  compounds  (EGFR  and  proteasome  
inhibitors)  as  candidate  drugs  through  an  agnostic  approach,  thus  providing  a  biological  
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validation  of  the  value  of  CiDD  as  an  screening  tool  to  identify  novel  drugs  to  be  tested  and  
further  developed  in  specific  tumor  subtypes.  
CiDD  also  addresses  the  important  issue  of  identifying  the  most  appropriate  cell  lines  as  
pre-‐‑clinical  models  for  cancer  researchers.    Systematic  comparisons  between  cancer  cell  lines  
and  tumor  samples  from  human  tissues  have  documented  substantial  differences  between  the  
two,  emphasizing  the  importance  of  making  genomically  informed  choices  when  identifying  
cell  lines  as  pre-‐‑clinical  models  of  a  tumor  subtype  122.    The  CCLE  provides  mutation  and  gene  
expression  data  that  allow  CiDD  to  make  these  molecularly  informed  decisions  in  selecting  cell  
lines.    In  our  BRAF  V600E  analysis,  CiDD  identified  7  large  intestine  cell  lines  harboring  the  
BRAF  V600E  mutation.  However,  only  5  of  the  7  were  predicted  to  be  BRAF  V600E  based  on  
CiDD’s  gene  expression  classifier,  suggesting  heterogeneity  among  the  BRAF  V600E  mutated  
cell  lines.    Helpfully,  CiDD  prioritized  those  cell  lines  into  2  groups  for  in  vitro  testing,  
proposing  that  5  of  the  7  BRAF  V600E  mutated  large  intestine  cell  lines  more  closely  resemble  
the  TCGA  CRC  BRAF  V600E  tumors  at  a  gene  expression  level.  
CiDD  has  some  limitations  that  could  restrict  its  application  in  specific  situations.  
Primarily,  CiDD  is  dependent  on  identifying  a  gene  expression  signature  representative  of  a  
phenotype  of  interest.  In  some  cases,  a  clinical  phenotype  or  mutation  may  not  actually  induce  a  
gene  expression  response.  In  other  clinical  contexts,  such  as  for  rare  mutations  and  infrequent  
clinical  phenotypes,  CiDD  may  not  have  the  power  to  identify  the  true  underlying  gene  
expression  signature  associated  with  the  phenotype,  because  CiDD  is  limited  by  the  number  of  
samples  available  in  TCGA  with  that  specific  phenotype.  In  these  rare-‐‑phenotype  analyses,  
CiDD  may  fail  to  identify  a  statistically  significant  gene  expression  signature  representative  of  
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the  phenotype  of  interest.  Researchers  interested  in  rare  clinical  or  molecular  subgroups  will  
need  to  consider  alternative  strategies  for  increasing  their  sample  sizes.  These  strategies  may  
include  aggregating  TCGA  tumor  types  or  grouping  mutations  or  clinical  phenotypes  in  
biologically  meaningful  ways,  such  as  aggregating  rare  mutations  at  a  gene  or  pathway  level  to  
increase  the  sample  size.    The  CiDD  command  that  generates  gene  expression  signatures  based  
on  defined  mutations  provides  support  for  aggregating  mutations  by  listing  amino  acid  
substitutions  explicitly,  specifying  types  of  mutations  (such  as  Nonsense  mutations)  or  by  
defining  sets  of  mutations  based  on  gene  and  gene  set  membership.    Additionally,  the  CiDD  
framework  does  not  support  the  identification  of  candidate  drug  combinations  to  target  tumor  
subtypes.    The  CMap  provides  drug-‐‑perturbed  data  that  were  generated  by  applying  
compounds  to  cell  lines  one  compound  at  a  time.    If  future  drug-‐‑perturbed  data  sets  provide  
gene  expression  data  of  multiple  compounds  being  applied  to  cell  lines,  incorporation  of  this  
data  into  CiDD  should  be  relatively  straightforward.    As  an  alternative,  the  computational  
identification  of  multiple  interacting  candidate  drugs  based  on  current  data  sets  is  a  potential  
area  for  future  CiDD  development.    
Of  course,  these  limitations  apply  more  generally  for  these  difficult  scenarios  and  are  not  
unique  to  CiDD.    In  fact,  CiDD  helps  address  these  limitations  by  being  easy  to  run  and  repeat  
to  test  multiple  hypotheses  quickly.    Further,  CiDD  is  a  framework  rather  than  a  specific  
method  per  se.    As  public  databases  evolve  and  expand,  and  as  robust  statistical  methodologies  
mature  for  cross-‐‑platform  expression-‐‑based  signature  identification,  CiDD  could  be  adapted  to  
incorporate  these  improved  components.    In  this  sense,  what  we  have  demonstrated  here  is  a  
“lower  bound”  of  sorts,  and  we  expect  more  powerful  findings  to  emerge  from  such  efficient  
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systems-‐‑based  computation.    Finally,  the  field  of  gene  expression  analysis,  particularly  for  
identifying  signatures  of  cancer  subtypes,  has  been  criticized  for  failing  to  adhere  to  standards  
of  repeatability  123.    Our  software  facilitates  repeatability  and  even  enables  replication  of  
findings  with  external  data  sets.    In  all  of  these  aspects,  we  expect  the  community  of  cancer  
genomic  researchers  to  benefit  from,  and  further  contribute  to,  this  framework.  
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